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	Abstract	
Renal transplantation is the definitive treatment for the end-stage renal failure. 
Despite concerted efforts to increase the number of available organs there 
remains a wide gap. Kidneys with small renal cell carcinoma have been used 
for transplantation after ex vivo resection of tumours with excellent results. 
Concerns regarding the behaviour of tumour under standard 
immunosuppression prevent this source from being popularised. We studied 
tumour behaviour with standard immunosuppression and immunosuppressives 
with anti-proliferative properties and the effect of MHC matching on tumour 
behaviour. Luciferase labelled Wistar rat kidney tumour cells were injected 
subcutaneously into Wistar or Lewis rats to mimic well and poorly matched 
groups. These were divided into groups receiving Cyclosporine, Sirolimus high 
and Sirolimus low dose and Leflunomide. Effects of matching on tumour 
rejection were studied by immunosuppression withdrawal in half of the animals 
within each group. Tumour progression was monitored with IVIS spectrum 
imaging system.  
When the immunosuppression was continued for the length of the study period 
with Cyclosporine immunosuppression, the tumour continued to grow in both 
strains. With high dose Sirolimus, the tumour was eradicated within 2 weeks in 
both Wistar and Lewis rats (p <0.05). Both strains receiving low dose Sirolimus 
also eradicated the tumour within four weeks of treatment (p <0.05). In 
Leflunomide group, 4/7 animals rejected the tumour within the 4 weeks of 
study period (p <0.05).  
	To study the effects of rejection and matching on the tumour behaviour, the 
immunosuppression was stopped after 2 weeks of treatment and the animals 
followed for another two weeks to study these effects. After treatment 
withdrawal, the tumour rejection was noted which was significantly stronger in 
poorly matched animals than in well-matched animals (p <0.05) in cyclosporine 
treated animals. 
These results appeared to be in line with our hypothesis, that newer 
immunosuppressive medications with anti-neoplastic effects may be better 
options after transplanting kidneys after small tumour ex-vivo resection.  
Acute rejection showed significant ability to lead to tumour eradication, more 
effectively in less well-matched animals than well-matched combinations.  Thus 
perhaps clinically, recipients of such restored kidneys should be less well 
matched and immunosuppressed with agents with anti-proliferative properties. 
These results will need to be replicated with further studies including closely 
monitored clinical studies before it can be popularised at a significant new 
source of precious organs. 
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FIGURE	19	 FLORESCENT	MICROSCOPY.	CLUMPS	OF	BP36B	CELLS	TRANSDUCED	WITH	GFP.	 3-91	
FIGURE	20	 IVIS	SPECTRUM	IMAGE.	BIOLUMINESCENCE	FROM	LUCIFERASE	TRANSDUCED	CELLS.	THE	
CONTROL	CELLS	(LEFT)	DID	NOT	SHOW	ANY	SIGNALS,	THE	BRIGHTEST	GLOWING	CELLS	(MIDDLE)	
WERE	TRANSDUCED	WITH	MOI	OF	2.5	AND	CELLS	WITH	MOI	OF	5.0	(RIGHT)	WERE	ALSO	POSITIVE	
FOR	THE	EXPRESSION	OF	LUCIFERASE	BUT	WERE	LESS	BRIGHT.	 3-94	
FIGURE	21	 IVIS	IMAGE	FOR	FLORESCENCE.	MOI	5.0,	CONTROLS,	MOI	2.5	AND	MOI	5.0	FROM	LEFT	TO	
RIGHT	 3-94	
FIGURE	22	 VENTRAL	VIEW	OF	BIOLUMINESCENT	SIGNALS	FROM	DEAD	RAT.	BOTH	THE	TRANSFECTED	
CELLS	AND	LUCIFERIN	(PROMEGA	BRIGHT	GLO	SYSTEM)	WERE	INJECTED	TO	SEE	IF	
SUBCUTANEOUS	INJECTION	WILL	LEAD	TO	SIGNALS	PICK	UP	BY	THE	IVIS	SPECTRUM	IMAGING	
SYSTEM.	4-99	
FIGURE	23	DORSAL	VIEW	OF	BIOLUMINESCENT	SIGNALS	FROM	DEAD	RAT.	BOTH	THE	TRANSFECTED	
CELLS	AND	LUCIFERIN	(PROMEGA	BRIGHT	GLO	SYSTEM)	WERE	INJECTED	INTO	THE	MEDIASTINUM	
TO	SEE	IF	IVIS	SPECTRUM	IMAGING	SYSTEM	WILL	PICK	UP	DEEP	SEATED	SIGNALS	IN	CASES	OF	
METASTASIS.	 4-100	
FIGURE	24	 WISTAR	RATS	WEIGHTS	 4-103	
FIGURE	25	 LEWIS	RATS	WEIGHTS	(AS	PER	CHARLES	RIVER)	 4-103	
	FIGURE	26	 KINETIC	CURVE	OF	LUCIFERIN.	CALCULATED	FOR	LEWIS	RAT	IN	THE	PILOT	STUDY.	THE	
RADIANCE	WAS	CALCULATED	BY	SUBTRACTING	THE	BACKGROUND	SIGNALS	FROM	THE	SIGNALS	
OF	REGION	OF	INTEREST	(ROI).	 4-107	
FIGURE	27	 ANAESTHETIC	CHAMBER	AND	ISOFLORENE	DELIVERY	SYSTEM	OF	IVIS	SPECTRUM.	 4-108	
FIGURE	28	 ANAESTHETIC	MANIFOLD.	NOSE	CONES	FOR	MAINTENANCE	OF	ANAESTHESIA	IN	THE	
IMAGING	CHAMBER	 4-108	
FIGURE	29	 TUMOUR	BEHAVIOUR	IN	THE	WELL-MATCHED	GROUP	WITH	NO	IMMUNOSUPPRESSION.	
THE	ENTIRE	TUMOUR	LOAD	WAS	CLEARED	WITHIN	TWO	WEEKS.	THE	THREE	LINES	REPRESENT	
THREE	WISTAR	RATS	IN	THIS	GROUP.	 4-110	
FIGURE	30	 TUMOUR	BEHAVIOUR	IN	THE	POORLY	MATCHED	GROUP	WITH	NO	
IMMUNOSUPPRESSION.	THE	ENTIRE	TUMOUR	LOAD	WAS	CLEARED	WITHIN	FIRST	WEEK.	THE	TWO	
LINES	REPRESENT	THE	LEWIS	RATS	IN	THIS	GROUP.	 4-111	
FIGURE	31	 TUMOUR	BEHAVIOUR	IN	THE	POORLY	MATCHED	GROUP	WITH	CSA	
IMMUNOSUPPRESSION.	THE	TUMOUR	CONTINUED	TO	GROW	WITH	TIME	DURING	THE	STUDY	
PERIOD.	THE	TWO	LINES	REPRESENT	THE	LEWIS	RATS	IN	THIS	GROUP.	 4-112	
FIGURE	32	 LEWIS	RAT	WITH	CYCLOSPORINE	IMMUNOSUPPRESSION.	THE	TUMOUR	INJECTED	INTO	
THE	RIGHT	FLANK	HAS	CONTINUED	TO	GROW.	 4-112	
FIGURE	33	 TUMOUR	BEHAVIOUR	IN	THE	POORLY	MATCHED	GROUP	WITH	CSA	
IMMUNOSUPPRESSION	STOPPING	AFTER	TWO	WEEKS.	THE	TUMOUR	CONTINUED	TO	GROW	WITH	
TIME	DURING	THE	INITIAL	HALF	WHILE	AFTER	STOPPING	THE	TREATMENT	THE	ENTIRE	TUMOUR	
LOAD	WAS	CLEARED.	THE	TWO	LINES	REPRESENT	THE	LEWIS	RATS	IN	THIS	GROUP.	 4-113	
FIGURE	34	 EFFECTS	OF	TREATMENT	WITHDRAWAL.	EXAMPLE	OF	A	RAT	AT	WEEK	2	(LEFT)(WITH	
IMMUNOSUPPRESSION)	AND	WEEK	4	(RIGHT)	(AFTER	STOPPING	THE	IMMUNOSUPPRESSION	FOR	
2	WEEKS).	THE	COLOURED	AREA	OVER	THE	FIR	IN	THE	RIGHT	IMAGE	IS	THE	“NOISE”	OF	THE	IVIS	
IMAGING	DUE	TO	LONG	EXPOSURE	TIMES	TO	DETECT	EVEN	VERY	LOW	RADIANCE	FROM	THE	
REGION	OF	INTEREST.	 4-114	
FIGURE	35	 ROLE	OF	ACUTE	REJECTION.	REJECTION	OF	ALL	OF	THE	INJECTED	TUMOUR	CELLS	IN	THE	
ABSENCE	OF	ANY	IMMUNOSUPPRESSION	IN	WELL-MATCHED	WISTAR	ANIMALS	WITHIN	TWO	
WEEKS.	 4-117	
FIGURE	36	 ROLE	OF	ACUTE	REJECTION.	REJECTION	OF	ALL	OF	THE	INJECTED	TUMOUR	CELLS	IN	THE	
ABSENCE	OF	ANY	IMMUNOSUPPRESSION	IN	POORLY-MATCHED	LEWIS	ANIMALS	WITHIN	JUST	ONE	
WEEK.	 4-120	
FIGURE	37	 DIRECT	COMPARISON	BETWEEN	WISTAR	AND	LEWIS	RATS.	COMPLETE	REJECTION	OF	
TRANSPLANTED	TUMOUR	CELLS;	STRONGER	IN	POORLY	MATCHED	LEWIS	ANIMALS	 4-121	
FIGURE	38	 WISTAR	RAT	WITH	RIGHT	FLANK	INJECTION.	THREE	WEEKS	AFTER	THE	INJECTION	OF	
TUMOUR	CELLS.	VERY	HIGH	SIGNAL	INTENSITY	FROM	THE	TUMOUR	IN	THE	RIGHT	FLANK	
SUBCUTANEOUS	TISSUE.	THIS	TUMOUR	WAS	PALPABLE	AT	THIS	STAGE	AND	GREW	EVEN	FURTHER	
TILL	THE	END	OF	STUDY	PERIOD.	 4-124	
FIGURE	39	 DISSECTION	OF	THE	RIGHT	FLANK.	THE	SKIN	IS	DISSECTED	OFF	THE	VENTRAL	ABDOMINAL	
WALL.	THE	TUMOUR	CLEARLY	VISIBLE	WITH	EVIDENCE	OF	INCREASED	VASCULARITY	AROUND	THE	
TUMOUR	 4-125	
FIGURE	40	 CSA	TREATMENT	CONTINUE	GROUP.	RAPID	GROWTH	OF	TRANSPLANTED	TUMOUR	CELLS	
TOWARDS	THE	END	OF	STUDY	PERIOD	REPRESENTED	BY	BRIGHT	BIOLUMINESCENT	SIGNALS.	 4-126	
FIGURE	41	 LEWIS	RAT	WITH	RIGHT	FLANK	INJECTION.	FOUR	WEEKS	AFTER	THE	INJECTION	OF	
TUMOUR	CELLS.	VERY	HIGH	SIGNAL	INTENSITY	FROM	THE	TUMOUR	IN	THE	RIGHT	FLANK	
SUBCUTANEOUS	TISSUE.	THIS	TUMOUR	WAS	PALPABLE	AT	THIS	STAGE.	 4-126	
FIGURE	42	 CSA	TREATMENT	CONTINUE	GROUP.	RAPID	GROWTH	OF	TRANSPLANTED	TUMOUR	CELLS	
TOWARDS	THE	END	OF	STUDY	PERIOD	REPRESENTED	BY	BRIGHT	BIOLUMINESCENT	SIGNALS.	 4-127	
	FIGURE	43	 FLOW	DIAGRAM	OF	PROTOCOL	TO	STUDY	ROLE	OF	REJECTION	AND	MATCHING.	AFTER	
TWO	WEEKS	OF	CONTINUED	IMMUNOSUPPRESSION	THE	TREATMENT	IS	WITHDRAWN	TO	STUDY	
THE	EFFECTS	OF	ACUTE	REJECTION.	 4-128	
FIGURE	44	 CSA	TREATMENT	WITHDRAWAL	GROUP.	WISTAR	RATS	AT	4	WEEKS	POST	TUMOUR	CELLS	
INJECTION.	THIS	IMAGE	WAS	TAKEN	AFTER	300	SECONDS	OF	EXPOSURE	(MAXIMUM)	TO	DETECT	
ANY	LEFT	OVER	SIGNALS	FROM	THE	TRANSFECTED	TUMOUR	CELLS.	THE	RAT	ON	THE	LEFT	SIDE	
HAS	REJECTED	THE	ENTIRE	TUMOUR	LOAD	WHILE	THERE	WAS	STILL	POSITIVE	SIGNALS	FROM	THE	
WISTAR	ON	THE	RIGHT	OF	THE	IMAGE.	 4-129	
FIGURE	45	 CSA	TREATMENT	WITHDRAWAL	IN	WISTAR	RATS.	CONTINUED	GROWTH	OF	THE	
TRANSPLANTED	TUMOUR	CELLS	UNDER	THE	INFLUENCE	OF	CSA	IMMUNOSUPPRESSION	TILL	TWO	
WEEKS.	THIS	WAS	FOLLOWED	BY	REDUCTION	IN	BIOLUMINESCENT	SIGNALS	DUE	TO	
WITHDRAWAL	OF	IMMUNOSUPPRESSION.	 4-130	
FIGURE	46	 CSA	POORLY	MATCHED	RATS.	LEWIS	RATS	AT	TWO	WEEKS	OF	CYCLOSPORINE	
IMMUNOSUPPRESSION.	BRIGHT	SIGNALS	WERE	ACHIEVED	FROM	ALL	THE	ANIMALS	TESTED.	 4-131	
FIGURE	47	 CSA	POORLY	MATCHED	RATS	WITH	TREATMENT	WITHDRAWAL.	LEWIS	ANIMALS	AT	FOUR	
WEEKS	AFTER	THE	INITIAL	INJECTION.	THIS	SCAN	WAS	DONE	TWO	WEEKS	AFTER	STOPPING	THE	
IMMUNOSUPPRESSION	AND	NO	SIGNALS	WERE	DETECTED	 4-132	
FIGURE	48	 CSA	POORLY	MATCHED	RATS	WITH	TREATMENT	WITHDRAWAL.	CONTINUED	GROWTH	OF	
THE	TRANSPLANTED	TUMOUR	CELLS	UNDER	THE	INFLUENCE	OF	CSA	IMMUNOSUPPRESSION	TILL	
TWO	WEEKS.	THIS	WAS	FOLLOWED	BY	COMPLETE	DISAPPEARANCE	OF	BIOLUMINESCENT	SIGNALS	
AFTER	THE	WITHDRAWAL	OF	IMMUNOSUPPRESSION.	 4-132	
FIGURE	49	 DIRECT	COMPARISON	OF	WISTAR	AND	LEWIS	RATS	WITH	CONTINUED	CSA	
IMMUNOSUPPRESSION.	THE	GROWTH	OF	TUMOUR	WAS	SIGNIFICANTLY	STRONGER	AMONG	
WELL-MATCHED	WISTAR	ANIMALS.	THE	SCANNING	SCHEDULE	IN	WEEKS	IS	SHOWN	AT	THE	X-AXIS.	 4-133	
FIGURE	50	 DIRECT	COMPARISON	OF	WISTAR	AND	LEWIS	RATS	IN	WITHDRAWAL	OF	CSA	
IMMUNOSUPPRESSION.		LEWIS	RATS	WERE	SIGNIFICANTLY	MORE	EFFECTIVE	IN	REJECTING	
TUMOURS	WHEN	COMPARED	WITH	THE	WELL-MATCHED	WISTAR	RATS.	 4-134	
FIGURE	51	 WELL-MATCHED	(WISTAR)	ANIMALS	WITH	CONTINUED	SIROLIMUS	
IMMUNOSUPPRESSION.	ALL	TUMOUR	LOAD	WAS	CLEARED	BY	THE	WEEK	TWO	OF	THE	STUDY	
PERIOD.	4-139	
FIGURE	52	 SIROLIMUS	HIGH	DOSE	WITH	CONTINUOUS	IMMUNOSUPPRESSION	IN	POORLY	MATCHED	
ANIMALS.	AGAIN	ALL	ANIMALS	REJECTED	THE	TUMOUR	CELLS	WITH	FIRST	TWO	WEEKS	OF	STUDY	
PERIOD.	THE	SCANNING	WAS	DONE	ONCE	EVERY	WEEK	(WEEK	0,	1,2,3,4)	 4-140	
FIGURE	53	 WELL-MATCHED	WISTAR	TREATMENT	WITHDRAWAL.	ANIMALS	AGAIN	REJECTED	THE	
TUMOUR	LOAD	WITH	THE	FIRST	TWO	WEEKS	OF	HIGH	DOSE	SIROLIMUS.	THERE	WAS	NO	
REAPPEARANCE	OF	TUMOUR	CELLS	AFTER	TREATMENT	WITHDRAWAL	AT	ANY	POINT	OF	STUDY	
PERIOD.	4-141	
FIGURE	54	 POORLY	MATCHED	TREATMENT	WITHDRAWAL.	IN	THESE	THREE	LEWIS	ANIMALS,	THERE	
WAS	SOME	RESIDUAL	SIGNALS	BY	THE	WEEK	TWO	SCANNING.	AT	WEEK	THREE	THERE	WERE	NO	
SIGNALS	LEFT	AGAIN	PROVING	THE	EFFECTIVENESS	OF	TREATMENT	WITHDRAWAL.	 4-142	
FIGURE	55	 LOW	DOSE	SIROLIMUS	TREATMENT.	WEEK	1	AND	WEEK	4	IVIS	IMAGES	OF	THE	WISTAR	
RAT	WITH	LOW	DOSE	SIROLIMUS	TREATMENT.	THERE	IS	COMPLETE	ELIMINATION	OF	TUMOUR	
LOAD	DURING	THE	STUDY	PERIOD.	 4-143	
FIGURE	56	 LOW	DOSE	SIROLIMUS	TREATMENT.	WELL	MATCHED	WISTAR	ANIMALS	WITH	
CONTINUED	IMMUNOSUPPRESSION	WITH	LOW	DOSE	SIROLIMUS,	AGAIN	WAS	SUCCESSFUL	IN	
CLEARING	ALL	THE	TUMOUR	LOAD	BY	WEEK	THREE	OF	SCANNING.	 4-144	
FIGURE	57	 POORLY	MATCHED	–	LOW	DOSE	SIROLIMUS.	WEEK	1	AND	WEEK	4	IVIS	IMAGES	OF	THE	
LEWIS	RAT	WITH	LOW	DOSE	SIROLIMUS	TREATMENT.	THERE	IS	COMPLETE	ELIMINATION	OF	
TUMOUR	LOAD	DURING	THE	STUDY	PERIOD.	 4-144	
	FIGURE	58	 LOW	DOSE	SIROLIMUS-LEWIS	RATS.	POORLY-MATCHED	LEWIS	ANIMALS	WITH	
CONTINUED	IMMUNOSUPPRESSION	WITH	LOW	DOSE	SIROLIMUS,	AGAIN	WAS	SUCCESSFUL	IN	
CLEARING	ALL	THE	TUMOUR	LOAD	BY	WEEK	FOUR	OF	SCANNING.	 4-145	
FIGURE	59	 WELL-MATCHED	RATS	WITH	LOW	DOSE	SIROLIMUS.	THE	TUMOUR	LOAD	WAS	REDUCING	
WHICH	CONTINUED	UPON	TREATMENT	WITHDRAWAL	AND	BY	THE	END	OF	STUDY	PERIOD	THERE	
WERE	NO	BIOLUMINESCENT	SIGNALS	LEFT.	 4-146	
FIGURE	60	 LEWIS	RATS-TREATMENT	WITHDRAWAL.	WEEK	0	AND	WEEK	4	IVIS	IMAGES	OF	THE	LEWIS	
RAT	WITH	LOW	DOSE	SIROLIMUS	TREATMENT	WITHDRAWAL.	THERE	IS	COMPLETE	ELIMINATION	
OF	TUMOUR	LOAD	DURING	THE	STUDY	PERIOD.	 4-147	
FIGURE	61	 LEWIS	ANIMALS	WITH	LOW	DOSE	SIROLIMUS	TREATMENT	WITHDRAWAL.	THE	TUMOUR	
LOAD	WAS	REDUCING	WHICH	CONTINUED	UPON	TREATMENT	WITHDRAWAL	AND	BY	THE	END	OF	
WEEK	THREE	THERE	WERE	NO	BIOLUMINESCENT	SIGNALS	LEFT.	 4-147	
FIGURE	62	 WELL-MATCHED	WISTAR	ANIMALS	IN	THE	LEFLUNOMIDE	TREATMENT	CONTINUE	ARM.	
THERE	WAS	A	STEADY	DECLINE	IN	THE	BIOLUMINESCENT	SIGNALS	FROM	THESE	ANIMALS	FROM	
TUMOUR	INJECTION	SITE.	DESPITE	WEAKENING	SIGNALS	NOT	ALL	THE	ANIMALS	REJECTED	
COMPLETE	TUMOUR	LOAD	BY	THE	END	OF	THE	STUDY	PERIOD.	 4-149	
FIGURE	63	 LEFLUNOMIDE	TREATED	WISTAR	ANIMALS-TREATMENT	WITHDRAWAL.	COMPLETE	
ELIMINATION	OF	THE	TUMOUR	LOAD	FROM	THE	WISTAR	RATS.	THERE	IS	CONSIDERABLE	
BACKGROUND	“NOISE”	WHICH	IS	DUE	TO	LONG	EXPOSURE	TIMES	TO	DETECT	ANY	SMALL	
RESIDUAL	TUMOUR	BIOLUMINESCENCE.	 4-150	
FIGURE	64	 TREATMENT	WITHDRAWAL	AFTER	TWO	WEEKS	IN	LEFLUNOMIDE	TREATED	ANIMALS.	BY	
THE	END	OF	STUDY	PERIOD	4/7	ANIMALS	HAVE	REJECTED	THE	TUMOUR	LOAD	AND	REST	WERE	
SHOWING	REDUCING	TUMOUR	LOAD.	 4-151	
FIGURE	65	 DIRECT	COMPARISON	BETWEEN	WISTAR	AND	LEWIS	RATS	AFTER	TUMOUR	CELLS	
INJECTION.	COMPLETE	REJECTION	OF	TRANSPLANTED	TUMOUR	CELLS;	STRONGER	IN	POORLY	
MATCHED	LEWIS	ANIMALS	 4-152	
FIGURE	66	 COMPARISON	BETWEEN	TREATMENT	CONTINUE/WITHDRAWAL	GROUPS	IN	CSA	
TREATMENT-WISTAR	ANIMALS.	AS	OPPOSED	TO	CONTINUED	TREATMENT,	THERE	WAS	
SIGNIFICANT	REDUCTION	IN	TUMOUR	LOAD	AFTER	TREATMENT	WITHDRAWAL.	FOR	COMPARISON	
PURPOSES	THE	BIOLUMINESCENT	RANGES	ARE	KEPT	SIMILAR	ON	Y	AXIS	HENCE	THE	FINAL	
READING	IN	CSA	GROUP	IS	OUT	OF	THE	SCALE.	 4-153	
FIGURE	67	 COMPARISON	BETWEEN	TREATMENT	CONTINUE/WITHDRAWAL	GROUPS	IN	CSA	
TREATMENT-LEWIS	ANIMALS.	AS	OPPOSED	TO	CONTINUED	TREATMENT,	THERE	WAS	SIGNIFICANT	
REDUCTION	IN	TUMOUR	LOAD	AFTER	TREATMENT	WITHDRAWAL.	FOR	COMPARISON	PURPOSES	
THE	BIOLUMINESCENT	RANGES	ARE	KEPT	SIMILAR	ON	Y	AXIS	HENCE	THE	FINAL	READING	IN	CSA	
GROUP	IS	OUT	OF	THE	SCALE.	BY	THE	END	OF	STUDY	IN	TREATMENT	WITHDRAWAL	GROUP,	ALL	
THE	ANIMALS	HAVE	CLEARED	THE	TUMOUR	LOAD	FULLY.	 4-154	
FIGURE	68	 DIRECT	COMPARISON:	TREATMENT	WITHDRAWAL	WISTAR	V	LEWIS.	ALTHOUGH	WELL	
MATCHED	ANIMALS	SHOWED	SIGNIFICANT	TUMOUR	REJECTION	AFTER	TREATMENT	
WITHDRAWAL,	THE	POORLY	MATCHED	LEWIS	ANIMALS	WERE	MOST	EFFECTIVE	IN	ELIMINATING	
COMPLETE	TUMOUR	LOAD.	THESE	RESULTS	WERE	CLEAR	IN	CSA	GROUP,	AS	THERE	WAS	
SIGNIFICANT	TUMOUR	LOAD	AT	THE	TIME	OF	WITHDRAWAL	OF	TREATMENT.	 4-155	
FIGURE	69	 SIROLIMUS	TREATMENT	LOW	DOSE.	THERE	WAS	NO	DIFFERENCE	BETWEEN	WELL-
MATCHED	AND	POORLY	MATCHED	STRAINS.	THIS	WAS	MOST	LIKELY	DUE	TO	EFFECTIVENESS	OF	
SIROLIMUS	AS	AN	ANTI	NEOPLASTIC	AGENT,	LEAVING	BOTH	ANIMAL	STRAINS	WITH	VERY	LITTLE	
TUMOUR	LOAD	AT	THE	TIME	OF	TREATMENT	WITHDRAWAL.	 4-157	
FIGURE	70	 DIRECT	COMPARISON	BETWEEN	WISTAR	RATS	ON	CSA	(LEFT)	OR	SIROLIMUS	HIGH	DOSE	
(RIGHT)	IMMUNOSUPPRESSION.	AS	OPPOSED	TO	STEADY	INCREASE	IN	TUMOUR	LOAD	WITH	CSA,	
THERE	WAS	COMPLETE	ELIMINATION	OF	BIOLUMINESCENT	SIGNALS	WITH	SIROLIMUS.	 4-158	
	FIGURE	71	 DIRECT	COMPARISON	BETWEEN	LEWIS	RATS	ON	CSA	OR	SIROLIMUS	(HIGH	DOSE)	
IMMUNOSUPPRESSION.	AS	OPPOSED	TO	STEADY	INCREASE	IN	TUMOUR	LOAD	WITH	CSA,	THERE	
WAS	COMPLETE	ELIMINATION	OF	BIOLUMINESCENT	SIGNALS	WITH	SIROLIMUS.	 4-158	
FIGURE	72	 DIRECT	COMPARISON	BETWEEN	WISTAR	RATS	ON	CSA	OR	SIROLIMUS	(LOW	DOSE)	
IMMUNOSUPPRESSION.	AS	OPPOSED	TO	STEADY	INCREASE	IN	TUMOUR	LOAD	WITH	CSA,	THERE	
WAS	COMPLETE	ELIMINATION	OF	BIOLUMINESCENT	SIGNALS	WITH	SIROLIMUS.	 4-159	
FIGURE	73	 DIRECT	COMPARISON	BETWEEN	LEWIS	RATS	ON	CSA	AND	SIROLIMUS	(LOW	DOSE)	
IMMUNOSUPPRESSION.	AS	OPPOSED	TO	STEADY	INCREASE	IN	TUMOUR	LOAD	WITH	CSA,	THERE	
WAS	COMPLETE	ELIMINATION	OF	BIOLUMINESCENT	SIGNALS	WITH	SIROLIMUS.	 4-160	
FIGURE	74	 DIRECT	COMPARISON	BETWEEN	WISTAR	RATS	ON	CSA	OR	LEFLUNOMIDE	
IMMUNOSUPPRESSION.	AS	OPPOSED	TO	STEADY	INCREASE	IN	TUMOUR	LOAD	WITH	CSA,	THERE	
WAS	GRADUAL	REDUCTION	OF	BIOLUMINESCENT	SIGNALS	WITH	LEFLUNOMIDE.	 4-161	
FIGURE	75	 PALPABLE	TUMOUR	IN	THE	RIGHT	FLANK	AT	THE	SITE	OF	INJECTION	4	WEEKS	PRIOR.	ON	
RIGHT,	COMPARISON	WITH	A	STANDARD	21	GAUGE	NEEDLE.	THIS	WAS	A	LEWIS	RAT	WITH	
CONTINUED	CYCLOSPORINE	IMMUNOSUPPRESSION	FOR	4	WEEKS.	 4-162	
FIGURE	76	 DISSECTION	OF	THE	RIGHT	FLANK	SKIN	OFF	THE	VENTRAL	ABDOMINAL	WALL.	THE	
TUMOUR	CLEARLY	VISIBLE	WITH	EVIDENCE	OF	INCREASED	VASCULARITY	AROUND	THE	TUMOUR.	 4-162	
FIGURE	77	 DISSECTION	AND	ISOLATION	OF	SUBCUTANEOUS	TUMOUR	IN	A	WISTAR	RAT	WITH	
CYCLOSPORINE	IMMUNOSUPPRESSION.	 4-163	
FIGURE	78	 CUMULATIVE	RISK	OF	CANCER.	CUMULATIVE	RISK	OF	CANCER	(EXCLUDING	NON-
MELANOCYTIC	SKIN	AND	LIP	CANCER)	IN	KIDNEY	TRANSPLANT	RECIPIENTS	BY	AGE	AT	
TRANSPLANTATION	 4-168	
FIGURE	79	 DEATH	RATE	ON	THE	KIDNEY	WAITING	LIST	BY	AGE	GROUP,	1994-2003	(229)	 4-174	
FIGURE	80	 FORWARD	AND	SIDE	SCATTER	OF	INCIDENT	BEAM	OF	LIGHT	AS	A	BASIC	PRINCIPLE	OF	
FLOW	CYTOMETRY.	 5-179	
FIGURE	81	 FORWARD	AND	SIDE	SCATTER.	AN	EXAMPLE	OF	FORWARD	AND	SIDE	SCATTER	OF	CELLS	
SEPARATED	FROM	A	WISTAR	RAT’S	SPLENIC		TISSUE	AFTER	EUTHANASIA.	THE	BIGGER	AND	MORE	
IRREGULAR	THE	CELL	SHAPE	THE	MORE	FSC	AND	SCC	THEY	CAUSE.	 5-180	
FIGURE	82	 BD	FACSCANTO	II	FLOW	CYTOMETER.	MAIN	FLOW	CYTOMETER	IS	ON	THE	LEFT	OF	THE	
PICTURE	AND	THE	DATA	IS	ANALYSED	BY	THE	ATTACHED	COMPUTER	TOWARDS	THE	RIGHT	OF	THE	
PICTURE.	 5-181	
FIGURE	83	 ROLE	OF	CD4+	AND	CD8+	T	CELLS	IN	SKIN	ALLOGRAFT	REJECTION.	DEPLETION	OF	CD8+	
CELLS	DID	NOT	HAVE	MUCH	EFFECT	ON	ALLOGRAFT	REJECTION	(SIMILAR	TO	CONTROLS).	WITH	
CD4+	CELLS	DEPLETION	THERE	WAS	ONLY	A	MODEST	INCREASE	IN	THE	ALLOGRAFT	SURVIVAL	
WHICH	WHEN	BOTH	THESE	CELL	POPULATIONS	WERE	DEPLETED	THEN	THERE	WAS	SIGNIFICANT	
INCREASE	IN	THE	SURVIVAL	OF	THESE	ALLOGRAFTS.	THIS	STUDY	HIGHLIGHTED	THE	IMPORTANCE	
OF	BOTH	THESE	CELLS	IN	REJECTION.	 5-182	
FIGURE	84	 REPRESENTATIVE	FLOW	DATA	SHOWING	THE	METHOD	OF	ANALYSIS.	SPLENIC	CELLS	ARE	
ISOLATED	AND	STAINED	TO	DETECT	ANTIGENS.	THE	CELLS	ARE	FIRST	ANALYSED	BY	FORWARD	
SCATTER	AND	SIDE	SCATTER	TO	IDENTIFY	LYMPHOCYTES.	THE	LYMPHOCYTE	POPULATION	IS	
GATED	(P1)	AND	THE	GATED	POPULATION	IS	THEN	ANALYSED	BY	FLUORESCENCE.	IN	THE	
REPRESENTATIVE	EXAMPLE	SHOWN	THE	LYMPHOCYTES	WERE	ANALYSED	TO	DETERMINE	THE	%	
OF	CD4+,	CD25+	CELLS	 5-190	
FIGURE	85	 COMPARISON	OF	CD4+	CELLS.	THE	DIFFERENCE	BETWEEN	THE	CD4	CELLS	DISTRIBUTION	
BETWEEN	LEWIS	AND	WISTAR	RATS.	THE	DIFFERENCE	WAS	STATISTICALLY	SIGNIFICANT	(P	0.028)	 5-193	
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1.1	 RENAL	FAILURE	
	
	
1.1.1	 	 Background	
	
Renal failure is one of the most common chronic medical problems with 
significant short and long-term morbidity and mortality.  The definition of chronic 
kidney disease is based on the presence of kidney damage (albuminuria) or 
decreased kidney function (glomerular filtration rate [GFR] <60 mL/min per 1.73 
m.) for 3 months or more, irrespective of clinical diagnosis (1)(2). 
The biggest issue with chronic kidney disease is of the insidious onset in most 
of the cases and presentation with the end organ dysfunction that is irreversible, 
making the early diagnosis of paramount importance to halt further end organ 
damage.  
End stage renal failure (ESRF)/Renal failure is defined as a GFR of less than 15 
mL/min per 1.73 m2, or the need for treatment with dialysis or transplantation(3).  
Aetiology of renal failure varies considerably and includes hypertension, 
diabetes mellitus, glomerular disease, polycystic kidney disease, urological and 
congenital problems among a long list of causes. Most of the causes of renal 
failure can affect the transplanted kidney as well, hence the need to control the 
underlying disease is of paramount importance in the long run(4)(5).  
Apart from the excretion of waste products, kidneys perform other very 
important functions including blood pressure control via renin angiotensin 
system, secretion of erythropoietin (85% of total body erythropoietin is secreted 
by interstitial cells of kidneys), acid base balance and conversion of 25 
hydroxycholecalciferol (storage form of Vitamin D) to 1, 25 
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dihydroxycholecalciferol (active form of vitamin D). 
 
1.1.2	 	 	Clinical	features	
	
The initial stages of chronic kidney disease are usually asymptomatic. Even 
during the late stages the features can be quite non-specific and in some cases 
leads to a late diagnosis. Peripheral oedema, uraemic symptoms, hypertension, 
anaemia leading to fatigue, reduced exercise capacity and in severe cases to 
heart failure. Other features include metabolic disturbances, uraemic 
encephalopathy, neuropathy, gastrointestinal, dermatological and immune 
dysfunctions.  
 
1.1.3		Treatment	options	
	
CKD leads to permanent loss of renal function and treatment of the condition is 
thus renal replacement therapy either in the form of dialysis or renal 
transplantation. 
 
1.1.3.1		 	Dialysis	
	
Dialysis was the only form of treatment for ESRF before transplantation. It can 
be either by haemodialysis or by continuous ambulatory peritoneal dialysis 
(CAPD). The basic principle of both forms is diffusion of excess waste products 
across a semi permeable membrane. In haemodialysis, it is the commercially 
available filters across which this diffusion occurs whilst in CAPD, it’s the 
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peritoneal cavity of the renal failure patient that acts as a diffusion membrane.  
There is a need for a vascular connection via either a large bore intravenous 
central line or through an arteriovenous fistula to enable high flow of blood 
required for haemodialysis. This can lead to its own complications including line 
infections, thrombosis, failure of fistulas, aneurysm and upper limb steal 
syndrome.  
Despite the effectiveness of dialysis, patients on dialysis remain unable to 
perform any of the endocrine functions of the kidney needing further 
interventions.  
The third form of renal replacement therapy; hemofiltration is where blood from 
patients is “ultra filtrated” over the semipermeable membrane and is then 
replaced with fluid of appropriate biochemical composition. This form of dialysis 
is usually reserved for acute renal failure. 
 
1.1.3.2		 	Transplantation	
	
Transplantation is the treatment of choice these days for ESRF. This is due not 
only to the improvement in the quality of life but also in the long-term survival of 
the patients(6). With the improvements in donor management, organ 
preservation and transport and continuously improving immunosuppression the 
graft and patient survivals are improving year on year.  
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1.2	 	 RENAL	TRANSPLANTATION	
	
	
1.2.1	 	 History	of	Transplantation	
	
The history of transplantation is long with multiple failures but persistence of 
committed individuals and teams lead to where we are now, where 
transplantation is considered the ideal choice in end stage organ failure. As 
opposed to other surgical fields, success of any organ transplantation required 
not only the perfection of surgical technique, and post-operative patient 
management but also was most heavily dependent on the immunosuppression 
of host, mastering the techniques of organ procurement and preservation as 
well as both the pre-operative and post-operative donor management.  
The biggest technical contribution came from the work of Alexis Carrel in early 
nineteenth century(7). In 1954 Joseph Murray with his team was responsible of 
first successful human transplant between identical twins (8). This was in the 
back draft of multiple unsuccessful attempts of human transplants and was a 
major step forward. The genetic barrier to transplantation was broken in 1959 
when one out of twelve patient survived long term after transplantation from 
non-identical twins after total body irradiation(9).  
The first insight into the rejection as an immunological event was provided by 
the ground-breaking work of P B Medawar in 1944(10). First case of relatively 
successful immunosuppression was in 1960 where methotrexate and 
cyclophosphamide was used in a recipient of her mother’s kidney which worked 
for 147 days(11). Use of cyclosporine as immunosuppressive for kidney 
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transplantation was a major step forward. Since then various refinements to 
existing class of immunosuppressive agents and the introduction of induction 
agents have brought kidney transplantation into the current modern era. 
1.2.2	 	 Transplantation	and	dialysis	
	
It is now known that kidney transplantation confers significant survival benefit 
over the patients over long-term dialysis, but earlier studies were unable to 
show this benefit. Multiple reason have been cited for that observation including 
bias of analysis where in transplant recipients the survival was calculated from 
the time of transplantation as opposed to time of start of the renal replacement 
therapy for the dialysis patients(6)(12)(13).   
Since these early reports all studies comparing the survival have shown 
significant improvement after transplantation across all categories(14)(15)(16). 
In general patients that are put on the waiting lists for transplantation are 
younger and healthier. Thus direct comparison between the mortality of patients 
on dialysis and these patients who later on have transplantation is biased 
towards the transplant group. But even when this bias was removed by studies 
with improved methodology, there was still significant survival benefit for the 
transplant recipients. According to a large study by Wolfe et al. who studied 
228,552 patients on treatment for renal failure with either dialysis or 
transplantation the annual death rate for all patients on dialysis was 2.6 times 
as high as that for patients on the waiting list, and the annual death rate for 
patients on the waiting list was 1.7 times as high as that for transplant 
recipients(17) 
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Figure 1 Comparison of mortality in all patients on dialysis. Wolfe et al.(17) 
 
 
1.3	 TYPES	OF	TRANSPLANTATION	AND	ORGAN	AVAILABILITY	
	
1.3.1	 	 Types	of	Renal	Transplants	
	
Renal transplantation can be broadly divided into living and deceased donor 
transplantation. 
	
1.3.2										Live	donor	transplantation	
	
Live donation (LD) rates have increased steadily in the last decade and now 
accounts for around half of all the transplant procedures performed in the UK 
according to the latest data by NHSBT. The organs could either be from live 
related or live unrelated donors. There are several benefits of live donations 
over the deceased donations which include low rates of delayed graft function, 
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significantly better long term outcomes, LD being an elective procedure it gives 
time for optimisation of the recipient and detailed assessment and consenting of 
the donor. Better outcomes are the direct result of either absent or negligible 
cold ischaemic times and absence of agonal period and primary warm 
ischaemia seen in donation after cardiac death (DCD) donations. Current five-
year graft and patient survivals are 91% and 96% respectively in the UK(18). 
The disadvantage of LD kidney transplants affects solely to the donors in the 
form of operative mortality (1:3000), post-operative complications, time off work 
and possible psychological side effects.  
	
Figure 2  Transplant activities in the UK (2003-2013). Number of deceased and living 
donors in the UK, 2003-2013. (18) 
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1.3.3		Deceased	Donation	
	
1.3.3.1	 Donation	after	Brain	Death	(DBD)	
	
The majority of organs procured from deceased donors are still from brain dead 
donors. The contribution of DBD in the total deceased donor pool has reduced 
over the past 10 years, with around 90% of these organs being DBD in 2003-
2004 to less than 60% in 2012-2013. This source was facilitated by the ethical 
framework established by the Harvard criteria of brain death in 1968(19), as 
before that time all organs had to be  procured after cardiac arrest.  
DBD donation occurs in a relatively controlled environment where the donor is 
declared brain dead after thorough brain stem testing by at least two expert 
clinicians after excluding reversible causes of coma. Although these organs are 
not subject to an agonal period and not primary warm ischaemia they are 
usually exposed to a cascade of damaging cytokines.  
1.3.3.2	 Donation	after	Circulatory	Death	(DCD)	
	
Previously known as Non Heart Beating Donation (NHBD) or Donation after 
Cardiac Death, this form of donation has consistently increased over the past 
few years in the UK and now accounts for more than 40% of all deceased 
donations. The organs are retrieved after the donor has been declared dead 
based on cardio-circulatory criteria. It’s not mere cardiac arrest that is defined 
as the point of death but there has to be a period of “no touch” before the 
patient can be declared dead according to dead donor rule(20). During this 
period, the brain would “die” thereby establishing brain death in addition to 
cardiac death ensuring the absence of pain and irreversibility. After establishing 
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death procurement can then proceed. This means that from the time of 
treatment withdrawal to the actual cardiac arrest the organs will be 
hypoperfused, then there is the period of cardiac standstill, when there is no 
perfusion of the organs at all which finishes when the cold perfusion starts. 
Warm organs with no perfusion leads collectively to organ damage. Based on 
how short these times can be within the permitted limits, DCD organs can be 
divided into Controlled and Uncontrolled. 
 
Controlled DCD  
 
This is further divided into Maastricht Category III and IV. (The term Maastricht 
criteria comes from the Consensus meeting held in Maastricht on Non Heart 
Beating Donation in 1994). Category III donors are the patients in ITU who are 
likely to die when the supportive treatment is withdrawn. The majority of DCD 
donors in UK are from this category. They are controlled because the treatment 
withdrawal only happens when the retrieval team is ready for organ 
procurement, thereby minimising the warm ischaemia times. 
Category IV DCD donation is when patient in ITU suffers brain death but the 
organs are only retrieved after circulatory death. 
 
Uncontrolled DCD 
 
Category I DCD includes dead on arrival to Accident and Emergency 
department. It has to be a witnessed cardiac arrest for these patients to be 
considered for donation.  
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These patients have usually been confirmed as dead outside of the hospital and 
are the type of donors used by The Madrid and Barcelona units (where a doctor 
is present in the ambulance).  
Category II DCD is where resuscitation has been attempted on the patient but it 
has been unsuccessful and the attempt ceases on arrival in hospital where 
death is declared. Only a very small number of organs are generated in the UK 
from these uncontrolled DCD donors as opposed to Spain, which is the world 
leader in donation and has a very well established Extra Corporeal Membrane 
Oxygenation (ECMO) programme to support these organs till they are formally 
retrieved. 
 
1.3.4	 	 Shortage	of	Allografts	
 
With renal transplantation now being recognised as the treatment of choice for 
the renal failure patients, there is increasing demand for new organs. Despite 
the efforts to increase the number of organs, there still remains a wide gap 
between the availability of organs and potential recipients. Over the last decade 
there has been a steady increase in the number of donors and transplants 
mostly from an increasing number of DCD and live-donors. In the last few years 
there has been some decline in the number of patients on the waiting lists but 
still the gap remains wide. There are multiple reasons for this wide gap. Firstly 
due to transplantation being a very successful and relatively safe procedure has 
made way for more elderly patients who years ago would not be considered 
suitable or too high risk for transplantation. The ageing population also means 
that there are more patients with ESRF. Obesity and worsening incidence of 
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diabetes has also increased this number. Plus the very success of 
transplantation has meant that more patients will be suitable for re 
transplantation once the first transplant fails.  
All these factors mean that there has been ever increasing pressure on the 
transplant waiting lists. For many years the annual number of patients added 
onto the waiting lists was fairly static at around 2000 but more recently this 
number has risen to around 3300 per year.  
In the UK there are around 21,000 patients on dialysis while only 7000 are 
currently on the waiting list for a kidney. Although most of these 21,000 patients 
will have significant medical problems precluding consideration for 
transplantation but had there been more organs available, quite possibly more 
of these patients could be considered for a transplant.  
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Figure 3 Discrepancy between the organs available and number of patients on 
transplant waiting list. Number of deceased donors and transplants in the UK, 2003-2013, and 
patients on the active transplant lists. (18) 
 
1.3.5	 	 Improving	organ	availability	
 
With so much stress on the availability of organs, various strategies have been 
used to increase the number of organs. Two broad ways are to improve the 
quality and survival of transplanted organs to reduce the number of patients 
going back on waiting list for a re-transplant and to look for new sources of 
organs. 
1.3.5.1		 Better	Immunosuppression	
	
Immunosuppression is no way near perfect but it definitely has come a long 
way. These days less than 25% of patients suffer acute rejections and early 
graft losses has been rare(21)(22). This better early function also translated into 
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better long term graft survival as the patients with higher post-transplant 
creatinine levels had a slow, steady decline in renal function as compared to 
patients with better function in the initial stages(4). Death with a functioning graft 
is one of the leading cause of graft loss(23). This is due mostly to 
cardiovascular disease, infection, malignancy and diabetes(24).  
Thus along with looking for new and improved immunosuppressive medications, 
there is a great desire to reduce cardiovascular risk factors, one of the biggest 
cause of death post-transplant beyond 1st year.  
 
1.3.5.2	 New	Sources	
 
The search for new sources of organs has been on going for a number of years 
now. With renal transplantation now being established as the gold standard 
treatment for ESRF, there is ever more increasing need to look for new sources.  
Over the years the type of patients accepted for donation has become less 
strict, both due perhaps to improved outcomes secondary to better 
immunosuppression and also due to increasing pressure. This lead to the 
Expanded Criteria Donors (ECD). These are donors over the age of 60 years or 
more; or over 50 years with either hypertension, raised creatinine or death by 
cerebrovascular(25).  
Improved donor management (short cold ischaemia, better perfusate, machine 
perfusion and possibly ECMO etc.) in DCD donors has led to increasing number 
of improved organs available for transplant.  
Similarly dual kidney transplant has been shown to be a viable option for 
marginal organs which otherwise would be discarded due to poor predicted 
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function post transplantation. Again when selected carefully they have shown 
comparable outcomes to standard criteria donors and superior results to ECD 
donors(26). 
For live donation kidney paired donation has the potential to increase the 
organs available for transplantation where there are issues of ABO or HLA 
incompatibility, sensitization of recipients, age or graft size difference(27). There 
are algorithms to create matches in the donor pool by simultaneous 2 way 
exchanges in most cases, although there are examples of more complex 
exchanges in the literature. 
ABO and HLA incompatible transplantation has also helped to increase the 
number of transplants. Ideally, however patients should be transplanted with 
matched ABO and compatible HLA combinations but in the absence of any 
available organs and potential of long wait on the waiting list the long term 
benefits of incompatible transplants out weight the risks(28). 
Despite all these innovative new ways to increase the donor pool, there still is 
an acute need to look for more organs. One such source is by using the kidneys 
removed for small renal cell carcinomas and transplanting them after ex vivo 
resection(29).  
 
 
1.4	 PRIMARY	RENAL	TUMOURS	
	
		
1.4.1	 Incidence	
 
Renal cell carcinoma accounts for around 2% of all cancers worldwide. The 
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majority of kidney cancers are RCC arising from the parenchyma of the kidney. 
The incidence of RCC has increased in Western countries in the last few years 
owing to the widespread use of US and CT scanning(30)(31). 
 
 
 
 
 
	
Figure 4 Incidence of RCC. Over the past decades, the incidence has gradually 
increased. This is due largely to increasing use of ultrasounds and CT scanning in 
clinical practice(32). 
 
 
Most RCC’s are now picked up at an early stage on investigations done for 
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other reasons(33). Furthermore the incidence of RCC in allografts will continue 
to increase as older people donate organs and graft survival is improved by 
better immunosuppression leading to older recipients with long time on 
immunosuppressive medications.  
Longitudinal studies have shown that many small tumours have a slow growth 
pattern with low metastatic spread in tumours of <3 cm(34). This increase in the 
incidence is seen across all stages of the renal tumours but the biggest 
increase has been noticed in the small renal tumours. Autopsy studies have 
shown that RCC are present in 1%–20% of patients dying from unrelated cases, 
meaning that many of the tumours will not prove to be clinically significant in the 
course of patient’s life. Due to these observations it’s not always easy to make a 
management plan for some of the small renal tumours. According to 
Bosniak(35), a series of 43 small renal cell tumours when followed up for a up 
to 8 years showed variable growth. In up to half of these tumours the growth 
rate was less than 4mm/year and when subsequently 29 of these tumours were 
resected the majority came back as RCC with only a few being onchocytomas. 
Despite the majority of these tumours being slow growing there were cases of 
distant metastasis in a few cases even with these small tumours in a 
subsequent series. Although small, the risk of distant spread remains. Thus in 
majority of the cases even these tumours require surgical resection as a 
general rule unless there are specific contraindications. 
	
1.4.2	 		 Clinical	features	and	Staging	
 
Clinical features of renal cell carcinoma can be very non-specific. The most 
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common symptom is haematuria (40%) followed by flank pain and less 
commonly a palpable mass. Other features like malaise, fever night sweats, 
hypocalcaemia and weight loss are the symptoms of advanced disease and 
metastasis.  
Renal carcinomas can also present with paraneoplastic effects due to cytokine 
release from the tumours (interleukin 6, erythropoietin). These can lead to 
hypertension, neuropathy, hypercalcaemia, raised erythrocyte sedimentation 
rate (ESR) and erythrocytosis. 
In the majority of cases RCC presents as an incidental finding on routine 
radiological investigations. The other big category is where the tumour presents 
with distant metastasis or paraneoplastic disease. Only 5-10% of cases present 
with the classic triad of haematuria, flank pain and palpable mass. The staging 
and TNM classification is as soon in table 1. 
 
Table 1. TNM classification and staging for renal cell carcinoma 
 
T1a 
 
 
Tumour < 4 cm in greatest dimension, limited to kidney 
 
T1b 
 
 
Tumour > 4 cm but < 7 cm in greatest dimension, limited to kidney 
 
 
T2 
 
 
Tumour ≥ 7 cm in greatest dimension, limited to kidney 
 
 
T3 
 
 
Tumour extends into major veins or invades adrenal gland or perinephric tissues, but 
not beyond Gerota’s fascia 
 
 
T3a 
 
 
Tumour invades adrenal gland or perinephric tissues but not beyond Gerota’s fascia 
 
 
T3b 
 
 
Tumour grossly extends into renal vein(s) or vena cava below diaphragm 
 
 
T3c 
 
 
Tumour grossly extends into vena cava above diaphragm 
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T4 
 
 
Tumour invades beyond Gerota’s fascia 
 
 
NX 
 
Regional lymph nodes cannot be assessed 
 
 
N0 
 
 
No regional lymph node metastasis 
 
 
N1 
 
 
Metastasis in a single regional lymph node 
 
 
N2 
 
Metastasis in more than one regional lymph node 
 
 
MX 
 
 
Distant metastasis cannot be assessed 
 
 
M0 
 
 
No distant metastasis 
 
 
M1 
 
Distant metastasis 
 
 
 
Stage  T stage N stage M stage 
I T1 N0 M0 
II T2 N0 M0 
III T1 N1 M0 
 T2 N1 M0 
 T3 N0 M0 
 T3 N1 M0 
IV T4 N0 M0 
 T4 N1 M0 
 Any T N2 M0 
 Ant T Any N M1 
TNM classification and staging of renal cell carcinomas Ng et al. (36) 
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1.4.3		Treatment	
	
Surgical treatment of renal cell carcinomas can either be with radical resection 
or Partial nephrectomy. 
For selected small RCC cryoablation or radiofrequency ablation can be utilised 
as primary mode of treatment. 
 
 
1.4.3.1		 Radical	nephrectomy	
	
Total nephrectomy can now either be performed via open or laparoscopic 
approach. It now is regarded as an alternate standard of care for the treatment 
of small renal cell carcinomas due to comparable long-term outcomes with 
partial nephrectomy.  
In classical radical nephrectomy, all the perinephric fat from the level of 
diaphragm is resected to include any local tumour extension, along with 
adrenalectomy and lymph node dissection(37). To prevent the patients from 
becoming adrenal insufficient, adrenal sparing radical nephrectomies are also 
performed. Pre-operative CT scanning is very important in planning the type of 
operation. It provides valuable information about the presence of local 
metastasis to the adrenal gland along with more significant distant disease. 
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The stage of the disease also heavily dictates the appropriateness of the type of 
operation. Tumours bigger than 7cm are best treated with radical nephrectomy, 
as the long-term outcomes are better. Generally patients with larger tumours 
(around 10cm) should have open radical surgery rather than 
laparoscopic(38)(39). 
Anatomical position of the tumour also has important bearing, as generally hilar 
tumours are much more difficult to treat with partial nephrectomy. Lymph node 
involvement or cavoartrial extension also should generally be treated with 
radical surgery(40)(41). 
 
1.4.3.2		 Partial	(Nephron-Sparing)	Nephrectomy		
	
Partial nephrectomy is a relatively new technique for the treatment of renal 
tumours and again can be performed via an open or laparoscopic approach. 
The following factors influence the choice of partial nephrectomy over the 
radical surgery 
- Solitary kidney 
- Small multiple tumours 
- Bilateral disease 
- Conditions predisposing patients to increased incidence of renal 
cancers (e.g. von Hippel-Lindau disease) 
- Patients with either established CKD or predisposed to get CKD 
Generally, most tumours less than 7 cm will be suitable for partial nephrectomy. 
With the long-term recurrence rates and patient survivals being comparable and 
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with the benefit of improved long-term eGFR than the radical nephrectomy 
patients, PN is now the first line treatment.  
During partial nephrectomy, the rest of the kidney should be examined for any 
synchronous tumour as its presence might mean the need to change to a 
radical operation. Again with most of the partial nephrectomies, the adrenal 
gland is left in situ due to low incidence of adrenal metastasis excluding the 
upper pole tumours with direct invasion(42).  
There is potential of leaving some tumour behind if the surgical margins are 
positive. For this reasons some centres routinely perform frozen section to 
confirm resection of positive margins but the evidence is not very clear on the 
use of frozen section as a few studies have indicated no significant difference in 
the recurrence free survival between the two cohorts(43)(44). 
1.4.4		Current	Guidelines	for	treatment		
	
Due to better and wider spread use of cross sectional imaging, there has been 
a steady increase in the number of incidentalomas (incidentally detected 
tumours). This has also meant that most of the renal tumours picked up these 
days are smaller in size, limited to the kidney and have relatively better out 
comes after appropriate treatment.  
There is a huge variation of type of renal tumours and there has been a gradual 
shift towards treating more and more patients with less aggressive surgical 
option of partial nephrectomy. Partly this is because around 20% of renal 
tumours removed turn out to be oncocytomas with very little malignant potential 
at all and RN may not be the best surgical treatment.  
The other big reason behind the shift towards NSS has been the recent 
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longitudinal and few randomized trials which have shown that the long term 
creatinines are better in partial nephrectomy cohort(45)(46)(47).  
This effect of improved renal function is due directly to preservation of the 
number of functioning nephrons. Patient factors and technical aspects such as 
ischaemia times are also important in the final eGFR but where more renal 
parenchyma was resected the eGFR was negatively affected even in PN 
patients(48)(49). 
Due to all these reasons, where technically and clinically feasible partial 
nephrectomy is preferred over the radical surgery.  
There is higher risk of urine leak, fistulas and bleeding (50)(51)(52) in patients 
undergoing partial nephrectomy which may make this procedure not the best 
possible option for a number of patients where the primary goal may be more 
importantly a quick and relatively less complicated procedure than mild to 
moderate preservation of renal function. 
1.4.4.1		 Current	situation	of	treatment	
	
There is also evidence that despite these clear recommendations there are 
large number of patients who undergo RN rather than PN(53). This is due to 
multiple reasons, including local expertise, patients’ choice, tumour anatomy 
and patients’ comorbidities.  
To further explore the current situation at a more local level we audited the 
practice at our hospital (Freeman hospital, Newcastle upon Tyne), which is a 
urology referral centre and has surgeons who regularly perform both radical and 
partial nephrectomies both via open and laparoscopic approaches. 
Table 2. Percentages of patients undergoing radical and partial nephrectomy 
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Year		 Total		 Radical	
Nephrectomy		
Partial	
Nephrectomy		
2004		 21		 18	(86%)		 3	(14%)		
2005		 18		 12	(67%)		 6	(33%)		
2006		 49		 37	(76%)		 12	(24%)		
2007		 42		 23	(55%)		 19	(45%)		
2008		 31		 19	(62%)		 12	(38%)		
 
The above table indicates the number of small renal tumours removed at our 
hospital alone. The pattern of surgery has been changing with more partial 
nephrectomies by keyhole surgery, which obviously wouldn’t be suitable for 
secondary procedure. However even with this there were 19 nephrectomies in 
2008. All of these kidneys could have been transplanted by the Cincinnati 
criteria (to be explained later). These numbers are from a centre with 
laparoscopic urological surgery available; many units around the UK don’t have 
this facility and therefore potentially do more radical nephrectomies for small 
renal cancers. If we could determine how we could treat inadvertent transfer of 
tumour cells in the presence of immunosuppression we could develop a safer 
strategy of using such kidneys and so develop an alternative source of donor 
organs. 
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1.5	 POTENTIAL	OF	USING	ORGANS	FOR	TRANSPLANTATION	
AFTER	TUMOUR	RESECTION	
	
	
1.5.1		Literature	review	
	
1.5.1.1	 Transplantation	after	partial	nephrectomy	
	
Normal practice when confronted with a tumour of kidney on procurement is to 
return it to the donor and not use any other organs (54). In cases of deceased 
donors it meant that the contralateral kidney couldn’t be used as well because 
of the concerns of micro metastasis and bilaterality of some of the renal cell 
carcinomas (RCC). Penn (55), reviewing the Cincinnati transplant tumour 
registry (CTTR), described a total of 14 cases of ex vivo resection of small renal 
cell cancers detected incidentally followed by transplantation. Frozen section 
was employed, and where margins were clear, kidneys were used although it is 
not clear whether all of the tumour bearing kidneys underwent frozen section. 
Of the cadaveric donors, the contralateral kidneys, all of which appeared 
healthy, were transplanted as well. Apart from these cases of renal carcinomas, 
there was one case of oncocytoma within the kidney, which was transplanted 
after resection. Of all the cases where the tumour was adequately resected 
before transplantation there was no recurrence in a follow-up ranging up to 210 
months. Buell et al. (54) presented 14 cases of transplantation after renal 
tumour resection from the same database as used by Penn. No recurrence has 
been noted up to a follow-up of 200 months. Median tumour size was 2.0 cm 
(range 0.5– 4.0 cm) and all were of low histological grade. They have described 
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two further cases since the initial data review with no recurrence and good graft 
function. A similar case series from Australia (56) only included elderly 
recipients or those with significant co morbidities and high chance of death 
without transplantation. Furthermore the recipients had high levels of HLA 
mismatching with the donors and were selected on the basis that if there was a 
recurrence to occur, stopping immunosuppression may help in tumour lysis by 
recipient’s immune response. 41 patients received kidneys after ex vivo 
resection of tumour of which 10 were reported as benign lesion on 
histopathology. One patient returned to dialysis after 30 months. 4 patients died 
of unrelated causes. There was only one recurrence noted 9 years after 
transplantation out of the remaining 30 patients. Notably this tumour recurrence 
was at a distance from the initial resection site, this therefore might not be a 
tumour recurrence but another primary within a “field” change renal tissue. The 
patient refused any further treatment, and the lesion has grown 0.2 cm in 18 
months since diagnosis. In a follow-up study on these patients this group has 
recently published long-term outcomes, which are significantly better than wait-
listed patients on dialysis and are comparable to the live unrelated transplants 
(57). Mannami et al.(58) from Japan published a series of 42 “restored” kidneys 
from live donors. Eight donors with small renal cell carcinoma (<3.5 cm) 
underwent donor nephrectomy and ex vivo resection of the tumour followed by 
transplantation of the kidney. Five patients were alive, three with functioning 
grafts, two died with functioning grafts from unrelated causes, and one was lost 
to follow-up. No tumour recurrence has been noted in any of these patients. 
Another 8 patients had donor nephrectomies, which had benign diseases of 
which 5 had partial resection and kidneys were used for transplantation. Three 
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recipients are alive with functioning grafts, while four have gone back to dialysis 
(after 3,18,51,73 months). One recipient died of unrelated pathology. There 
have also been 6 case reports (59)(60)(61)(62)(63)(64) of live related kidney 
donation when a tumour was detected incidentally in or ex vivo and the kidney 
was transplanted after resection. No recurrence has been noted in any of these 
cases with a follow-up of up to more than 10 years.  
 
 
1.5.1.2	 Partial	Nephrectomy	for	Tumours	Diagnosed	after	
Transplantation	
	
Renal cell carcinoma represents around 4.6% of all the tumours in allograft 
recipients with only 10% of these occurring in the allograft itself (55). The other 
main subgroup is when a tumour was detected after transplant. Again the 
standard practice here has been to perform transplant nephrectomy (65) with 
the patient invariably returning to dialysis and normally being put on a waiting 
list for another transplant if feasible. 
Until now, more than 50 cases of allograft renal cell tumours have been 
described in the literature of which at least 35 cases have had nephron sparing 
surgery (NSS) for their allograft tumour (66)(67)(68)(69)(70)(71)(72)(73)(74). 
Tumour sizes have ranged, from 0.5 to 4.0 cm although there have been two 
case reports of larger (6–8 cm) tumours all being successfully treated with NSS 
(68)(67). Postoperative follow-up is from one month to more than 10 years with 
one recurrence 5 years after NSS in renal allograft (75). This was in a 74-year-
old recipient five years after initial transplant. A 2.4 cm RCC was incidentally 
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detected without any evidence of distant metastasis. It was treated with radical 
nephrectomy and the patient has been disease free on haemodialysis after that. 
		
1.5.1.3	 Contralateral	Transplanted	Kidney	with	a	Renal	
Tumour	
	
These kidneys again are normally not used as RCC can be bilateral especially 
the papillary subtype (76). Penn has described 14 cases in which the 
contralateral kidney was transplanted from patients with renal tumour. One 
patient had recurrence in the allograft, which was removed for rejection. This 
patient died 75 months after transplantation from a de novo cancer of one of his 
own kidneys. The remaining patients did not have any recurrence with a follow-
up ranging from 0.5 to 153 months. 
Nicol et al. (56) described 2 similar cases with no recurrence. Barrou et al. (76) 
has described a case of two allograft recipients from a single donor with a 
tubulopapillary tumour (17mm) in the right kidney; only the left kidney was 
utilized for transplantation. Shortly after transplantation, the recipient underwent 
an ultrasound (US) examination of the allograft, which did not reveal any 
tumour. Three months later a biopsy was done for rejection, which revealed a 
poorly differentiated tumour, and the patient underwent radical allograft 
nephrectomy. No additional chemotherapy was given apart from discontinuation 
of immunosuppression (prednisolone and azathioprine). Lymph nodes that had 
been noted to be enlarged on CT scan disappeared two month after 
nephrectomy. The patient underwent re transplantation two years later and was 
disease free and dialysis independent at 3-year follow-up. Another patient 
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received the heart transplant from the same donor but died from bony 
metastasis from the renal cell carcinoma. 
	1.5.1.4	 Accidental	Transplantation 
 
In at least 4 cases (55)(61)(69)(77) there have been accidental transplantation 
of RCC mistaken as a benign pathology on procurement. Partial 
nephrectomy/enucleation in all these cases was performed before 
transplantation with adequate resection margins. Routine histopathology 
revealed the resected tumour to be malignant. All recipients retained the 
allograft because of complete excision of the tumour and were kept under close 
follow-up with no recurrence so far. The cases where there have been 
transplantation of tumour, either partially resected or unrecognized at the time 
of transplant have resulted in disastrous outcomes (55)(76)8. 
 
 1.5.1.5	 	Miscellaneous	
	
Manammi et al.(58) reported a series of 8 patients who underwent nephrectomy 
for a distal ureteric transitional cell carcinoma (TCC). One patient had a 
recurrence of TCC after 15 months and was offered graft nephrectomy but 
opted for partial resection of ureteric tumour to prevent returning to dialysis. He 
died three years after partial resection from a squamous cell carcinoma of lung 
with liver metastasis. His TCC also had squamous metaplasia and a DNA study 
to determine exact origin of primary tumour could not be established because of 
inadequate tissue samples. The remaining patients were either alive with 
functioning grafts or died of unrelated causes. 
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	1.5.1.6	 	Opinion	of	Patients	and	Transplant	Specialists 
 
Transplantation of kidneys with cancers is a novel idea not only among patients 
but also among the transplant community. To be able to exploit this potential 
donor pool it is of utmost importance that both the health care specialists; 
transplants surgeons and nephrologists and the patients (both donors and 
recipients) are comfortable with the idea of using such kidneys. To determine 
this, structured questionnaires were sent to focus group of patients on the North 
East renal transplant waiting list, post nephrectomy patients for small renal 
cancer, nephrologists and transplant surgeons in the UK. 
Results are shown in Table 3 and have a generally high response rate. Those 
respondents that had lost their kidney, removed for tumour, had the highest 
consent rate and patients potentially receiving such kidney the lowest. The 
transplant surgeon and nephrologists had views somewhere in between. This 
survey was done in UK from where there have been no case reports of using 
organs after removal of tumour and but still the response was largely 
favourable. Given that since this survey there has been an increase in total 
number of such organs being utilized, one can extrapolate that current belief 
may be more favourable. 
Table 3: Opinions of transplant patients and clinicians  
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Opinion of Patients and Transplant Specialists (29) 
 
	1.5.1.7	 	Summary	of	literature	review  
 
One of the worries about transplantation of tumour-affected kidneys is the 
potential of tumour recurrence and growth in a state of potential immune 
inattention due the immunosuppressive therapy. Renal cell carcinoma is known 
to be an immunogenic tumour (78) but in the presence of immunosuppression? 
If there was any transplantation of tumour cells in the host, then there is a 
potential of continued growth in a host with a compromised immune system. 
Furthermore, immunosuppression in itself has been known to increase the 
incidence of de novo malignancy (79)(80). Because of these concerns, an 
immunosuppressive agent with no potential to increase de novo malignancy 
and better still to have antitumour activities would probably be ideal.  
The incidence of RCC has increased in Western countries in the last few years 
owing to the widespread use of US and CT scanning (81)(33). Most RCC are 
now picked up at an early stage on investigations done for other reasons. 
Furthermore the incidence of RCC in allografts will continue to increase as older 
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people donate organs and graft survival is improved by better 
immunosuppression. Longitudinal studies have shown that many small tumours 
have a slow growth pattern with low metastatic spread in tumours of < 3 cm 
(82)(34). Autopsy studies have shown that RCC are present in 1–20% of 
patients dying from unrelated cases, meaning that many of the tumours will not 
prove to be clinically significant in the course of patient’s life (83)(84). 
The gold standard treatment of resectable renal cell carcinoma has been radical 
nephrectomy. Recent evidence has changed this practice dramatically as 
survival after radical nephrectomy (RN) and partial nephrectomy (PN) has 
shown to be comparable (85). Favourable outcomes have been observed after 
NSS for < 4 cm RCCs and RN has been described as “surgical overkill” (86) for 
these tumours. 
Furthermore, local recurrence after NSS has been reported to be < 5% with 
recurrences mostly associated with large and multifocal tumours. A significant 
risk of dying in patients on dialysis particularly in older patient has been one of 
the driving forces to increase the number of kidney donors. Renal 
transplantation seems to confer a substantial survival advantage over dialysis in 
patients with end-stage renal failure (87). A significant number of patient 
accepted for dialysis are older patients, who have a mortality risk of 25%. With 
longer waiting times for a transplant, it is inevitable that many of the patients will 
die before they can receive a transplant which would have improved their 
quality of life and longevity(87). Furthermore 16 to 23% of suspicious lesions 
resected from kidneys are either benign or of low malignant potential (88)(89) 
and not using these kidneys with small tumours after partial nephrectomy for 
transplantation seems wastage of precious organs when one considers the 
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benefits of transplantation over dialysis. 
 
A suspicious lesion found at multiorgan retrieval should have an excision biopsy 
and histological confirmation of clear margins before any of the organs can be 
transplanted. A malignant lesion in the kidney when unrecognized and 
transplanted continues to grow under the immunosuppression carries high risk 
of metastasis and can result in fatal outcome. If the biopsy confirms clear 
margins with favourable histology then these organs could be used for 
transplantation, as risk of recurrence is very low. The situation is more complex 
when it comes to using restored organs from live (related/unrelated) renal cell 
carcinoma patients. Major difference being that these are living cancer patients 
first and therefore must never be treated primarily as potential organ donors to 
prevent any bias in treating their primary problem which may lead to provision of 
less than optimal treatment and ultimately harm to these patients. This is shown 
by Takahara et al. (90) in their review of Mannami et al. series concerning a 
ureteric carcinoma patient, where adherence to standard practice for treating 
these tumours was not practiced with disastrous consequences. With changing 
trends, radical nephrectomy is now regarded as an alternate standard of care to 
partial nephrectomy for T1a tumours when partial nephrectomy is not 
technically feasible. This is due to the comparable oncological outcomes after 
partial nephrectomy and evidence that radical nephrectomy is an independent 
predictor of low GFR. A positive outcome for a recipient can never justify harm 
to a live donor; on the contrary, for a transplant with a live donor to be regarded 
as a success means that both the recipient and the donor have done well(91). 
Live related donors in Nicol et al. series were given the options of observation, 
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radical or partial nephrectomy without any mention of the possibility of use of 
organs for transplantation. Only after the patients had decided to opt for radical 
nephrectomy possibility of domino donation was discussed. This approach has 
the benefit of making sure that patients make their own decisions without any 
pressure from clinicians. Another important factor is to make sure that beliefs of 
the clinician do not affect the patient’s treatment choices. 
Importance of detailed informed consenting cannot be over emphasised for the 
recipients of such restored organs. All the relevant information especially of the 
origin of the organ and potential of recurrence and associated risk must be 
discussed fully and the patients understanding checked. Routine follow-up of 
the patients with annual US have been suggested to make sure any recurrence 
is diagnosed as early as possible. Tumours have been detected at early stage 
with better outcomes because of regular follow-ups. If one kidney is found to 
have a tumour it is important that the other kidney is closely followed up. It is 
easier in the live donor setting when the donor can be carefully followed up but 
in cadaveric donation there has to be a central database for tracking the 
contralateral kidney (70) which might be transplanted into a recipient in a 
different unit.  
Immunosuppression is essential after transplant and unfortunately this has been 
associated with the higher incidence of cancers in recipients as opposed to the 
general population (80). Certain newer immunosuppressive agents have anti-
tumour (92) activity and their use can, in theory not only reduce the chances of 
recurrence but they can also be used to treat patient should a recurrence occur. 
 
Furthermore the Human Tissue Act 2004 (93) that covers the use of organs for 
Chapter	1—35	
	
transplant in the UK allows anyone to be a donor including live related and 
unrelated (altruistic donor) provided there is adequate consenting. This means 
that donation can also occur from patients suffering from small renal cell 
carcinoma who have radical nephrectomy as primary treatment provided 
measures are taken to ensure that these patients are treated appropriately in 
the first place and both donor and recipients had given informed consent. 
 
1.6	 	 ROLE	OF	IMMUNOSUPPRESSION	IN	
TRANSPLANTATION	
 
Longevity of successful renal transplants relies most heavily on perioperative 
and postoperative immunosuppression. Refinements in selection of patients, 
surgical techniques and HLA matching all have important role in allograft 
survival but the biggest improvement in graft survival was noted with the 
introduction of cyclosporine immunosuppression.  
1.6.1	 	 Evolution	of	immunosuppressive	agents	
	
Since the introduction of renal transplantation into clinical practice various 
strategies have been utilised to prevent the rejection. This included 
transplantation from identical twins, whole body radiation followed by bone 
marrow transplantation along with renal transplantation during the very early 
days of transplantation. Although it was initially thought that the success of 
transplantation was dependent on simultaneous bone marrow and renal 
transplantation, later it was shown that some success could be achieved with 
cytoablation and corticosteroids.  
After initial success, the next logical step was to look for immunosuppressive 
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medications to prevent rejection. The initial work was done with methotrexate 
and cyclophosphamide, which lead to severe bone marrow depression but 
moderate allograft survival (143 days) without needing bone marrow ablation. 
This lead to the development of the less toxic 6-mercatopurine and later 
azathioprine which though variable in success but at least was not as morbid to 
recipients as frequently. Azathioprine inhibits DNA and RNA synthesis by 
interfering with the purine synthesis. This in turn blocks the lymphocyte 
proliferation and the production of interleukin 2 (IL-2). 
Another improvement in immunosuppression came in 1960s in the form of 
heterologous anti-lymphocyte globulin (ALG)(94). It was used with azathioprine 
and improved allograft survival further but due to its heterologous nature it was 
used more for rescue of rejection occurring after transplant. The more ‘refined’ 
monoclonal OKT3 superseded it for a short time though most transplant 
specialists preferred the side effects of ATG to those of OKT3 (the first 
monoclonal antibody against all T cells). 
During this period there were steady improvements in allograft survival but the 
biggest change came about with the introduction of cyclosporine in early 1980s 
when it was shown to significantly reduce acute rejection rates seen early soon 
after transplantation. This point in transplantation is often regarded as a major 
breakthrough as it paved the way for other solid organ transplantations. These 
were mainly the vital organs which though possible to transplant, their 
dysfunction produced death of the recipient. Such that for the transplant 
recipient to survive, success of the simpler non-vital graft had to be sorted first. 
 
 
Chapter	1—37	
	
1.6.2	 	 Calcineurin	inhibitors	(CNIs)	
	
Cyclosporine (CsA) has been the most widely used CNI up to most of 1980s 
and 1990s for solid organ transplantation until FDA approved tacrolimus in 1997 
which lead to it becoming the first line CNI treatment in most of the developed 
countries. By 2003, around 67% of new kidney transplant recipients were being 
discharged on Tacrolimus as a maintenance therapy(95).  
Although shown to be more potent in preventing rejection than cyclosporine, 
Tacrolimus shares the basic mechanism of action with CsA. 
1.6.2.1	 Mechanism	of	action	
	
Due to lack of precise in vitro tests of acute rejection and its effects on 
transplanted allografts most of the initial understanding of the mechanism of 
action of CsA had been based on its vitro effects on lymphocytes(96). These in 
vitro studies have shown that it is a potent inhibitor of generation of cytotoxic T 
cells as opposed to azathioprine and steroids in patients with solid organ 
transplantation(97). 
The mechanism of action of CsA at molecular level was not described until early 
1990s (98) when it was shown to be mainly as a result of CsA binding to 
cyclophilins in the cell cytoplasms(99).  This complex then binds to Calcineurin, 
a calcium dependent phosphatase that normally has a pivotal role in 
transcription of interleukin-2 (IL-2). Thus Calcineurin inhibition by CsA leads to 
inhibition of IL-2 production and other lymphokines which in turn prevents 
further proliferation of CD4+ T cells and cytotoxic T cells from its 
precursors(100)(101). 
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CsA is also shown to exert its immunosuppressive effects by increasing the 
production of transforming growth factor (TGF)-β both by normal T cells and 
also in individuals with renal transplantation(102). This in turn inhibits IL-2 
production and IL-2 stimulated up regulation of IL-2 receptors, hence affecting T 
cell responses(103). 
1.6.2.2	 Benefits	and	side	effects	
 
Even from the early days of renal transplantation CsA has shown to be more 
effective than azathioprine based immunosuppressive protocols in terms of 
long-term patient and graft survival. This was shown (fig 5) by a multicentre 
European trial in 1993(104) 
 
	
Figure 5 CsA and AzA comparison for long- term graft survival. CsA had better 
survival when compared to AzA (104) 
 
Since then CsA has been used in various combinations with azathioprine, 
steroids, mycophenolate and induction agents with steady improvements of 
graft survival rates. 
The groups of patients benefiting mostly were the elderly, very young, patients 
An excellent randomized multicenter trial was conducted
in Canada, in which cyclosporine and prednisolone therapy
was compared with standard therapy based on azathioprine
and prednisolone in 209 cadaver renal allograft recipients.54
In this first analysis, actuarial graft survival at 1 year was
84% in the cyclosporine group compared with 67% in
patients receiving standard therapy, with patient survivals of
97% and 90%, respective y, in the two groups. At 3 years,
graft survival was 69% in the cyclosporine-treated group
and 58% in the control group, a less striking difference than
in the initial analysis.15 Patient survival was 90% in the
cyclosporine group and 82% in the control group. A detri-
mental effect on graft survival was seen in cyclosporin -
treated patients if they received kidneys that had been
preserved for longer than 24 hours or if the surgical anasto-
mosis time took longer than 45 minutes, suggesting that
cyclosporine nephrotoxicity is more likely to occur in kidneys
that have some ischemic damage.
In Minneapolis, all HLA-mismatched living or cadaver
donor transplants were eligible for a trial in which
cyclosporine plus prednisolone was compared with conven-
tional therapy of azathioprine, steroids, and antilymphocyte
globulin.91,235,236 All patients had had a splenectomy and at
least 5 U of blood before transplantation. The trial com-
prised 230 patients and included cadaver and living related
transplants and diabetic and nondiabetic recipients. Overall
graft survival rates at 2 years were 82% in the cyclosporine
group and 77% in the control group, and patient survival
was 88% and 91%, respectively. In the living related trans-
plants, graft survival at 2 years was 87% in the cyclosporine
group and 83% in the control group, whereas the 2-year
graft survival figures in the cadaver transplants were 78%
and 73%, respectively. These differences in survival were not
significant, but the cumulative incidence of rejection
episodes in the first year after transplantation in the
cyclosporine group was half that in the control group, as was
the incidence of infection.
Similarly, Starzl and colleagues,313,314 first at Denver
(where treatment was not standardized) and then at
Pittsburgh, reported impressive results with cyclosporine
and prednisolone (at a maintenance dose of 20 mg/day after
a burst of high-dose prednisolone) in primary and second-
ary cadaver transplants. Graft survival was about 90% at 
1 year in primary cadaver transplants. In 26 patients 
who received 27 cadaver second transplants, 1-year graft 
survival was 78%. After that initial experience, virtually all
contraindications to the use of cyclosporine in renal trans-
plantation were disregarded, and in 96 primary cadaver
grafts, patient survival at 1 year was predicted as 90%, and
graft survival was predicted as 80%.314 Early anuria was not
considered a contraindication to cyclosporine, which was
sometimes considered to be the result of rejection or
nephrotoxicity, or both, although it did cause diagnostic
problems in the anagement of patients.
In the Sydney controlled trial of cyclosporine versus aza-
thioprine, prednisolone, and antilymphocyte globulin,
60 patients receiving first cadaver grafts were entered, and
graft survival of 70% at 1 year was similar in both groups.
P rsistent anuria after transplan ation was a major problem
in the cyclosporine group.297 In the Oxford trials, all patients
were started on cyclosporine, but were randomly assigned at
3 months either to azathioprine and prednisolone or to
remain on cyclosporine. The objective was to reduce
nephrotoxicity.227,229 This approach is discussed later in this
chapter.
This early experience with cyclosporine in prospective
controlled trials and in uncontrolled observational studies
indicated that cyclosporine was a major advance in
immunosuppressive therapy, as was evident in the
Collaborative Transplant Study, which had data from more
than 200 transplant centers and several thousand renal
transplants.249 Many side effects had become evident, the
major one being nephrotoxicity, and so subsequent proto-
cols were designed to obtain the same improved immuno-
suppression achieved with cyclosporine, but with 
a reduction in side effects resulting from lower doses of
cyclosporine (Table 16-2).
CYCLOSPORINE WITH OR WITHOUT
STEROIDS
The initial use of cyclosporine in Europe was based on the
experimental data and the early Cambridge experience,
using a high dose of cyclosporine alone (monotherapy),
whereas in North America cyclosporine was used with
steroids. Gradually, most units added steroids to their
cyclosporine protocols, but not with any convincing evi-
dence that steroids were necessary. In the United States, there
had been a tendency to use high-dose steroids, at least in the
early weeks after transplantation. Four prospective con-
trolled trials comparing cyclosporine alone with
cyclosporine and steroids were performed.83,123,160,210,316
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Figure 16–1 Graph showing actual graft
survival with cyclosporine compared with aza-
thoprine and steroids, one of the first random-
ized controlled trials of cyclosporine versus
azathioprine and steroids.16
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with diabetes and sensitized patients as in pre cyclosporine era most of these 
patients were thought not suitable for transplantation. 
Despite being a revolutionary drug in the field of transplantation CsA is not 
without its side effects. The most important side effect is of nephrotoxicity, 
which can be immediate, acute or chronic.  
Acute nephrotoxicity is thought to be the result of reduction in blood flow and 
increased vascular resistance. It is quite important to differentiate this from 
acute rejection as the treatment course is completely opposite for these two 
conditions. 
Chronic CsA nephrotoxicity is also a big problem in the long term and is thought 
to be a result of increased circulating levels of TGF-ß. 
Apart from major nephrotoxic side effects, CsA can cause hypertrichosis, 
hyperkalemia, hypomagnesemia, hyperuricaemia, glucose intolerance, 
reversible hepatotoxicity, neurological disturbances and minor gastrointestinal 
upsets. 
1.6.2.3	 Cancer	risk	
	
One of the other most serious adverse effects of CsA is development of 
neoplasia. As with other immunosuppressive medicines there is an increase in 
the incidence of lymphomas(105) and skin cancers post solid organ 
transplantation. The normal tumour scavenging ability of the competent immune 
system is disabled leading to more aggressive and invasive tumours. 
The effects of CsA on tumour development are studied in detail and it is 
believed that the overall level of immunosuppression is also important as well 
as the specific agents used. It has been shown by Hojo that, independent of its 
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immunosuppressive effect, CsA can lead to morphological changes including 
increased cell motility and anchorage independent invasive growth leading to 
increased number of metastasis in a mouse model. These effects were 
attributed to the raised TGF-ß levels associated with CsA treatment as these 
were counteracted by anti TGF-ß monoclonal antibodies(106). Tumour 
angiogenesis by vascular endothelial growth factor dependent mechanism can 
also account for the increased incidence of tumours with CsA treatment (107) 
as opposed to Rapamycin.  
CsA also increased IL-6 production in Epstein Barr virus infected cells which 
leads to increased proliferation of B cells and possibly be the cause of 
lymphoproliferative disorders(108).  
 
1.7	 NEWER	IMMUNOSUPPRESSIVES	WITH	ANTI-NEOPLASTIC	
EFFECTS	
	
The search for an ideal immunosuppressive agent did not stop after CsA 
showed initial promising results as it had some major side effects in the long run 
especially chronic allograft nephrotoxicity blunting the initial advantage over 
contemporary immunosuppressives and also the increased incidence of cancer. 
Sirolimus, everolimus and Leflunomide are a few agents, which have both the 
immunosuppressive properties and also are known for anti-neoplastic effects. 
1.7.1			Mammalian	Target	of	Rapamycin	(mTOR)	inhibitors	
	
Two of the most common mTOR inhibitors are Sirolimus and Everolimus. Most 
of the animal and clinical studies for mTORs have been done with Sirolimus. 
These agents are very closely related to each other although in future there 
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may emerge some important clinical differences.   
1.7.1.1	 Mechanism	of	action	
	
Sirolimus is a fermentation product of the microorganism Streptomyces 
hygroscopicus. It is a potent inhibitor of T and B cells as a response to antigen 
stimulation. For the activation of lymphocytes there has to be interaction of 
interleukins and IL receptors as well as co-stimulatory molecules (CD28), which 
then leads to activation of TORC1 complexes. Sirolimus binds to FK binding 
protein 12(FKBP 12) and this complex blocks the activation of TORC1 complex 
leading to cell cycle arrest in late G1 phase(109). 
It also has a direct inhibitory effect on the apoptosis of dendritic cells which 
have a pivotal role in the transplant immunology(110). It also inhibits cytokine 
and growth factor stimulated proliferation of the fibroblasts, tumour cells and 
smooth muscle cells(111)(112)(113). 
 
1.7.1.2	 Role	in	transplantation	
 
There have been several studies looking at the role of sirolimus either as a 
primary immunosuppressive agent or as a replacement of cyclosporine. The 
Sirolimus European Renal Transplant Study Group, which looked at first 
cadaveric renal transplant recipients receiving either CsA based or sirolimus 
based primary immunosuppression showed very similar graft and patient 
survivals as well as episodes of acute rejections(114). Similar results were 
noted when azathioprine used in the above-mentioned study was replaced with 
mycophenolate mofetil (MMF). The acute rejection rates and patient and graft 
survivals were similar with different side effect profile(115). An RCT performed 
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in 2006 compared sirolimus MMF and prednisolone with tacrolimus based 
immunosuppression and again showed these two to be comparable although 
the acute rejection rate was higher in sirolimus based regime but it did not reach 
statistical significance(116). Two large trials from USA showed significantly 
improved acute rejection rates and graft survivals with CNI based 
immunosuppression when compared to sirolimus based treatments(117)(118). 
The Rapamune US study group showed reduced acute rejection rates with 
sirolimus when compared with azathioprine in CsA and steroid based regimes 
but the 12-month creatinine was lower in sirolimus group(119).  
Sirolimus has also been used as sole agents in the maintenance phase of 
immunosuppression after transplantation. One of the first big trials with more 
than 400 patients from Manchester showed better creatinine clearance in the 
sirolimus arm when it was used as a maintenance immunosuppressive after the 
withdrawal of CsA at 3 months post transplant(120). An RCT from Cambridge 
suggested that the impaired graft function possibly due to CNI nephrotoxicity 
could be reversed with sustained improvement at 2 years post transplant by 
conversion to sirolimus at three months. This along with other similar studies 
point to potential benefits of sirolimus as a maintenance agent in terms of graft 
function and to potentially reduce the incidence of chronic allograft 
nephropathy(121). 
1.7.1.3	 Side	effects	
	
It was the result of large studies where sirolimus was used alone rather than in 
combination with CsA that shed light on potential side effects of sirolimus. Most 
of the side effects are the result of the immunosuppressive and anti proliferative 
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effects although some remain to be clearly explained so far.  
The risk of infection is not much different from other immunosuppressive 
agents. This effect is most probably due to its immunosuppressive properties. 
Hyperlipidaemia can be a problematic side effect as most of the renal transplant 
patients are arteriopaths as well and are already at a high risk of heart disease. 
More than half of the patients on sirolimus treatment develop increased levels of 
triglycerides and cholesterol, which may also have implication with chronic 
allograft rejection(122). 
Among one of the most serious side effects is pneumonitis. Symptoms can vary 
from fever, fatigue cough to pulmonary failure. 
From a surgical point of view, delayed wound healing is an important side 
effect. This may lead to skin and soft tissue infections or poor wound healing 
internally at the anastomosis sites e.g. ureteric anastomosis. These effects 
have been linked to its effects on fibroblasts and neovascularization. 
Developments of lymphocoeles are also more common in patients on sirolimus 
treatment. 
Other side effects include skin rashes sometimes needing dose reduction or 
even withdrawal of treatment, anaemia, thrombosis, aphthus ulcers, proteinuria 
among other minor side effects. 
1.7.1.4	 Effects	on	neoplasia	
	
mTOR inhibitors belong to the relatively new group of immunosuppressive 
medications, which have some anti tumour potential as well. This effect can be 
very useful as all the patients on immunosuppression are at an increased risk of 
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developing malignancies and if a good immunosuppressive agent can also be 
able to have potent anti tumour properties then it can solve this major issue. 
Both in vitro and in vivo studies have shown that sirolimus has both these 
properties. Although mTOR inhibitors have potent immunosuppressive effects, 
which in itself are risk factors for tumour cells to evade one’s immune system, 
but it’s anti tumour effects are significantly potent as well. 
There are several studies which suggest that with sirolimus based 
immunosuppression the over all rates of de novo malignancies are significantly 
less than CsAs. A large retrospective analysis was performed on post transplant 
malignancies in more than 33 thousand deceased donors from 264 centres in 
USA. This study looked at both the skin and non-skin solid organ malignancies 
rates and showed that the rate of malignancies with sirolimus/everolimus and 
mTOR plus CNI combination was 0.6% as compared to CNI alone which was 
1.81%(92).  
Efficacy of mTOR inhibitors has also been shown in cases of advanced renal 
cell carcinoma. A large double blind trial randomised 272 patients into an 
Everolimus group and 138 in a placebo arm for the treatment of advanced renal 
cell carcinoma. There was progression of disease in 37% of patients in the 
treatment arm as opposed to 65% in the placebo arm (p 0.0001) with a median 
disease free survival of 4.0 versus 1.9 months(123). 
Similar encouraging results were noted when Everolimus was used for the 
patients with advanced pancreatic neuroendocrine tumours. 207 patients in the 
treatment were compared with 203 patients in placebo arm and were found 
have significantly better progression free survival of 11 months as compared to 
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4.6 months in the placebo arm (p <0.001). 34% of patients were still alive at 18 
months as compared to 9% with placebo(124). 
mTOR inhibitors were found to be useful in hepatocellular carcinomas and in 
advanced breast carcinomas as well(125)(126). 
mTORs have been shown to be effective for the post transplant 
lymphoproliferative disorders as well. A case of complete remission of 
disseminated PTLD has been reported in literature after conversion to 
sirolimus(127). 
With an increasing cohort of patients on immunosuppression post transplant 
there is an increasing incidence of Kaposi’s sarcoma. mTOR inhibitors have 
been found useful for their treatment as well. A case series of 25 patients with 
cutaneous Kaposi’s sarcoma when converted from cyclosporine to sirolimus 
showed complete biopsy proven remission within 6 months of treatment(128). 
These effects of mTOR inhibitors are very encouraging and over the past 10 
years there has been mounting evidence on their efficacy. Although by no 
means these are the perfect solutions but a medication to be 
immunosuppressive and anti neoplastic in transplant setting is very useful 
feature that we wished to explore. 
1.7.2	 	 Leflunomide	
	
Leflunomide has also been used for immunosuppression after solid organ 
transplantation with variable success. It has been the analogues of the 
metabolites of Leflunomide that have shown most promise, as the half-life of the 
drug is more manageable. The metabolites of leflunomide are called 
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malononitrilamides (MNAs) and FK778 is the most common and well-studied 
agent in organ transplantation. 
Currently leflunomide is used approved as a disease-modifying agent for 
rheumatoid arthritis, although there are several possible applications of this 
drug. 
1.7.2.1	 Mechanism	of	action	
	
Leflunomide exerts its immunosuppressive and anti-inflammatory effects 
through multiple pathways. The most important mechanism of action is the 
inhibition of pyrimidine synthesis. Activated lymphocytes depend exclusively on 
the de novo synthesis of the uridine monophosphate, as they are unable to use 
the pyrimidine salvage pathway. Leflunomide inhibits the mitochondrial enzyme, 
dihydroorotate dehydrogenase which is responsible for the production of 
pyrimidines(129)(130), leading to the inability of lymphocytes to synthesise RNA 
and DNA. 
The other main mode of action of leflunomide is the inhibition of tyrocine 
phosphorylation. With the substitution of uridine in vitro, the inhibition of 
dihydroorotate dehydrogenase pathway occurs with no effect on tyrocine 
phosphorylation pointing to a separate mechanism of action(131).  
1.7.2.2	 Role	in	transplantation		
	
Leflunomide is currently only licenced for the use in rheumatoid arthritis 
patients. But in past it has been used for solid organ transplantation.  
A phase II multicentre study looked at the primary end point of acute rejection in 
renal transplant recipients. The study divided patients into 3 groups; high dose 
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leflunomide, low dose leflunomide and placebo, with all groups receiving 
tacrolimus and corticosteroids. A total of 149 patients were randomised into 
these groups. There was no significant difference between the graft survival, but 
the acute rejection rates were lower in leflunomide group (26.5%, 25.9%) as 
opposed to placebo (39.1%)(132).  
There has also been evidence in animal studies that leflunomide can reduce the 
chronic rejection in allografts(133). 
1.7.2.3	 Side	effects	
	
Most of the insight into the side effects of leflunomide has come from the 
studies where it was used for the treatment of arthritis. A phase II trial of 358 
patients divided into leflunomide, sulphasalazine and placebo, looked at the 
efficacy and safety profile of leflunomide for arthritis patients has shown that the 
most common side effects were diarrhoea (17%), nausea (10%), alopecia (8%), 
and rash (10%). There were transient abnormalities in the liver function of the 
leflunomide group of patients(134). There have also been reports of anaemia, 
microangiopathy, oesophagitis and electrolyte disturbances(135)(136). 
Leflunomide has shown to have some anti proliferative effects along with 
immunosuppression and hence is a suitable agent for the inclusion in our 
study(137)(138)(139)(140). 
 
1.8	 TRANSPLANT	IMMUNOLOGY	
 
Much of the improvement in the outcomes of the allografts after transplantation 
has been due to the development of better immunosuppressive agents, and it 
Chapter	1—48	
	
has been the improving understanding of the immunology of transplantation that 
has paved the way for better immunosuppressive agents. 
Immunological response after transplantation is a dynamic multifaceted process 
with a wide range of activation and stimulatory mechanisms involved.  
Immunological response to the transplantation can be divided into various 
stages; pre transplantation and post transplantation or by the type of immune 
system – innate or adaptive. 
 
1.8.1	 	 Innate	immune	response	to	transplantation	
 
Even before the organs are transplanted there is plenty of trauma or tissue 
injury leading to activation of innate immune response against the transplanted 
tissue.  
In cases of donation after circulatory arrest, there is organ injury due to first by 
warm ischaemia and then by variable periods of cold ischaemia followed by 
reperfusion injury. In case of donation after brain dead (DBD) donors the 
overwhelming release of cytokines as direct result of neuroendocrine responses 
due to brain death also leads to activation of complement and coagulation 
cascades even before the organs are transplanted. 
Up regulation of cell surface adhesion molecules including P selectins and 
integrins along with the milieu of cytokines helps in the migration of immune 
mediator cells. There are suggestions that the more the initial injury to the 
organ, the worse the immunological outcomes(141) probably as a result of the 
induction of proinflammatory cytokines including interleukin 1 (IL-1), IL-6 and 
tumour necrosis factor (TNF-α)(142).  
The complement system normally is activated as a response to non specific 
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infections but it can also be stimulated as a result of hypoxia and tissue injury 
(143)(144) which is a hallmark of organ transplantation as a result of 
procurement process. 
1.8.2	 	 Adaptive	alloimmunity	
	
Adaptive immunity or the specific or acquired immunity is more specific and 
directed than the innate immunity. Hence it requires the effector cells to be 
stimulated and then migrate to the site of interest, which is allograft in 
transplantation. The whole process is an intricate combination of antigen 
presentation, allorecognition and then activation, migration and targeting of the 
allograft by the effectors cells. 
These stages are of paramount importance and are discussed. 
1.8.2.1	 Antigen	recognition	and	presentation	
	
The immune system distinguishes self from non-self antigens to prevent auto 
immunity. The histocompatibility antigens are unique to every individual of even 
the same species and thus are the targets of the immune system in clinical 
transplantation. The most important and well characterised is the Major 
Histocompatibility Complex (MHC) antigens but more recently the role of minor 
histocompatibility antigens have been recognised as well.  
Genes in the MHC locus are divided into class I, II and III but class I and II are 
thought to exert the most influence on the allograft rejection.  
Class I MHC proteins are expressed on almost all nucleated cells and generally 
activate the CD8+ T cells and normally present proteins synthesised 
intracellularly. Class II MHC complexes are expressed on B-lymphocytes, 
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dendritic cells and some endothelial cells. These complexes are generally 
responsible for activation of CD4+ cells and generally process extracellular 
peptides although this is not absolute as there can be some cross 
presentation(145).  
There are three ways the antigens are presented. In the direct antigen 
presentation the donor derived MCH proteins as well as other allogeneic 
proteins will be presented to recipient T cells by the donor antigen presenting 
cells. Even with the elimination of leukocytes for the allograft, which is essential 
for the direct pathway of antigen presentation, the rejection can still occur. The 
second type of antigen presentation is via the indirect pathway where the 
antigens derived from the donors are processed and presented by the recipient 
antigen presenting cells to the recipients T cells leading to downstream 
activation of cytokines leading to rejection response(146).  
In the ‘semi direct’ pathway the donor APCs transfer cellular membrane proteins 
and MHCs to the recipient APCs. These chimeric APCs then stimulate both 
CD4 + and CD8+ T cells.  
1.8.2.2	 Role	of	co	stimulation	
 
Once the antigens are presented to the T cells receptors (TCR), their fate is 
largely dependent on the type of co stimulation at the time of antigen 
presentation. These cells depending on the co stimulatory signal can start 
proliferating, become anergic or develop into memory cells. 
It has been shown that where there is absence of co stimulatory signals through 
a lack of stimulatory cytokines, T cells can become anergic, which can be 
reversed by replacing the missing cytokines(147). There are a large number of 
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co-stimulatory signals but probably the most studied one is CTLA 4, which 
inhibits T cell activation. 
Broadly speaking co stimulatory interactions are either from CD28-B7 family or 
tumour necrosis factor receptor (TNFR) / tumour necrosis factor (TNF) family.  
CD28 is present on the T cell surface and it interacts with CD80 and CD86. 
Interaction of CD28 with CD80/86 promotes activation of T cells while CTLA 4 
interaction with CD80/86 inhibits T cell activation. 
CD40 ligand (CD154) is expressed on the surface of activated T cells. This 
interacts with CD40 and is needed for the activation of B cells and dendritic 
cells. These interactions lead to production of different cytokines, which activate 
various effector cells. 
 
1.8.2.3	 T	cell	differentiation	and	the	role	of	regulatory	cells	
 
After the initiation of immune response by antigen presentation to TCR, naive T 
cells differentiate into helper T cells. These cells mostly are CD4+ and once 
activated also express CD154. Generally Th1 differentiation is promoted by IL-
2, Th2 by IL-4, Th17 by IL-6 and Treg by TGF-β. 
Th1 cells have been shown to be responsible for acute rejection associated with 
transplantation(148)(149) while Th2 and Treg cells are implicated in the negative 
feedback mechanisms leading to protection from alloimmunity(150). This has 
lead to a vast interest in their role to prevent allograft rejection.  
CD4+ CD25+ regulatory cells are the most well studied group of regulatory 
cells. Earlier experiments have suggested that these regulatory cells are 
needed to prevent autoimmunity. After thymectomy of an adult rat and split 
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dose gamma irradiation the rats developed autoimmune diseases. This has 
been shown to be reversed by transfer of CD4+ CD25+ Treg cells(151)(152). 
More recently their role in prevention of allograft rejection has been studied. 
These T cell subsets were isolated in the long term surviving cardiac (153)(154) 
and pancreatic(155) allografts pointing towards their role in the development of 
tolerance. 
1.8.2.4	 Humoral	mechanism	of	rejection	
	
Two main mechanism of tissue damage by antibodies are either through the 
activation of complement or antibody dependent cellular cytotoxicity. If a patient 
is transplanted a kidney who already has preformed antibodies against the 
MHC of the transplanted organ, it will lead to hyper-acute rejection. This type of 
rejection is also seen if the organ is transplanted across the ABO blood group 
without implementing the immunosuppressive protocols of ABO incompatible 
transplantation (antibody removal). These scenarios of hyper acute rejection are 
quite rare these days due to the refinements in tissue typing and cross 
matching. Development of these antibodies could be because of multiple 
previous blood transfusions where the recipient gets sensitized by the HLA 
antigens of the WBCs in the blood, previous pregnancies where it’s the 
exposure to the paternal antigens which leads to the development of an 
antibody response or previous transplant or via cross reactivity of various 
infective agents’ antigens. 
The humoral arm of adaptive immune system also plays an important role in the 
long term as well. Donor HLA specific antibodies (DSA) can develop during the 
episodes of acute rejections. Presence of DSA is an adverse sign for the 
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allograft both for the short and the long term as its quite difficult to treat and can 
show resistance to treatment with antilymphocytes and steroids regimes(156). 
Positivity of C4d staining (157) on renal biopsy is an indicator of the antibody 
mediated rejection and necessitates a more intensive therapeutic rescue 
regimen. 
1.8.3	 	 Role	of	Natural	Killer	(NK)	cells	
 
Natural killer cells are an important part of innate immune response. Their main 
role has been against the cancer cells and virus infected cells as a first line of 
defence. Although most of the NK cells are present in peripheral blood, lymph 
nodes and bone marrow, they can be recruited to the sites of inflammation by 
various cytokines(158). A lack of MHC class I expression either completely or 
even partially can lead to recognition by NK cells and leads to the lysis of these 
cells. Many of the cancer cells lack normal MHC expression thus making them 
susceptible to attack by NK cells.  
NK cells also play active role in adaptive immunity by their interaction with the 
dendritic cells that can be positively or negatively influenced by them. Some T 
cells also express NK cell receptors which influences their interaction with the 
other cells of adaptive immune system(159).  
The response from NK cells is much quicker than T and B cells as it’s due 
mostly to the preformed secretory granules containing effectors with properties 
to induce apoptosis. There also is some evidence of memory with NK cells as 
the second response to the same antigens is even quicker than the initial 
stimulus(160). 
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1.9	 	 TUMOUR	IMMUNOLOGY	
	
1.9.1	 		 Immunological	response	to	tumours	
	
As tumour cells are also usually self,  the majority of the antigens associated 
with them do not incite an immune response due to the tolerance process. Still 
there are few antigens that are recognised by either the innate immune system 
or adaptive immune response of the host. The antigens could be originating 
from tumour / viral genes, they could be the result of mutation in normally 
occurring genes or they could be the result of overexpression of normal genes 
or foetal antigens(161). All these processes make these tumour antigens 
susceptible to recognition by MHC and therefore attack by the T cells. 
Broadly, tumour antigens can be divided into two categories. 
 
1.9.1.1	 Tumour	specific	antigens	
 
These antigens are produced from the tumour cells and may be the result of 
several mutations. These antigens are thus new and so can lead to induction of 
cell-mediated immune response. The majority of these antigens are the result of 
chemical or viral exposure. The T cells then eliminate the cells expressing these 
antigens thus either leading to complete destruction of the tumour load or 
selecting the cells, which either express these antigens at very low level or don’t 
express them at all. Thus making them invisible to the immune system. 
Virally induced tumour antigens can be similar among different tumours induced 
by the same virus and injecting hosts with the cells from one type of tumour can 
protect them from the other tumours caused by the same virus. This principle is 
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used for the production of vaccine for cervical cancer where human papilloma 
virus is present in 80% of invasive tumours(162). 
1.9.1.2	 Tumour	associated	antigens	
 
These antigens are not specific to the tumour and are either produced at some 
stage of development or are produced at very low levels and tumour cells alter 
their expression positively. Alpha foetoprotein (AFP) is normally expressed 
during the embryonic stages of development and is only present in very small 
amounts in non-pregnant adults. Its levels are raised to many folds in liver 
cancers and it forms an important prognostic indicator. Similarly 
carcinoembryonic antigen (CEA) is overexpressed by a proportion of colonic 
cancers. In some types of breast cancers HER2 antigens are overexpressed 
which is not an embryonic antigen. 
1.9.2	 		 Immune	response	to	tumour	development	
 
There are several pathways that regulate the human cells and prevent tumour 
development. Just because of the mere numbers of cells present in humans 
and multiple stimuli from carcinogens, without these protective mechanisms life 
would be impossible. Nucleotide excision repair (NER) pathway is one of the 
several well characterised ways by which unregulated growth is prevented(163). 
There are other simpler mechanisms where disruption of extracellular-matrix 
association can lead to apoptosis. If the tumour cells evade these basic defence 
mechanisms then there is the specific protection by the immune system. 
The immune system can help achieve this by either protecting against tumour 
inducing viruses and reducing pre tumour inflammatory response or by 
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specifically attacking the tumour/tumour associated antigens. 
Immune system can both protect and indirectly promote the tumour growth 
contrary to the initial belief, a model called immune-editing. Initial studies have 
shown the importance of T, NK T cells and NK cells in their role of tumour 
destruction as in their absence animals are more prone to develop several 
cancers. But more recent studies have shown that cancers developed in animal 
models with deficient immune system are much more immunogenic than the 
animals with intact immunity. This observation points towards these tumours 
being naturally selected to be less immunogenic and thus more able to evade 
host response. Perhaps this is the final step required for any tumour to evade 
the host immune system as otherwise hosts with normal immune systems 
should destroy all the tumour load(164).  
Vesely et al. describe this process of immune-editing in three stages(165) Fig 6. 
The first phase is elimination where cancer cells are attacked by the immune 
system and are destroyed. The second phase of equilibrium is where there is a 
balance between the growth of tumour cells and destruction and the final stage 
is escape where least immunogenic tumours evade the immune system and 
undergoes the phase of exponential growth(165). 
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Figure 6 Immune-editing. Three stages of Elimination of cancer cells (first stage), 
Equilibrium between growth of tumour cells and destruction (second stage) and Escape 
associated with exponential growth (third stage). (165) 
 
Key immunological players of cancer eradication are natural killer (NK) cells and 
certain macrophages from the innate immune system and TH1 and cytotoxic T 
cells of adaptive immune system as well as antibody response to tumours by B 
cells. Conversely, TH2 and Treg cells’ prominence in the tumour milieu is an 
adverse prognostic sign. Again there are several pathways through which the 
tumour cells evade the natural defence of the hosts including reduced MHC 
expression or selection of such tumour cells which are less immunogenic, up-
regulation of anti-apoptotic mediators and lack of co-stimulatory signals which 
are essential to mount an immune response and in its absence can lead to 
tolerance of the tumour. 
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1.10	 	 SUMMARY	OF	LITERATURE	REVIEW	
 
The use of organs affected by small renal tumours have been attempted in past. 
Most of the initial reports of the use of these organs have been retrospective 
studies. One of the very first reports of the use of organs affected with small 
renal cell carcinomas was from the Cincinnati group where Penn(55) looking at 
Cincinnati transplant tumour registry (CTTR), described a total of 14 cases of ex 
vivo resection of small renal cell cancers detected incidentally followed by 
transplantation. There were no recurrences from these cases and the other 
organs were transplanted from these donors without any adverse effects. 
Similar results were reported by Buell(54) again with no recurrence. Later on 
Nicol (56) presented a quite impressive case series from Australia where these 
kidneys with small renal tumours were transplanted after ex-vivo resection after 
careful selection of recipients. Their group chose elderly patients or patients 
with comorbidities and high chance of death without transplantation. All the 
recipients had full informed consent and were given the choice of rejecting 
these organs. Of the 41 kidneys transplanted after ex vivo resection, 10 had 
benign pathology and 31 had a malignant tumour. There was only one case of 
recurrence that was away from the site of resection. Similar case series were 
reported from Japan(58) with no recurrence. All these and several case 
series(29) point towards the unexpectedly promising results after transplanting 
these organs after tumour resection.  
Similarly there are more than 50 cases of allograft renal tumours, which have 
been successfully treated by partial nephrectomy rather than graft nephrectomy.  
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Chapter 2  
EXPERIMENTAL DESIGN 
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2.1	 Research	hypothesis	
 
The main aims of our study were 
 
• To assess the role of standard immunosuppressive agents on 
transplanted tumour growth and compare with immunosuppressive 
agents with anti-neoplastic properties. 
• To assess the role of matching on tumour growth  
• To assess the role of rejection in eliminating transplanted tumour load. 
 
There are more than 7000 new cases of renal cell carcinomas diagnosed in the 
UK every year and more than 50% of these are T1a tumours (less than 4 cm 
unilateral tumours). The current standard of treatment for these tumours is 
partial nephrectomy and radical nephrectomy is now regarded as an alternate 
standard. Despite this there still are a large number of patients undergoing 
radical nephrectomy for these small tumours due to various reasons. There is a 
potential of these organs to be restored by ex vivo resection of the tumours and 
then be transplanted. The current literature, although quite limited, is very 
encouraging. Although the long term incidence of recurrence and patient 
survival are comparable between patients undergoing partial nephrectomy and 
radical nephrectomy(85) and this is one of the main reason of partial 
nephrectomy now being regarded as a standard procedure for these tumours in 
a urological setting , the situation after transplantation is more complicated.  
Transplant recipient are on life long immunosuppression and as explained 
earlier, host immune system is an important barrier to tumour development and 
growth. In the event of any inadvertent tumour transplantation in these patients 
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the results could be devastating.  
The main aim of this research project was to look at the role of different 
immunosuppressive agents on tumour development and growth in a transplant 
setting to identify the immunosuppressive agents, which can be most suited to 
situations where these restored organs are transplanted.  
The hypothesis was that under the influence of regular immunosuppression any 
transplanted tumour load will continue to grow. Also perhaps there will be an 
ideal form of immunosuppression that could be used for these restored organs. 
Certain immunosuppressive agents with anti neoplastic properties (Sirolimus 
and Leflunomide) could be used in these situations and the anti neoplastic 
properties utilised to rid of any inadvertently transplanted tumour from the host.  
The other observation from a pure immunological point of view is of the role of 
matching in transplantation. The better-matched organs could incite less of an 
immune response against them and vice versa. As the tumours are also derived 
from the donors, they share most of the antigens with them apart from the 
tumour specific or tumour derived antigens. In cases of tumour transplantation 
along with these restored organs or tumour recurrence in these kidneys 
matching can possibly play an important role. Our hypothesis was that the 
tumour derived from more mismatched donors will incite a more robust rejection 
response thereby producing a better clearing of any tumour load. This situation 
can be used as a helpful aid to other treatments when a recurrence is 
diagnosed in these organs. A graft nephrectomy will be required for most of 
these situations followed by withdrawal of all immunosuppression. In this 
scenario, without any immunosuppression the hosts immune system will be 
better equipped to reject any left over tumour load e.g.; in local lymph nodes. 
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Barrou et al. (76) has described a case of two allograft recipients from a single 
donor with tubulopapillary tumour (17mm) in the right kidney; only the left kidney 
was utilized for transplantation. Shortly after transplantation, the recipient 
underwent an ultrasound (US) examination of the allograft, which did not reveal 
any tumour. 3 months later a biopsy was done for rejection, which revealed a 
poorly differentiated tumour, and the patient underwent radical allograft 
nephrectomy. No additional chemotherapy was given apart from discontinuation 
of immunosuppression (prednisolone and azathioprine). Lymph nodes that had 
been noted to be enlarged on CT scan disappeared two month after 
nephrectomy. The patient underwent re transplantation two years later and was 
disease free and dialysis independent at 3-year follow-up. This example 
suggests that hosts immune system can be used for rejection of any left over 
tumour and by transplanting organs with less well matching perhaps this 
rejection of tumours will be even stronger.  
 
The immunosuppressive agents used for our project were Cyclosporine, 
Sirolimus and Leflunomide. This choice of immunosuppression gave us the 
opportunity to assess the tumour behaviour under “normal” 
immunosuppression without any anti neoplastic effects (cyclosporine) and 
newer agents with some antiproliferative properties.    
The tumour was transplanted into two different strains of rats to mimic well-
matched and poorly matched groups. The role of matching and rejection of 
tumour is compared in these two groups after withdrawal of any 
immunosuppression. 
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To enable real time in vivo monitoring, a highly sensitive IVIS spectrum 
imaging system was used for analysis. At the end of the study period further 
analysis by flow cytometry was performed to assess immunological response 
to the tumour in the transplant setting. 
Our project can be outlined as below  
	
Figure 7 Flow sheet showing project outline. 
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Figure 8 Schematic diagram outlining the project methodology. 
   
2.2	 Subcutaneous	injection	of	renal	tumour		
 
The purpose was to induce a tumour by injecting a known number of tumour 
cells under the surface of the skin. Such a model has been used previously 
(166).  The normal immunosuppression used in this situation was 
cyclosporine. After inoculation of 1.2×107 tumour cells the animals were 
monitored for four weeks and then euthanased to measure their tumour size 
and then they underwent a post mortem to determine whether or not there 
has been distant spread. After tumour injection 5 initial groups were 
developed: one with no immunosuppression (control), then four groups one 
receiving the standard immunosuppressive drug cyclosporine which was 
administered for 4 weeks or the test immunosuppressive anti-proliferative 
drugs: again administered for 4 weeks. The animals receiving 
immunosuppression were further divided into treatment continue group where 
immunosuppression was continued for 4 weeks and treatment withdrawal 
group where immunosuppression was stopped after two weeks; to assess the 
role of rejection with no immunosuppression.  
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We used two different rat strains; Wistar and Lewis. The cell line was from 
Wistar origin and was developed after exposure to an oral carcinogen and 
were shown to be stable(167). Well-matched groups were mimicked when 
these tumour cells were injected into Wistar animals and poorly matched 
when these tumour cells (of Wistar origin) were injected into Lewis rats. 
 
 
 
2.3	 Monitoring	the	tumour	
	
To enable in vivo visualisation and objective estimation of tumour load as a 
measure of tumour behaviour in our model we transfected the cell line with 
Luciferase and Green Florescent Protein (GFP).  Stably transfected cells 
were then selected for injection in the subcutaneous tissue and the animals 
were scanned in IVIS Spectrum imaging system to monitor the tumour 
growth. Towards the end of the study period of 4 weeks the animals were 
euthanased by schedule 1 of Home Office protocol and a formal post mortem 
was performed to assess any distant metastasis. 
2.4	 	 Choice	of	Immunosuppressive	agent	
	
We studied the effects of three immunosuppressive agents on the 
transplanted tumour behaviour.  
2.4.1	 	 Cyclosporine	
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This, along with tacrolimus is the most commonly used immunosuppressive 
agent used in clinical transplantation. CsA revolutionised the 
immunosuppression by significantly reducing the rates of acute rejection in 
1990s compared to previous agents. Although from the mid of 2000s, 
tacrolimus has taken over as the most commonly used primary 
immunosuppressive agent, they both are Calcineurin inhibitors and share 
mechanism of action and side effects. One of the important side effects of 
CsA is the increased incidence of tumour development as is with most of the 
immunosuppressive agents. These effects are thought to be due to increased 
cell mobility and increased anchorage independent growth and also due to 
increased angiogenesis(106)(107). 
	
2.4.2	 	 Sirolimus	
 
The profile of Sirolimus fits very well to the research hypothesis of an 
immunosuppressive medication that has antineoplastic properties as well. 
Although the rates of acute rejection may be slightly better with CNIs when 
compared to Sirolimus, its potency as antineoplastic agent has been tested 
for different tumours. Sirolimus behaved as a one of the two test agents in the 
study to exploit these anti tumour effects. We used two different doses of 
Sirolimus; the high dose (2.0mg/kg/day) as used in many animal studies for 
urothelial tumours (168) and low dose (0.5mg/kg/day) normally used to study 
the immunosuppressive effects(169)(170).  
2.4.3	 	 Leflunomide	
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The other immunosuppressive we used for our research was Leflunomide. 
Leflunomide exerts its immunosuppressive and anti-inflammatory effects 
through multiple pathways. The most important mechanism of action is the 
inhibition of pyrimidine synthesis. Activated lymphocytes depend exclusively 
on the de novo synthesis of the uridine monophosphate, as they are unable 
to use the pyrimidine salvage pathway. Leflunomide inhibits the mitochondrial 
enzyme, dihydroorotate dehydrogenase which is responsible for the 
production of pyrimidines(129)(130), leading to the inability of lymphocytes to 
synthesise RNA and DNA.  
Leflunomide is currently only licenced for the use in rheumatoid arthritis 
patients. But in past it has been used for solid organ transplantation.  
It has shown improved outcomes when used with CNIs and steroids (132) and 
also has shown reduced acute rejection rates in animal models (133). 
Various studies have shown anti tumour role of these 
agents(171)(138)(172)(139), which makes leflunomide suitable to assess our 
hypothesis. 
 
2.5	 Grant	and	licence	
 
The work carried out in this project was appropriately licenced. The project was 
licenced through Home Office animal licence (Licence no. PPL 60/4042) for a 
total of five years. The animal work on our project lasted from June 2010-Feb 
2012. I held personal licence granted by Home office after successfully 
completing modules 1-4 of animal handling, kept at all times in the animal 
department of Newcastle University.  
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The grant was provided by Northern Counties Kidney Research Fund (NCKRF). 
The Initial grant was of £3000 for the pilot work and the subsequent grant was 
for £ 19,270.54 (Grant reference BH111133). 
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Chapter 3  
DEVELOPMENT OF STABLY 
TRANSFECTED RAT TUMOUR CELL 
LINE 
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3.1	 INTRODUCTION	
 
Transfection of the cell line with luciferase and Green florescent protein was 
one of the very important steps of our experiments. Despite the rapid growth 
(24 hours), without any transfection with luciferase and GFP, all the 
assessment of the tumour growth under experimental conditions would have 
been very subjective with high chances of bias and human error. Using the 
objective method of measuring the tumour load with IVIS Spectrum Imaging 
system as described in more detail later prevented this.  
Injecting native cells into rats means that tumours can only be detected once 
palpable and the rats would have required sacrificing. Transfecting the cells 
with a reporter gene allows the real-time monitoring at subclinical levels and 
the rats can be kept alive throughout the study period. 
Plus, without knowing the effects of the different immunosuppressive agents 
on tumour growth, it would have been impossible to determine any subtle 
changes. If there was not a big difference in the effectiveness of one 
immunosuppressive over the other then these changes would have gone 
unnoticed.  
Apart from refining the results and removing the bias to a great deal from 
these experiments, transfection of our cell line also meant that the animals 
had to undergo the experiments for shorter period. Because of the very high 
sensitivity of the IVIS imaging system we needed a lot less tumour load to be 
able to study the effects of immunosuppressive agents and the role of 
matching on them. This was a major refinement, leading to lot less animal 
stress during these experiments.	
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3.2	 FLUORESCENCE	AND	BIOLUMINESCENCE	
	
Bioluminescence results in the release of photons, which can be picked up by 
photon sensitive equipment. The photon emission is secondary to the 
generation of an exited high-energy state of the electrons in the molecules, 
which are inherently unstable. When the molecules come back to their resting 
state, this leads to energy production in the form of photons emission. 
There are some basic differences between bioluminescence and 
fluoroscence. For any sort of florescence there has to be an external source 
of energy, in the form of light that is used to excite the molecules from its 
resting state while in bioluminescence this is a chemical process. Usually the 
amount of light emitted by the florescent assays is much higher than the 
bioluminescent assays, as there is an external source of energy, so the 
amount of energy delivered can be increased to a great deal. But this does 
not translate to the better overall sensitivity of these assays. This is due to the 
fact that any estimation of photons must be calculated by subtracting the 
background “noise” or background signals. As there is an external source of 
energy, usually the background signal is also very bright in cases of 
florescence, hence reducing the overall sensitivity of the assay. 
The photons needed to excite the fluorochromes can also interfere with the 
results of the assays. But in biological samples, the tissues may have their 
own inherent florescence that can interfere with the final results. 
These issues are much less of a problem in cases of bioluminescence as 
there is no external light source required. This means that inherent 
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florescence will also not be interfering with the analysis. Due to these, there is 
a very small background signal making any light measurement far more 
sensitive towards the experimental assay. 
Thus bioluminescence is preferred over the florescent processes although 
florescence has its important uses as well, especially in light microscopy and 
flow cytometric analysis where bioluminescence cannot be used or has very 
limited role. 
The most commonly used bioluminescent enzyme is Firefly Luciferase 
(others are Renilla luciferase and Aequorin). 
3.2.1	 Firefly	Luciferase	
	
This is a naturally occurring enzyme found in firefly and in bacterial species 
such as Vibrio sp. and results in bioluminescence in these organisms. The 
chemical process leading to light (photon) emission has the following steps. 
Conversion of Luciferin (substrate of Luciferase) to high-energy state 
Oxyluciferin, which is an unstable molecule. This is an active process 
needing an input of energy in the form of ATP and requires oxygen. 
This high energy state of oxyluciferin is unstable and thus gets converted to 
the stable low energy state of oxyluciferin, releasing the energy absorbed in 
the initial reaction as photons. 
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Figure	9	 Schematic	 of	 mechanism	 of	 bioluminescence	 (173).	 Cells	 are	 initially	 transfected	 with	 Luciferase	
enzyme.	Once	transfected,	these	cells	have	the	ability	to	emit	light	in	the	form	of	photons	in	the	presence	of	O2,	
ATP	and	luciferase.	
	
3.2.2	 Green	Florescent	Protein	(GFP)	
	
This is another naturally occurring protein that has excellent florescent 
properties and has been used as a reporter extensively. The enhanced form 
of GFP (eGFP) is preferred now because it offers higher intensity emissions 
after blue light excitation(174).  
The other benefit of GFP has been the ease of determining the transfection 
process with florescent microscopy. It is useful for flowcytometry as opposed 
to the bioluminescent proteins. 
3.3	 	 IVIS	SPECTRUM	IMAGING	SYSTEM	
 
This is an imaging modality specifically designed to image small animals for 
the detection of florescent and/or bioluminescent signal with very high 
sensitivity. A schematic diagram of the imaging system is shown in the figure 
below.  
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This can be divided into three distinct parts; 
Imaging Chamber 
This contains a sound proof, light tight imaging chamber with heated stage to 
keep the anaesthetised animals’ body temperature regulated. It has 
integrated gas anaesthesia and an Oxygen delivery mechanism. 
The stage is motor controlled to adjust the lens position for the best possible 
image capture.  
CCD Camera 
A highly sensitive back illuminated CCD camera, with 13.5-micron pixels. The 
camera is thermoelectrically cooled to -90°C to reduce the background noise. 
 
Lenses  
There is 6-inch diameter optics with focal length varying from f/1-f/8. It also 
homes an emission filter. 
The basic purpose of this arrangement is  
• To be able to capture the faintest possible light signals with minimal 
detectable radiance of 70 photons/sec/sr/cm2 
• To reduce the background noise, which is achieved by keeping the 
animals anaesthetised so that there is no movement and maximum 
amount of information is gathered, by means of super cooling of the CCD 
camera and by the use of complex software algorithms to calculate the 
actual signals and subtracting the background “noise”. 
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Figure 10 Schematic diagram of IVIS Spectrum taken from the IVIS manual.  
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Figure 11 IVIS spectrum imaging system. Used for our experiments in Newcastle 
University. Main chamber homes the anesthetised animals. Anaesthetic delivery system 
mixes oxygen with anaesthetic gases both to induction chamber and main chamber. 
Computer software is used to analyse the acquired data. 
 
 
Principle of IVIS spectrum  
Florescence 
Emitted light from the excitation filter wheel feeds through a fibre optic bundle 
to illuminate the specimen from either the top, in epi-illumination (reflectance) 
mode, or from underneath the stage. If the specimen has fluorochrome it will 
absorb the light of excitation wave length and emit its own light of certain 
wave length depending upon the fluorochrome. This light is then picked up by 
the super cooled CCD cameras through an array of filters to create the 
image. The software in the attached CPU has the ability to subtract the 
background illumination from the final signal received, generating the true 
reading of fluorescence. 
	
Main	chamber	
Computer	monitor	
for	software	
Anaesthetic	delivery	
system	and	
anaesthetic	chamber	
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Bioluminescence 
The specimen was placed in the light proof dark chamber and luciferin was 
added to the sample to start the reaction with luciferase. Exposure times can 
be either automatic or it can be set to capture the images depending on their 
light emission. Again the photons produced are picked up by the CCD 
camera. Again for the accuracy of the measurement of light emission, the 
background noise is subtracted from the original image. 
To enable the real time monitoring of the rat kidney tumour cells, these were 
transfected with luciferase. This is described along with the basic cell culture 
below. 
 
 
 
 
3.4	 MATERIALS	AND	METHODS	
 
3.4.1	Cell	culture	
	
The cell line used throughout the experiments was BP36B, a rat renal tumour 
cell line. Basic cell culture techniques were practiced and perfected on A549 
(human lung carcinoma) (175) before embarking on the transfection of the 
BP36B cell line. 
The rat tumour cell line, BP36b, was acquired under a standard MTA from the 
Cell Bank at the RIKEN BioResource Centre (Ibaraki, Japan). These cells 
were developed by Tokuzen et al. (167) by exposing the Wistar male rats to 
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N-ethyl-N-hydroxyethylnitrosamine (EHEN),a known carcinogen, and by 
feeding EHEN to 6 weeks old male Wistar rats for 3 weeks, 14 rats showed 
the presence of the tumour. The cells were isolated and cultured in RPMI 
1640 with 10% FCS and antibiotics in the humidified incubator with 5% CO2 
at 37°C.  
Tokuzen et al. developed three rat renal tumour cell lines (BP13, BP30 and 
BP36B). All of these cell lines had epithelial appearance in monolayers and 
were moderately differentiated basophilic tumours of proximal tubular origin.  
The cell line chosen for our experiments was BP36B as the doubling time of 
this cell line was 17 hours as compared to 29 and 21 hours respectively for 
the other tumour cell lines. Also this cell line was most successful in inducing 
tumour in a xenotransplant model after pre-treatment of the nude mice with 
anti-asialo GM1 antibody (an NK cell depleting antibody)(176).  
This cell line was reported very stable even after 100 passages. The cell 
characteristics were tested in the cell lines for up to 3 years from the receipt 
and the doubling times and the cell line characteristics have remained stable 
throughout this period. These cells were then split into 6 flasks initially and 
later on 1:8 splitting ratio was adopted once the cell line was stabilised in 
our lab.   
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Figure 12 Light microscopic appearance of BP36B rat renal tumour cell line (10X). 
These cells grew in monolayer and remained epithelial in appearance. The doubling 
times were consistent with the reported times by the cell bank. 
 
 
Figure 13 Light microscopic appearance of BP36B rat renal tumour cell line (40X). 
These cells grew in monolayer and remained epithelial in appearance. The doubling 
times were consistent with the reported times by the cell bank. 
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The cell culture medium (Roswell Park Memorial Institute RPMI-1640) was 
purchased from the Biosera® Labtech International Ltd. and was stored at 2-
8°C. L-Glutamine (Sigma-Aldrich Company Ltd) was added at a 
concentration of 0.3g/l. along with heat inactivated FBS (Sigma-Aldrich 
Company Ltd) to a concentration of 10% to prepared final enriched medium 
for cell culture usage. 
To avoid microbial contamination Penicillin and Streptomycin (1,000 units of 
Penicillin and 0.1 mg if streptomycin/ml) (Sigma-Aldrich Company Ltd) were 
used routinely for all the cell cultures as per protocol of the cell culture lab. 
When required Amphotericin B was also added to a final concentration of 
2.5mg/lit to prevent fungal infection.  
Our cells were cultured in multi-well plates and flasks with porous caps in an 
open incubator system. The average temperature of the incubator was kept 
at 37°C with a CO2 concentration of 5% in a humidified environment. For 
buffering purposes, the RPMI 1640 used for our cell cultures contained 
2gm/lit of sodium bicarbonate.  
3.4.2	Thawing	of	cryopreserved	cell	line	
 
The cells were kept in liquid nitrogen and were carefully removed. These 
eppendorfs were then quickly placed in pre-heated water baths at 37°C. This 
reduces the damage to the cells that can accompany slow thawing of the 
cryopreserved cells. The aim was to thaw the cells in less than a minute.  
The eppendorf was then transferred to the hood and wiped with 70% alcohol. 
The cells along with the contained medium were then transferred to a centrifuge 
tube containing the RPMI1640 that again was warmed at 37°C and cells 
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centrifuged at 200g for 5 minutes to form a clear pellet.  
The centrifuge tube was then brought back in the hood and the excess medium 
decanted carefully to avoid disturbing the cell pellet at the base at this stage.  
Then the cells were re-suspended in the RPMI 1640 medium (supplemented 
with L-Glutamine, 10% FBS and antibiotics). Care was taken to re-suspend 
cells gently by repeated pipetting of the medium.  
Next the cells were transferred into two 75cm2 flasks containing approximately 
30 mls of culture medium to fully immerse the cells.  
These flasks were then closed with porous caps and inspected under light 
microscope before being incubated at 37°C in humidified CO2 incubator.  
A record book was kept updated in the lab for any changes to the number of 
cryopreserved cells. 
To ensure a constant growth rate the cells were subcultured at a confluence 
of approximately 70-90%. Typically this resulted in passaging the cells two to 
three times a week.  
Cells were passaged by removing the media and washing with Dulbecco’s 
Phosphate Buffered Saline (DPBS) gently to remove any left over culture 
media. Pre-warmed trypsin was added to cover the cell layer all over; 
typically between 3-5 mls for 75cm2 flasks. The flask was gently rocked and 
left for 1-2 minutes to allow the cells to detach from the flask. 
After this 5-10 mls of culture media was added to inactive the trypsin and 
prevent cell damage. The cells were then pelleted by centrifugation at 400 g 
for 5 minutes and re- suspended in fresh culture media prior to distribution 
into new flasks and place back in the incubator. 
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3.4.3	Cryopreservation	
	
The cells undergo both karyotypic and phenotypic changes if they are sub 
cultured for long time. To prevent this and keep them as original to their initial 
properties it is important to cryopreserve them. Weaimed to cryopreserve our 
cell line as soon as there was a surplus.  
Weadopted following protocol for freezing the cells 
The cells were cryopreserved at a high concentration. As there is cell 
damage during the thawing process, it is important to start with a higher 
concentration of healthy cells for cryopreservation. Wenormally used at least 
on T75 flask for this purpose that roughly contains 7.5×106 cells. 
After trypsinization of the cells they were re-suspended in the growth medium 
to inactivate the trypsin followed by centrifugation for 5 minutes.  
The supernatant was decanted and the cells were suspended in 1 ml of 
freezing medium. The freezing medium was prepared before the start of the 
freezing process and included 70% RPMI, 20% FBS and 10% Dimethyl 
Sulfoxide (DMSO).  
These suspended cells were then transferred into the pre-labelled Eppendorf 
tube. This was then placed in the polycarbonate container for gradual 
freezing. This contained isopropyl alcohol which helps in lowering of the 
temperature of the cells 1-2°C per minute. This is important as it prevents cell 
damage by either too rapid or too slow cooling. 
The cells were left in the -80°C freezer overnight and then next day were 
transferred into the liquid nitrogen in a dedicated Dewar. 
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Labelling of the cells included type and passage of cells and date of freezing. 
This was recorded in the nitrogen lab book as well. 
 
3.5	 RESULTS	
	
3.5.1	Puromycin	kill	curve	
 
For the selection of the transfected cells, puromycin was used. The adequate 
dosing was calculated by undertaking the kill curve.  
BP36B cells were grown in 24 well tissue culture plate in 0.5 ml of culture 
medium.  
These cells were cultured till they reach around 70% confluence to get the 
best results. This was followed by adding rising concentration of puromycin 
into the wells. Weused the following concentrations; 1mg/ml, 2mg/ml, 
4mg/ml, 6mg/ml, 8mg/ml, 10mg/ml, 12mg/ml, 15mg/ml, 20mg/ml. This was 
done in duplicates.  
In the final well the cells were cultured in normal growth medium without any 
puromycin and they acted as controls. The culture medium was replaced 
every 2 days for 10 days and the wells were examined for any signs of visual 
toxicity e.g.; separation of the cells for the adherent surface of the multi-well 
plate.  
The cells with 10mg/ml of puromycin were completely destroyed within 1 
week while with 6 and 8 mg/ml concentrations there were still some cells left 
in the medium beyond 7 days; hence 10mg/ml was used as the final 
concentration in the experiments to select the stably transfected cells. 
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Figure 14 Selection antibiotic. Schematic diagram of the concentration of 
Puromycin in the multi-well plate to determine the kill curve. The boxes represent the 
wells with the concentration. 
 
	
3.5.1	 	 Transfection	
 
Transfection is the process of introducing nucleic acids into cells by non-viral 
methods. Transduction is the process whereby foreign DNA is introduced into 
another cell via a viral vector. These are common methods to introduce a 
foreign gene into host cells. Weused viral vector to transduct our cell line. 
Wetried transfection with two different vectors as with the first set of 
experiments, the cell line failed to transfect. 
 
3.5.1	 	 Failed	transfection	
 
The initial attempt of transduction was done with Firefly luciferase lentiviral 
particles acquired from GeneCopoeiaTM Rockville, USA. In this vector the 
luciferase and Puromycin genes were under the CMV promoter.  
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Figure 15 Lentiviral vector. These were used for transduction of tumour cells 
initially. The tumour cells successfully formed monocolonies but were not 
bioluminescent. Both luciferase and Puromycin genes was under CMV promoter. Figure 
from literature provided by vendor. 
 
These viral particles were delivered on dry ice from local distributor from 
France.  
Transduction was performed according to the instructions by the 
manufacturer.  
Prior to transduction the cells were grown in the cell culture to make sure they 
were not infected and there was no change in the growth pattern. 
At day 1, 5 x 104 cells were plated in a well in 12 well-plate. These were 
grown in the standard culture medium with the necessary antibiotics for 24 
hours at 37°C with 5% CO2 overnight.  
On day 2 for each well, Weprepared 0.5 ml of virus suspension diluted in 
complete medium with Polybrene at a final concentration of 5–8 µg/ml to 
increase the permeability. Following concentrations of the letivirus (0.1µl, 5µl, 
10µl, 50µl and 100µl) to determine the most appropriate concentration for 
best transfection results.  
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The cells were infected by removing the old culture medium and replacing it 
with 0.5 ml of diluted viral supernatant. The lentivirus and the medium were 
gently mixed by rotation. Vortex was avoided as per instruction by the 
manufacturer.  
For one well, Weadded 0.5ml of complete DMEM with Polybrene. This well 
behaved as control. The plate was placed for 2 hours at 4-8°C and then 
transferred to 37°C incubator with 5% CO2 and incubated overnight. On day 
3 the cells were split and medium was replaced and on day 4 the culture 
medium was replaced not containing any polybrene and incubated for 
another 48 hours. 
From day 6 the selection process was started with Puromycin at a dose of 
10ug/ml as calculated by the kill curve. The old medium was replaced with 
fresh complete medium containing the puromycin every 3–4 days until drug-
resistant colonies became visible. This time in our experiment was around 7-
9 days. 
Intriguingly, the antibiotic selection was very clear with stable monocolony 
formation upon usage of puromycin but Wewas not able to elicit any 
luciferase expression. This was later found to be due most probably due to 
mycoplasma infection. 
The expression of luciferase was tested by using IVIS spectrum imaging 
system but no bioluminescent signals were detected. 
These experiments were repeated twice with similar results. The 
manufacturer was consulted and the cells were attempted a re-transfection 
with a new batch of the same lentivirus without any success. 
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To increase the chances of any subtle expression of luciferase, Weeven 
undertook the ultrasonic lysis of these cells but were still unable to detect any 
successful transfection. 
3.5.2	 	 Successful	transfection	
	
Following the initial failed attempts at transfecting the cells, Wechanged the 
vector.  
The other change was that this time the viral vector also carried the gene for 
eGFP as well as Luciferase. The vector used was LVP 020 from GenTarget 
Inc San Diego, USA. These came in dry ice; with a total volume of 200uL 
containing 1×107 IFU/ml. Luciferase was expressed under a tetracycline 
includible suCMV promoter. These were able to express high levels of 
luciferase without any induction. CMV promoter is one of the strongest 
promoters when compared to other RNA polymerase II promoters and hence 
it was advantageous that the most important gene (luciferase) was under its 
promotion.  
 
	
Figure 16  Lentiviral construct. Luciferin was expressed under suCMV 
promoter. This lentiviral construct also expressed GFP. The puromycin and GFP genes 
were under the influence of Rsv promotor. The tumour cells once transducted were 
successfully expressing luciferase and GFP. Lentiviral construct from the GenTarget Inc 
San Diego, USA information sheet.   
The GFP and Puromycin were both under the Rous sarcoma virus (Rsv) 
promoter(177). 
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The protocol from the manufacturer for transduction was followed in principle.  
The cells were seeded as previously in a 24 well plates in the RPMI 1640 
medium with antibiotics at a rough seeding of 5×104 cells in 0.5ml of medium. 
The cells were around 40% confluent at the time of transduction. 
On day 1, the old culture medium was replaced with the fresh medium. The 
lentiviral particles were thawed to the room temperature. Three different 
concentrations of the lentiviral particles were added to the cell lines (5uL, 
10uL, 25ul and 50uL). These meant that the multiplicities of infection MOI 
were 1, 2, 5 and 10 respectively. These cells were incubated in the CO2 
humidified incubator at 37°C for 72 hours.  
The culture medium was then changed with the one containing puromycin. 
The optimal dose of puromycin was calculated prior to these experiments as 
below. The optimal dose of Puromycin was found to be 10ug/ml. The cells 
were grown in this medium under standard conditions and the medium 
changed every 2-3 days.  
There were different rates of growth of cells with differing MOIs. The cells 
with MOI of 5 were the fastest to grow and there were 2-3 monocolonies in 
the multiwell plate. Cells infected with MOI of 2 were the second fastest to 
form monocolonies while the cells with MOI of 1 were very slow to grow and it 
took them 3 weeks before any appreciable monocolony formation was 
noticed.  
Once the cells were growing to near confluence in the monocolonies they 
were trypsinised and transferred initially to petri-dishes and then to 25cm2 
flasks followed by 75cm2 flask.  
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Figure 17  Visible monocolonies. Cells transfected with a MOI of 5.0. 
Magnification of 10X.  
	
Figure 18 Slow growing monocolonies. Very slow growth rate and not very clear 
monocolonies formed by the cells infected with MOI of 1.0. Magnification 10X. 
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3.6	 	 IN	VITRO	CONFIRMATION	OF	TRANSFECTION	
	
For	the	confirmation	of	successful	transduction	Weused	three	methods.		
3.6.1	 	 Florescence	microscopy	
	
This was the easiest method of determining successful transduction. The fact 
that the cells were being selected with puromycin was already an indirect 
indication that they would be expressing GFP as well, as both of these genes 
were under the same promoter sequence in the viral vector.  
The cells were tested under the florescent microscope to assess 
transduction. There were two controls for this. First were the BP36B cells with 
no transduction.   
	
Figure 19 Florescent microscopy. Clumps of BP36B cells as seen with florescent 
microscopy. To get brighter signals, the cells were trypsinised and concentrated before 
being examined under florescent microscope. 
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The other control was BP36B cell line with Floroscene diacetate (FDA). This 
is normally used for cell viability testing. The control cells did not show any 
significant florescence. The cells with FDA produced easily visible staining 
under microscopy. Then our transfected cells with MOI of 2 and 5 were 
examined under the same settings and the cells in clumps revealed good 
florescent signal. 
3.6.2	 	 Luminometer	for	luciferase	
	
The expression of luciferase as a marker of successful transfection was 
elicited by light emitted after the lysis of the transfected cells followed by the 
exposure to luciferin. Weused premade Bright-Glo™ Luciferase Assay 
System from Promega Corporation Wisconsin, USA.  
The cells were trypsinised and suspended in the culture medium and equal 
amount of Bright-Glo reagent was added in the Eppendorf tubes. Both the 
cells and the reagent were at room temperature to aid cell lysis. 
This was left for 2 minutes then these were transferred to the Luminometer. 
After 10 seconds of exposure, the cells gave following readings. 
Table 4: Bioluminescent signals from luminometer. Cells with different MOIs 
were used for the measurements. Maximum signals were seens with the cells 
transfected with MOI of 2.5. 
Control	 MOI	2.5	 MOI	5.0	 MOI	5.0	
14.7/10sec	 >9999/10sec	 1487/10sec	 3980/10sec	
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3.6.3	 IVIS	spectrum	imaging		
 
The cells were tested in the IVIS spectrum imaging system as well, for 
conformation of transduction. Weagain used Bright-Glo™ Luciferase Assay 
System to lyse the cells and expose them to the luciferin. The Eppendorf 
tubes were then transferred to the IVIS and images were taken at the 
standard exposure time of 30 seconds for controls, cells with MOI of 2.5 and 
the ones with MOI of 5.0 after waiting for 2 minutes to allow for the lysis of the 
cells.  
The cells were initially examined for the expression of luciferase by the 
bioluminescence and then for GFP for florescence.  
The photon emission was brightest with cells transduced with MOI of 2.5 when 
compared to the cells with MOI of 5.0. This was in keeping with the luminometer 
readings undertaken previously. The control cells did not exhibit any 
bioluminescence. 
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Figure 20 IVIS Spectrum image. Bioluminescence from luciferase transduced cells. 
The control cells (Left) did not show any signals, the brightest glowing cells (middle) 
were transduced with MOI of 2.5 and cells with MOI of 5.0 (right) were also positive for 
the expression of luciferase but were less bright. 
	
Similar results were noticed when the florescence was tested for these cells. 
Again the cells infected with MOI of 25 were the brightest and there was no 
signal from the control cells.  
	
Figure 21 IVIS image for florescence. MOI 5.0, Controls, MOI 2.5 and MOI 5.0 from 
left to right 
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4.1	 IN-VIVO	ANALYSIS	FOR	PROOF	OF	CONCEPT	
	
After making sure that the cell line was successfully transfected and we were 
able to reliably track the tumour growth in real time, the next stage was to check 
the behaviour of tumour in vivo before assessing different immunosuppressive 
medicines. 
4.1.1	Aims	
	
Before embarking on the live animal work it was important to make sure that the 
luminescent signals would be picked up when these cells are injected in the 
animals. For this purpose weused recently culled animals. This was important, 
as the cells would be injected in the subcutaneous tissue as compared to the 
transparent and thin Eppendorf tubes which could easily transmit the emitted 
light from these cells, in other words this was to check the penetrance of the 
emitted light.  
The other issue that could affect these animal studies was the auto florescence 
of the animals. This is more of a problem for GFP signals but not an issue for 
luciferase, as it does not exist in rats naturally. 
The third important issue was the ability of detecting signals from any deep-
seated metastasis of the tumour tissue should it happen during the study 
period.  
4.1.2	Methods		
	
The injection of cells and the subsequent detection of florescence were as 
follows 
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The animals were humanely culled by schedule 1 of the home office protocol.  
As these were dead animals, it was important to inject the cells in the 
subcutaneous tissue along with the substrate, luciferin. Hence, weagain used 
the Bright-Glo system from Promega as described earlier to inject these 
animals. 
The fur was shaved on the ventral aspect of the animal and a subcutaneous 
injection of cells mixed with Bright-Glo was done in the right flank. 
A deep injection was done on the left flank near the spleen and on the right side 
deep in the groin region. 
The animal was then transferred in the IVIS machine and image was taken with 
automatic exposure. 
Then the carcass was turned dorsum up and again was injected with the cell 
and reagent mixture in the mediastinum. Again the animal was transferred into 
the dark chamber and image acquisition performed. 
4.1.3	 	 Results		
	
With subcutaneous injection in the right flank, there was a very bright signal 
after 30 seconds of exposure.  
There was a good signal from the deep injection in the left flank and the right 
groin region. This signal was less intense than the more superficially placed 
cells in the right flank. As both the injections were done at the same time and 
the photon intensity of the right sided injection was very high compared to the 
other injection, the minimum units or signal pick up were quite high. This was 
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not of any clinical significance but an important lesson was learnt here was that 
if there was one very intense signal at one area and a weaker signal from an 
adjacent area on the same frame then the weaker signal may not be picked up 
in that image.  
To reduce any false negative results due to this phenomenon, whenever there 
was an intense signal and a chance of distant spread, weused to cover the 
brighter area to look for weaker signals. 
The deep injection in the mediastinum also produced good signals after an 
exposure time of 60 seconds.  
 
	
Figure 22 Ventral view of bioluminescent signals from dead rat. Both the 
transfected cells and luciferin (Promega Bright Glo system) were injected to see if 
subcutaneous injection will lead to signals pick up by the IVIS spectrum imaging system. 
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Figure 23 Dorsal view of bioluminescent signals from dead rat. Both the transfected cells 
and luciferin (Promega Bright Glo system) were injected into the mediastinum to see if 
IVIS spectrum imaging system will pick up deep seated signals in cases of metastasis. 
 
As these analyses were only to see if the bioluminescence was picked up in 
rats with our model, no background noise was calculated and there were no 
radiance calculations. 
4.2	 	 PILOT	ANIMALS:	IN-VIVO	ANALYSIS	
 
4.2.1	 	 Aims	
	
After the proof of the concept, firstly that the cells were successfully expressing 
luciferase and later that wewould be able to detect these signals through these 
Deep	mediastinal	
injection	
	
	
	
Subcutaneous	Right	flank	
injection	from	dorsum		
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rats after subcutaneous injection, wewanted to experiment on small number of 
animals to make sure that all the above still held in the living animal scenario.  
  
4.2.2	 	 Methods	
	
Pilot study on live animals looked at followings 
• Tumour growth in well matched (Wistar) and poorly matched (Lewis) rats 
with no immunosuppression 
• Tumour growth in the presence of Cyclosporine 
• Role of rejection by stopping immunosuppression after 2 weeks. 
	
4.2.2.1	 Cell	preparation	
 
The cells even when fully trypsinised did not separate from each other 
completely and remained in clumps. This made it difficult to determine the exact 
number of cells by cell counters, flowcytometry or by haemocytometers.  
To standardize the numbers of cells injected into the animals weused two 
75cm2 flasks at approximately 80% confluence for injection. This gave a tumour 
load of around 1.2×107 cells per animal at the time of subcutaneous injection 
which is similar to the literature figures of between 106-108 cells in small 
animals(178)(179).  
After the cells were trypsinised they were transferred into the 20ml tube 
containing complete medium and were transferred to the animal facility in 
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Newcastle University. There the cells were spun and the medium discarded and 
cells washed gently with DPBS twice before being suspended in 100uL of 
DPBS for the injection. 
 
 
4.2.2.2	 Animal	housing	conditions	
	
All the rats were housed in the animal facility of Newcastle University to very 
high standards. The facility is run by senior veterinary and technical 
professionals and is regularly monitored by the home office staff to ensure 
animal well-being is not compromised at any stage.  
The rats were bought from Charles River® Margate United Kingdom. These 
animals were housed for a week for acclimatisation before any intervention was 
performed. The starting weight of the rats was between 70-80gm as they grow 
quite quick; especially Wistar rats and dosing of luciferin can become an issue 
with bigger animals. weonly used male Wistar and Lewis rats for these 
experiments to avoid any hormonal fluctuations during the study period. 
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Figure 24 Wistar Rats weights   Figure 25 Lewis Rats weights 
(Charles River)  
Difference in weight gain between the two species 
	
 
All the rats were kept in clean quite uncluttered rooms. There was a separate 
procedure room to prevent any distress to the other rats. The light dark cycle 
was 14 hours/ 10 hours. The rooms temperature was kept between 20-24°C at 
all times.  
The bedding was wooden shaving, which was kept dry and changed regularly. 
Tap water was supplied without any restrictions and animals were fed pelleted 
chow. 
 
4.2.2.3	 Tumour	cell	injection	
 
The animals were anaesthetised as per protocol described later. Right flank of 
the animals were shaved in preparation of the injection.  
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A 25 G needle was used for the subcutaneous injection of the tumour cells. 
Before any injection of the cells, a small proportion of these cells were checked 
in the IVIS machine by adding Bright-Glo to make sure they were still 
expressing the luciferase.  
The flank skin was pinched and after gentle mixing of the cells in the syringe 
they were injected in the subcutaneous plane. 
A single syringe was used for injecting one animal. weavoided vigorous shaking 
to minimise the trauma to the cells, although a gentle flick before the injection 
was done to make sure they were adequately suspended in the medium. 
4.2.2.4	 Intraperitoneal	Luciferin	injection	
	
To enable the animals to bio-luminesce, substrate of luciferase, luciferin was 
injected into the rats. The easiest way of injecting these animals with multiple 
luciferin injections was through intraperitoneal injections as repeated 
intravenous administration through tail vein can lead to thrombosis and prevent 
further luciferin delivery. 
The preferred site was the left lower abdominal quadrant with a 21-gauge 
needle.  
The dose of luciferin was calculated for all the animals before starting the 
experiments based on their weights.   
The animals were manually restrained with the head pointing down to get the 
bowel out of the way of injection and then the luciferin was injected with a 
needle just penetrating the abdominal wall. 
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The luciferin was bought from Gold biotechnology® Missouri USA. This was D-
Luciferin, potassium salt that was water-soluble. The luciferin was dissolved in 
PBS to make the stock solution with a concentration of 80mg/ml. This was 
achieved by dissolving 1 gm of GoldBio Luciferin in 12.5mls of PBS. The 
recommended dose of luciferin was 150mg/kg body weight of the rat and the 
optimal concentration for IP injection was 15mg/ml. For a 100gm rat this came 
to 1ml of the solution to get the recommended concentration of 150mg/kg. 
weused the following formula to calculate the dose  
 
 
 
 
4.2.2.5	 Luciferin	kinetic	curve	
 
At the beginning of every new batch of animals the kinetic curve of luciferin was 
calculated. Intraperitoneal (IP) injection of luciferin has to be absorbed through 
the peritoneal membrane and then it gets into the blood stream, followed by the 
delivery to the subcutaneous right flank region where the transfected cells were 
transplanted. This process can vary a lot depending on multiple variables 
 
Dose of Luciferin  =  0.15 × Weight of rat in grams  
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including the size of the animal, accuracy of the injection, temperature of the 
injected luciferin and the general well being of the animal as well as the 
conscious status of the rat.  
To minimise any variability wetried to keep these variables to as minimum as 
possible and also calculated the kinetic curve of luciferin. It gave a rough 
estimation of the peak absorption of the drug in that particular rat which could 
be generalised for similar animals.  
Kinetic curve was calculated by multiple exposures to the IVIS camera after IP 
injection (Fig 26). Five minutes after the injection the animals were first scanned 
and every two minutes for a total of 25 minutes then onwards. The brightest 
reading occurred when there was a maximum concentration of luciferin 
available at the target tissue and that time was the optimal for further imaging.  
For our experiments this time was 15 minutes after the luciferin injection. To 
reduce any bias even further, wealways took two reading when imaging the 
animals on either side of the 15 minutes and the higher reading was used for 
the analysis.  
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Figure	26	Kinetic	 curve	 of	 Luciferin.	 Calculated	 for	 Lewis	 rat	 in	 the	 Pilot	 study.	 The	 radiance	was	 calculated	 by	
subtracting	the	background	signals	from	the	signals	of	Region	of	Interest	(ROI).	
 
4.2.2.6	 Anaesthetic	protocol	
  
The animals were induced in the anaesthetic induction chamber of either the 
IVIS spectrum machine or the separate induction chambers in the procedure 
room.  
Before the experiments wemade sure that the vaporiser containing Isoflorane 
and the Oxygen tank were full. Firstly the Oxygen was turned on at a flowmeter 
rate of 1 litre/minute and the rat was placed in the induction chamber and the lid 
secured. The stopcock to the induction chamber was then opened with the 
vapour dial at 3% for isoflorane. Normally it took the animals 2-3 minutes before 
they fell unconscious. At this stage the stopcock was turned for the imaging 
chamber of the IVIS and the animals were placed there with their noses 
0	
500	
1000	
1500	
2000	
2500	
3000	
3500	
4000	
5	 7	 9	 12	 15	 18	 20	 25	 30	
Av
er
ag
e	
Ra
di
an
ce
	
Times	of	imaging	
Kineec	curve	of	D-Liciferin	
Average	radiance	
Chapter	4-108	
	
positioned into the nose cones. At this point the concentration of the isoflorane 
was between 1-2% depending on the size of the rats.  
Once the animals were there and they were stably anaesthetised, the imaging 
was commenced. 
	
Figure	27	Anaesthetic	chamber	and	isoflorene	delivery	system	of	IVIS	spectrum.	
	
	
Figure	28	Anaesthetic	manifold.	Nose	cones	for	maintenance	of	anaesthesia	in	the	imaging	chamber	
	
	
4.2.2.7	 	 Experimental	protocol	
 
The cells were trypsinised, washed, prepared and injected according to the 
above-mentioned protocols. After the injection of the cells, the animals were 
Charcoal	filters		
	
	
	
Isoflorene	container	with	vapour	dial	at	the	
top	
Anaesthetic	chamber	for	induction	
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also injected with luciferin and then scanned in the IVIS spectrum. The animals 
were scanned under the automatic exposure if there were positive signals and 
in the absence of any signals they were exposed for the maximum exposure of 
5 minutes to detect any faint signals. 
After the first scan the animals were recovered in the cages under direct 
observation until mobile.  
After the initial scan, the animals were scanned once every week for a total of 4 
weeks. After the end of the study period of 4 weeks these animals were culled 
by schedule 1 as per home office protocol by cervical dislocation and a post 
mortem performed to detect any gross metastasis. Harvesting of spleen and 
enlarged lymph nodes was performed at this stage for flow cytometric analysis. 
 
4.2.3	 	 Results	
 
4.2.3.1	 Tumour	growth	in	well	matched	(Wistar)	and	poorly	
matched	(Lewis)	rats	with	no	immunosuppression	
	
4.2.3.1.1 Well-matched group 
	
Wistar rats were injected with 1.2×107 BP36b cells in the right flank and the 
animals were scanned on the day of injection and then every week for 4 weeks. 
Generally there was a steady decline in the number of cells as depicted by 
reducing luminescence on IVIS images. By week 1 most of the cells were 
“rejected” and by the 2nd week there was no residual luminescence at all (fig 
29). This demonstrates that in the absence of any immunosuppression there 
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was a trend to eliminate the tumour load. As it was the Wistar cell line injection 
into Wistar rats, this group was a well-matched combination. Despite the cell 
line and the animals of being of similar strain, they were not identical as Wistar 
rats are out bred. Due to the small number of animals, no statistical analysis 
was performed at this stage. 
 
	
Figure 29 Tumour behaviour in the well-matched group with no 
immunosuppression. The entire tumour load was cleared within two weeks. The three 
lines represent three Wistar rats in this group. 
	
	
4.2.3.1.2 Poorly matched group 
	
Two Lewis rats were injected with 1.2 × 107 cells into the right flank. The 
animals were scanned on day 0 and then once every week. Tumour present at 
day 0 of injection disappeared at 1st week IVIS scan as opposed to the Well-
matched Wistar group above, where tumour took two weeks to clear from the 
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immuno-competent animals. This was in line with the hypothesis that the 
tumour would be rejected quicker in a poorly matched animal. 
 
	
Figure 30 Tumour behaviour in the poorly matched group with no 
immunosuppression. The entire tumour load was cleared within first week. The two lines 
represent the Lewis rats in this group. 
	
4.2.3.2	 Tumour	growth	in	the	presence	of	Cyclosporine	in	Lewis	
rats	
	
Two Lewis rats were injected into the right flank with 1.2 × 107 cells under the 
cyclosporine immunosuppression which was continued for four weeks. The 
dose of cyclosporine was selected to be 25mg/kg/day as per the commonest 
dose in literature for immunosuppression purposes(180)(181)(182). Animals 
were scanned every week in the IVIS spectrum. In the presence of cyclosporine 
the tumour continued to grow for the duration of the study with rapid exponential 
growth towards the later half.  
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Figure 31 Tumour behaviour in the poorly matched group with CsA 
immunosuppression. The tumour continued to grow with time during the study period. 
The two lines represent the Lewis rats in this group. 
	
	
Figure 32 Lewis rat with cyclosporine immunosuppression. The tumour injected 
into the right flank has continued to grow. 
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4.2.3.3	 Role	of	rejection	by	stopping	immunosuppression	after	
2	weeks.	
	
Two Lewis rats were injected with 1.2 × 107 cells into the right flank under the 
immunosuppression of cyclosporine. To study the effects of rejection the 
treatment was continued for two weeks and then stopped. Imaging of these 
animals was carried out until 4 weeks after the original injection. Under the 
immunosuppression the tumour kept on growing while after stopping the 
immunosuppression the tumour disappeared within 2 weeks highlighting the 
possible role of rejection(fig33).  
 
	
Figure 33 Tumour behaviour in the poorly matched group with CsA 
immunosuppression stopping after two weeks. The tumour continued to grow with time 
during the initial half while after stopping the treatment the entire tumour load was 
cleared. The two lines represent the Lewis rats in this group. 
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Figure 34 Effects of treatment withdrawal. Example of a rat at Week 2 (left)(with 
immunosuppression) and week 4 (right) (after stopping the immunosuppression for 2 
weeks). The coloured area over the fir in the right image is the “noise” of the IVIS 
imaging due to long exposure times to detect even very low radiance from the region of 
interest.	
	
The basic purpose of these experiments was to make sure that the proposed 
intervention would be possible before embarking on the large-scale 
experiments. With these preliminary experiments wedetected the trend of 
tumour cells being rejected as any other allogeneic transplanted tissue.  
With the initial success of these experiments, westarted the experiments on the 
proposed groups. 
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4.3	 	 CONTROL	GROUP	TO	STUDY	BEHAVIOUR	OF	TUMOUR	
WITHOUT	IMMUNOSUPPRESSION	IN	A	WELL-MATCHED	
COMBINATION		
	
4.3.1	 	 Background	
	
The tumour cells were derived from the Wistar rats and when they were 
transplanted into the Wistar animals, they behaved as a well-matched 
combination. As the Wistar rats were out bread animals, despite being of the 
same strain, there were some differences between the animals’ MHC and the 
cell line. This arrangement mimicked the human situation very closely, where 
even in very good matches between the donor and the recipients there are still 
some differences in the HLA loci. Thus this was therefore a good model to study 
the effects of tumour transplantation. 	
4.3.2	 	 Aim	
	
The main aim was to test animals without immunosuppression and so monitor 
the growth of the tumour in non-immunocompromised situations, as these 
animals then behaved as the controls for the study period.  
These experiments also gave insight into the role of matching on the 
transplanted tumour behaviour. 
4.3.3	 	 Tumour	injection	and	analysis	
	
There were a total of 6 animals in this group. All were Wistar male rats, which 
were acclimatised for one week before the tumour injection in the right flank 
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under anaesthesia. Before the injection of the cells they were tested and 
confirmed for bioluminescence.  
The animals were scanned on the day of injection, and once a week there after 
as per above-mentioned protocol. As these animals were not under the 
influence of any immunosuppressive medication, the scanning of these animals 
was stopped once there were no further bioluminescent signals detected, 
meaning that the entire tumour load had been rejected.  
In this group weobserved that there was a reduced signal to the initial radiance 
on the 1st week’s scan and by the second week all the animals had rejected the 
tumour cells completely.  
After the last scan these animals were culled. A careful post mortem failed to 
detect any gross tumour growth either at the site of initial injection or any 
evidence of enlarged lymph nodes.  
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Figure 35 Role of acute rejection. Rejection of all of the injected tumour cells in the 
absence of any immunosuppression in well-matched Wistar animals within two weeks. 
 
For the data analysis, after the animals were scanned in the IVIS spectrum, the 
regions of interests (ROI) were designated manually. A region of interest (ROI) 
is a user-specified area in an optical image, which the software uses to create, 
and computes objective values of the photon emission which is direct 
representation of the number of healthy luciferase expressing cells. This data 
was then used for statistical analysis. weused two types of ROI; measurement 
ROI which measured the signal intensity in an area of the image with positive 
signals or initial injection (in case of no signals) and an average background 
ROI that measured the average signal intensity in a user-specified area of the 
image that was considered background. 
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The image data output was in photons and emission of photons from the region 
of interest was calculated as radiance, which was displayed in 
photons/sec/cm2/sr. 
While the counts are a relative measure of the photons incident on the CCD 
camera, the photons are absolute physical units that measure the photon 
emission from the subject. 
The radiance unit of photons/sec/cm2/sr is the number of photons per second 
that leave a square centimetre of tissue and radiate into a solid angle of one 
steradia (sr). Measurements in units of radiance automatically take into account 
camera settings (for example, integration time, binning, f/stop, and field of view). 
As a result, images of the same subject acquired during the same session have 
the same signal amplitude regardless of the camera settings because the 
radiance on the animal surface does not change. The advantage of working 
with image data in the photons mode is that camera settings can be changed 
during an experiment without having to adjust the images or the measured ROI 
data. 
	
	
4.4	 CONTROL	GROUP	TO	STUDY	BEHAVIOUR	OF	TUMOUR	
WITHOUT	IMMUNOSUPPRESSION	IN	A	POORLY	MATCHED	
COMBINATION	
	
	
4.4.1	 	 Background	and	aims	
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Lewis rats are an inbred strain and are hence syngeneic. These animals are 
immunologically compatible in cases of transplantation between the individuals. 
But there are significant differences between Lewis and Wistar strains, meaning 
when these animals were injected with the tumour cells of Wistar origin, this 
group behaved as a poorly matched combination in comparison to the above 
group of Wistar animals. 
Again the aim was to test animals without immunosuppression in order to 
monitor the growth of the tumour in non-immunocompromised situations, as 
these animals then behaved as the controls for the study period for Lewis strain.  
These experiments also gave insight in to the role of matching on the 
transplanted tumour behaviour. 
	
4.4.2	 	 Tumour	injection	and	analysis	
 
There were a total of 6 animals in this group. All were Lewis male rats, which 
were acclimatised for one week before the tumour injection in the right flank 
under anaesthesia. Before the injection, the cells were tested for 
bioluminescence.  
The animals were scanned on the day of injection, and once a week there after 
as per above-mentioned protocols. As these animals were also not under the 
influence of any immunosuppressive medication the scanning of these animals 
was stopped once there were no further bioluminescent signals detected.  
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In this group again wenoticed the rejection of transplanted tumour cells but this 
was much faster when compared to Wistar control rats. All the animals rejected 
the entire tumour load within the 1st week of injection of tumour cells. To 
confirm further, these animals were again scanned for the 2nd week and again 
did not reveal any residual tumour load.   
After the last scan these animals were culled and a careful post mortem 
conducted. This examination failed to detect any gross tumour growth either at 
the site of initial injection nor were there any enlarged adjacent lymph nodes.  
These results were in line with our hypothesis that the response to the 
transplanted tumour could be dependent on the degree of matching between 
the host and the donor. This finding can have important bearing when it comes 
to transplantation 
with restored 
kidneys after 
tumour resection. 
	
 
Figure 36 Role of acute rejection. Rejection of all of the injected tumour cells in the 
absence of any immunosuppression in poorly-matched Lewis animals within just one 
week. 
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4.4.3	 	 Comparison	
	
Figure 37 Direct comparison between Wistar and Lewis rats. Complete rejection of 
transplanted tumour cells; stronger in poorly matched Lewis animals 
 
When	both	these	groups	were	compared,	there	was	a	statistically	significant	difference	
between	the	two	groups	in	terms	of	tumour	rejection	(p	<0.05).	This	is	in	line	with	our	
hypothesis,	that	with	increasing	mismatch	between	the	donor	cells	(Wistar	origin)	and	
hosts,	there	will	be	stronger	rejection	response.	
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4.5	 CYCLOSPORINE	GROUP	
	
Next welooked at the effects of cyclosporine on the transplanted tumour cells. 
This was really important because in clinical scenarios if there is inadvertent 
tumour transmission along with the restored kidneys (after T1a tumour resection 
followed by transplantation), the patients would not be immuno-competent as 
they would most likely be on at least one or two immunosuppressive 
medications. This, we know, takes away one of the body’s first lines of defence 
against de novo and transplanted tumours(165) hence making these patients at 
much higher risk of unchecked tumour growth.  
To check our hypothesis of the effects of immunosuppression on tumour 
growth, and role of matching and rejection on the tumour load elimination 
wedivided these animals into two groups for each strain; ones with continued 
immunosuppression for 4 weeks of study period and one with two weeks of 
immunosuppression and two week after withdrawal to study rejection. 
4.5.1	 	 With	continued	immunosuppression	
	
In this group of rats, the treatment with cyclosporine was continued for the 
entire study period of four weeks to study its effects on transplanted tumour 
cells. 
Cyclosporine was given at a dose of 25mg/kg/day. The cyclosporine was 
started 2 days before the injection of the rats with transfected tumour cells to 
make sure there was adequate level of cyclosporine in circulation at the time of 
the injection. The cyclosporine was administered by oral gavage. After initial few 
gavages the animals were more acclimatised and tolerated the procedure 
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without much resistance. There were no incidences of gavage failure or any 
trauma associated with it.  
The dosing was done once everyday in the mornings without fail. The oral 
solution was used and the formulation was Neoral® oral solution (Novartis 
Pharmaceuticals Corporation New Jersey, USA). 
To further look at the effects of matching on tumour dynamics this treatment 
‘continued’ group was further divided into well-matched and poorly matched 
animals. 
 
4.5.1.1	 Well-matched	and	poorly	matched	combination	
 
There were a total of four Wistar rats in this group. The area of injection of 
tumour cells was shaved at the time of injection and was kept shaved to reduce 
any background interference with the signals and also to enable us to identify 
the area of initial injection site. This helped in marking the Regions of Interests 
(ROIs) when analysing the results. With continued immunosuppression 
webegan to palpate the tumours at the site of initial injection, which continued to 
grow till the end of the study period.  
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Figure 38 Wistar rat with right flank injection. Three weeks after the injection of 
tumour cells. Very high signal intensity from the tumour in the right flank subcutaneous 
tissue. This tumour was palpable at this stage and grew even further till the end of study 
period. 
	
Based on the bioluminescent signals there was initially a steady growth of the 
tumour till third week of the continued immunosuppression followed by 
exponential growth leading to formation of palpable tumour masses in the right 
flank. This perhaps was due to neo-angiogenesis as was evident on gross post 
mortem examination of these rats. 
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Figure 39 Dissection of the right flank. The skin is dissected off the ventral 
abdominal wall. The tumour clearly visible with evidence of increased vascularity around 
the tumour 
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Figure 40 CsA treatment continue group. Rapid growth of transplanted tumour cells 
towards the end of study period represented by bright bioluminescent signals. 
 
	
Similarly there were six Lewis rats in the other group. Same protocol of tumour 
injection and monitoring was adhered to for these animals as well. 
Again, by the end of the study period there were palpable tumours in the right 
flank.  
	
	
Figure	41	Lewis	 rat	 with	 right	 flank	 injection.	 Four	 weeks	 after	 the	 injection	 of	 tumour	 cells.	 Very	 high	 signal	
intensity	from	the	tumour	in	the	right	flank	subcutaneous	tissue.	This	tumour	was	palpable	at	this	stage.		
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Despite the fact that these animals were poorly matched to the injected tumour 
cells, under the influence of cyclosporine there was uninterrupted growth in 
these rats as well. 
With continued cyclosporine immunosuppression, there was both gross and 
indirect (bioluminescent) evidence of continued tumour growth in both strains. 
	
	
Figure	42	CsA	 treatment	 continue	 group.	 Rapid	 growth	 of	 transplanted	 tumour	 cells	 towards	 the	 end	 of	 study	
period	represented	by	bright	bioluminescent	signals.	
	
	
4.5.2	 	 With	treatment	withdrawal	
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In this protocol the rats were given the cyclosporine for two weeks. To assess 
the role of rejection on the tumour cells we experimented with the treatment 
withdrawal protocol. The animals were scanned like the previous protocols. But 
after two weeks of treatment, the cyclosporine was stopped but animals were 
kept alive for another 2 weeks without any treatment. These were scanned as 
normal to monitor the tumour growth.  
	
Figure	43	Flow	 diagram	 of	 protocol	 to	 study	 role	 of	 rejection	 and	 matching.	 After	 two	 weeks	 of	 continued	
immunosuppression	the	treatment	is	withdrawn	to	study	the	effects	of	acute	rejection.	
	
	
4.5.2.1	 Well-matched	and	poorly	matched	combination	
	
In this group, the rats were given standard 25mg/kg/day of cyclosporine via oral 
gavage as previously for two weeks. The animals were scanned once every 
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week. At the two-week mark, the cyclosporine was stopped and rats were 
continued to be scanned once every week for another week till the end of study 
period. At the end of a total of four weeks, all the animals were euthanased and 
post mortem performed as usual. 
There were a total of eight animals in this group. There were strong 
bioluminescent signals from these rats till the immunosuppression was stopped. 
After that the bioluminescence started to reduce and eventually disappeared in 
majority of the animals. At the end of the study period, there were still four 
Wistar rats with positive tumour load. 
	
Figure	44	CsA	 treatment	withdrawal	 group.	Wistar	 rats	 at	 4	weeks	post	 tumour	 cells	 injection.	 This	 image	was	
taken	after	300	seconds	of	exposure	(maximum)	to	detect	any	left	over	signals	from	the	transfected	tumour	cells.	
The	rat	on	the	left	side	has	rejected	the	entire	tumour	load	while	there	was	still	positive	signals	from	the	Wistar	
on	the	right	of	the	image.		
	
	
By	the	end	of	the	study,	half	of	the	animals	have	rejected	the	tumour	fully	while	the	
rest	still	had	considerable	load	of	the	tumour	cells.	This	was	in	contrast	to	the	animals	
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in	the	well	matched	treatment	continued	group	where	the	tumour	continued	to	grow	
in	all	the	animals.	
	
	
	
Figure	45	CsA	treatment	withdrawal	in	Wistar	rats.	Continued	growth	of	the	transplanted	tumour	cells	under	the	
influence	of	 CsA	 immunosuppression	 till	 two	weeks.	 This	was	 followed	by	 reduction	 in	 bioluminescent	 signals	
due	to	withdrawal	of	immunosuppression.	
	
Again with the Lewis rats the treatment with cyclosporine was continued for two 
weeks, at which point the treatment was stopped and once weekly scanning 
was continued.  
There were a total of six Lewis rats in this group. Again under the cyclosporine 
immunosuppression the tumour continued to grow but after stopping the 
immunosuppression, by the end of the study period there was no detectable 
bioluminescence from any of the animals. 
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Figure	46	CsA	poorly	matched	 rats.	 Lewis	 rats	at	 two	weeks	of	 cyclosporine	 immunosuppression.	Bright	 signals	
were	achieved	from	all	the	animals	tested.		
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Figure	47	CsA	 Poorly	 matched	 rats	 with	 treatment	 withdrawal.	 Lewis	 animals	 at	 four	 weeks	 after	 the	 initial	
injection.	This	scan	was	done	two	weeks	after	stopping	the	immunosuppression	and	no	signals	were	detected	
	
	
	
	
Figure	48	CsA	 Poorly	matched	 rats	 with	 treatment	 withdrawal.	 Continued	 growth	 of	 the	 transplanted	 tumour	
cells	 under	 the	 influence	 of	 CsA	 immunosuppression	 till	 two	 weeks.	 This	 was	 followed	 by	 complete	
disappearance	of	bioluminescent	signals	after	the	withdrawal	of	immunosuppression.	
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4.5.3		Comparison	
	
When the results of the two strains (Wistar and Lewis) were compared head to 
head, we found that under the influence of continued cyclosporine 
immunosuppression the tumour continued to grow in both strains. The growth 
was exponential towards the end of the study period, most likely due to 
neoangiogenesis.  
The growth of tumour was significantly more in Wistar group of animals as 
compared to Lewis at the end of 4 weeks (p<0.05).	
	
Figure	49	Direct	 comparison	 of	Wistar	 and	 Lewis	 rats	 with	 continued	 CsA	 immunosuppression.	 The	 growth	 of	
tumour	was	significantly	stronger	among	well-matched	Wistar	animals.	The	scanning	schedule	in	weeks	is	shown	
at	the	X-axis.	
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When comparison was made between the two strains, representing well 
matched and poorly matched combinations, after withdrawal of treatment the 
poorly matched animals appeared significantly well equipped to reject any 
tumour load than well matched Wistar animals. The most likely explanation of 
this effect is the level of MHC matching, mounting stronger acute rejection 
response in the less well-matched animals. Again on direct comparison the 
results were statistically significant	(p	<0.05).		
	
	 	 	 Wistar	 	 	 	 	 	 Lewis	
Figure	50	Direct	comparison	of	Wistar	and	Lewis	rats	in	withdrawal	of	CsA	immunosuppression.		Lewis	rats	were	
significantly	more	effective	in	rejecting	tumours	when	compared	with	the	well-matched	Wistar	rats.	
	
4.6	 SIROLIMUS	TREATMENT	GROUP		
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After finishing the control group of cyclosporine immunosuppression, we looked 
at the effect of Sirolimus immunosuppression on the transplanted tumour 
behaviour. 
4.6.1	 			 Background	
	
The reason for selecting Sirolimus was two fold. Firstly, Sirolimus has shown 
promising results due to its anti neoplastic properties. Secondly, long-term 
treatment with cyclosporine can lead to chronic allograft nephropathy and 
preservation of a smaller (resected) kidney with a non-nephrotoxic drug could 
be preferable. 
The most important reason for using an mTOR inhibitor was the possibility of 
tumour regression in an immunosuppressed host. 
Sirolimus is a fermentation product of microorganism Streptomyces 
hygroscopicus. It is a potent inhibitor of T and B cells as a response to antigen 
stimulation. For the activation of lymphocytes there has to be interaction of 
interleukins and IL receptors as well as co-stimulatory molecules (CD28), which 
then leads to activation of TORC1 complexes. Sirolimus binds to FK binding 
protein 12(FKBP 12) and this complex blocks the activation of TORC1 complex 
leading to cell cycle arrest in late G1 phase(109). 
It also has a direct inhibitory effect on the apoptosis of dendritic cells which 
have a pivotal role in the transplant immunology(110). It also inhibits cytokine 
and growth factor stimulated proliferation of the fibroblasts, tumour cells and 
smooth muscle cells(111)(112)(113).  
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Sirolimus has also been used as a sole agent in the maintenance phase of 
immunosuppression after transplantation. One of the first big trials with more 
than 400 patients from Manchester showed better creatinine clearance in the 
sirolimus arm when it was used as a maintenance immunosuppression after the 
withdrawal of CsA at 3 months post transplant(120). An RCT from Cambridge 
suggested that the impaired graft function possibly due to CNI nephrotoxicity 
could be reversed with sustained improvement at 2 years post transplant by 
conversion to sirolimus at three months. This along with other similar studies 
point to potential benefits of sirolimus as a maintenance agent in terms of graft 
function and to potentially reduce the incidence of chronic allograft 
nephropathy(121). 
There are several studies, which suggest that with sirolimus based 
immunosuppression the over all rates of de novo malignancies are significantly 
less than CsAs. There was a large retrospective analysis performed on post 
transplant malignancies in more than 33 thousand deceased donors from 264 
centres in USA. This study looked at both the skin and non-skin solid organ 
malignancies rates and showed that the rate of malignancies with 
sirolimus/everolimus plus CNI combination was 0.6% as compared to CNI, 
alone which was 1.81% (92).  
Efficacy of mTOR inhibitors has also been showed in cases of advanced renal 
cell carcinoma. A large double blind trail randomised 272 patients into 
everolimus group and 138 in placebo arm for the treatment of advanced renal 
cell carcinoma. There was progression of disease in 37% of patients in the 
treatment arm as opposed to 65% in the placebo arm (p</= 0.0001) with a 
median disease free survival of 4.0 versus 1.9 months(123). 
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Similar encouraging results were noted when everolimus was used for the 
patients with advanced pancreatic neuroendocrine tumours. 207 patients in the 
treatment were compared with 203 patients in placebo arm and were found to 
have significantly better progression free survival of 11 months as compared to 
4.6 months in the placebo arm (p <0.001). 34% of patients were still alive at 18 
months as compared to 9% with placebo(124). 
mTOR inhibitors were found to be useful in hepatocellular carcinomas and in 
advanced breast carcinomas as well(125)(126). 
mTORs have been shown to be effective for the post transplant 
lymphoproliferative disorders as well. A case of complete remission of 
disseminated PTLD has been reported in literature after conversion to 
sirolimus(127). 
With increasing cohort of patients on immunosuppression post transplant there 
is an increasing incidence of Kaposi’s sarcoma. mTOR inhibitors have been 
found useful for their treatment as well. A case series of 25 patients with 
cutaneous Kaposi’s sarcoma when converted from cyclosporine to sirolimus 
showed complete biopsy proven remission within 6 months of treatment(128). 
These effects of mTOR inhibitors are very encouraging and over the past 10 
years there has been mounting evidence on their efficacy. Although by no 
means these are the perfect solutions but a medication to be 
immunosuppressive and anti neoplastic in transplant setting is very useful 
feature that wetried to explore.  
4.6.2	 	 Dose	
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The dose used in animal studies varies between the types of intended 
intervention. For its immunosuppressive and inhibitory effects on vascular 
intimal hyperplasia the dose range is reported to be between 0.3-0.5mg/kg/day 
orally. The studies where both cyclosporine and sirolimus have been used 
together the target dose was lower to achieve the therapeutic levels due to 
synergism in the pharmacokinetics(183)(184)(185).  
Where Rapamycin was used for the treatment of urothelial carcinomas, the 
most common dose used was 2mg/kg/day(168)(186). 
For our experiments, we used two different doses of sirolimus. The lower dose 
weused was 0.5mg/kg/day while the high dose tested was 2mg/kg/day. 
4.6.3	 		 Sirolimus	high	dose	
	
4.6.3.1	 With	continued	immunosuppression	
	
Again this group was divided into well-matched and poorly matched animals. 
There were 6 animals in each group tested. 
 
 
4.6.3.1.1 Well-matched and poorly matched combination 
	
1.2 × 107 cells were injected into the Wistar and Lewis rats in the right flank as 
per protocol under general anaesthesia. Sirolimus was started a day before the 
tumour injection and was continued for a total of four weeks of treatment via 
oral gavage. There were 6 Wistar rats in this group and the behaviour of tumour 
Chapter	4-139	
	
was studied by once weekly IVIS spectrum scanning under general 
anaesthesia.  
With sirolimus dosing, all the Wistar animals were free of tumour load at the 
third scanning (two weeks from the day of subcutaneous injection).  
This effect was stronger in the high dose group (2mg/kg/day) when compared to 
low dose group (0.5mg/kg/day). 
	
Figure	51	Well-matched	 (Wistar)	 animals	 with	 continued	 sirolimus	 immunosuppression.	 All	 tumour	 load	 was	
cleared	by	the	week	two	of	the	study	period.	
 
With high dose of sirolimus all the six Lewis rats cleared the tumour load as 
evident by lack of any IVIS bioluminescent signals by week two of study period. 
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Figure	52	Sirolimus	high	dose	with	continuous	immunosuppression	in	poorly	matched	animals.	Again	all	animals	
rejected	the	tumour	cells	with	first	two	weeks	of	study	period.	The	scanning	was	done	once	every	week	(Week	0,	
1,2,3,4)	
	
4.6.3.2	 With	treatment	withdrawal	
	
To study the role of acute rejection in tumour elimination these animals were 
given sirolimus immunosuppression for initial two weeks from tumour injection 
and then the immunosuppression was withdrawn till the end of the study period. 
Tumour behaviour was monitored with once weekly IVIS imaging as previously. 
This group was further divided into two subgroups based on matching. 
 
4.6.3.2.1 Well-matched and poorly matched combination 
	
There were 6 rats in each of these high dose groups. 
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All the animals had rejected the tumour cells by the week 2 of IVIS spectrum 
scanning. All the animals were scanned till the completion of the study period of 
four weeks even if there was no detectable signal while the study was still 
underway. This helped not only in confirming the initial results but also ruled out 
absence of signals due to technical problems. 
 
	
Figure	53	Well-matched	Wistar	treatment	withdrawal.	Animals	again	rejected	the	tumour	load	with	the	first	two	
weeks	 of	 high	 dose	 sirolimus.	 There	was	 no	 reappearance	 of	 tumour	 cells	 after	 treatment	withdrawal	 at	 any	
point	of	study	period.	
 
 
	
There were six animals in poorly matched group as well but three animals died 
during scanning. This was completely unexpected and happened during the 1st 
scanning episode for these animals. All the other variables were similar to any 
other scanning protocol after tumour injection. These animals were acclimatised 
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for a week before any experimentation, were kept in same conditions to the rest 
of the animals, the anaesthetic protocol was similar as well. Other animals 
studied and scanned that day did not have any adverse effects. The post 
mortem examination of these animals did not reveal any thing unusual either. 
The tumour load was eliminated fully by week three scanning. 
 
	
Figure	54	Poorly	matched	treatment	withdrawal.	In	these	three	Lewis	animals,	there	was	some	residual	signals	by	
the	week	 two	scanning.	At	week	 three	 there	were	no	signals	 left	again	proving	 the	effectiveness	of	 treatment	
withdrawal.	
 
 
4.6.4	Sirolimus	low	dose	
	
4.6.4.1	 With	continued	treatment		
		
Similarly this group was divided into two to include both Wistar and Lewis 
strains. 
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4.6.4.1.1 Well-matched and poorly matched combination 
	
This group consisted of 6 Wistar and 6 Lewis rats receiving 0.5mg/kg/day of 
sirolimus. By week 3, all the animals had rejected the entire tumour load. This 
was consistent with the earlier finding with the high dose group, apart from a 
slightly longer time taken for tumour cells elimination. 
 
 
	
Figure	55	Low	dose	sirolimus	treatment.	Week	1	and	week	4	IVIS	images	of	the	Wistar	rat	with	low	dose	sirolimus	
treatment.	There	is	complete	elimination	of	tumour	load	during	the	study	period.	
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Figure	56	Low	dose	sirolimus	treatment.	Well	matched	Wistar	animals	with	continued	immunosuppression	with	
low	dose	Sirolimus,	again	was	successful	in	clearing	all	the	tumour	load	by	week	three	of	scanning.	
 
 
	
Figure	57	Poorly	matched	–	Low	dose	sirolimus.	Week	1	and	week	4	IVIS	images	of	the	Lewis	rat	with	low	dose	
sirolimus	treatment.	There	is	complete	elimination	of	tumour	load	during	the	study	period.	
Time points 0,1,2,3 & 4 weeks
B
io
lu
m
in
es
ce
nc
e 
ph
ot
on
s/
se
c/
sr
/c
m
2
1 2 3 4 5
-100000
0
100000
200000
300000
Sirolimus low dose Well matched animals 
Chapter	4-145	
	
	
Figure	58	Low	dose	sirolimus-Lewis	rats.	Poorly-matched	Lewis	animals	with	continued	immunosuppression	with	
low	dose	Sirolimus,	again	was	successful	in	clearing	all	the	tumour	load	by	week	four	of	scanning.	
	
4.6.4.3	 Treatment	withdrawal	
	
This group was divided into Wistar and Lewis animals as well. 
4.6.4.3.1 Well-matched and poorly matched combination 
	
This group had 6 Wistar rats receiving low dose sirolimus treatment for two 
weeks followed by discontinuation. Again all the animals rejected the tumour 
load at the end of the study period of 4 weeks. By the time the treatment was 
withdrawn, the tumour load was already reducing. This was in contrast to the 
cyclosporine group. 
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Figure	59	Well-matched	 rats	 with	 low	 dose	 sirolimus.	 The	 tumour	 load	 was	 reducing	 which	 continued	 upon	
treatment	withdrawal	and	by	the	end	of	study	period	there	were	no	bioluminescent	signals	left.	
	
4.6.4.4	 Poorly	matched	treatment	withdrawal	
	
This group had 6 Lewis rats receiving low dose sirolimus treatment for two 
weeks followed by discontinuation. In this group, all the animals rejected the 
tumour load by week 3 of the study period. Again this effect was in accordance 
to the previous observations that the rejection of the tumour is significantly 
stronger in the less well-matched group of rats. Due to the very strong primary 
effect of sirolimus itself, there was no significant difference between these 
groups on direct comparison. This observation was most likely due the fact that 
at the time of treatment withdrawal, the tumour load is already so small that we 
fail to elicit any significant differences between these groups. 
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Figure	60	Lewis	 rats-Treatment	 withdrawal.	 Week	 0	 and	 week	 4	 IVIS	 images	 of	 the	 Lewis	 rat	 with	 low	 dose	
sirolimus	treatment	withdrawal.	There	is	complete	elimination	of	tumour	load	during	the	study	period.	
	
	
	
Figure	61	Lewis	 animals	 with	 low	 dose	 sirolimus	 treatment	 withdrawal.	 The	 tumour	 load	 was	 reducing	 which	
continued	upon	treatment	withdrawal	and	by	the	end	of	week	three	there	were	no	bioluminescent	signals	left.	
	
		
4.7	 	 LEFLUNOMIDE	
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4.7.1	 	 Background	and	dosing		
	
Leflunomide has both immunosuppressive and anti-inflammatory effects. The 
main effect is exerted by its inhibition of pyrimidine synthesis pathway. This 
prevents the availability of pyrimidine to the lymphocytes, which depend solely 
on the de novo synthesis of the pyrimidines as they lack the pyrimidine salvage 
pathway.  
Although currently not used as a standard immunosuppressive in solid organ 
transplantation but it has been used previously with promising results 
comparable to the cyclosporine immunosuppression. Various studies have 
shown anti tumour role of these agents(171)(138)(172)(139)(140), which makes 
leflunomide suitable to assess our hypothesis. 
The dose of leflunomide used for our experiments was 20mg/kg/day. This was 
based on the various dose ranges used in literature for rats in transplantation 
models. The doses range from 5mg/kg/day to 35 mg/kg/day(187)(188)(133). 
The powdered form of leflunomide was purchased from Stratech Scientific Ltd. 
Suffolk, United Kingdom. The powdered form is not soluble in water and hence 
was dissolved in DMSO according to the literature and manufacturer’s 
instructions(189)(190)(191). 54mg leflunomide was dissolved in 1 ml of filtered 
DMSO to make up stock solution that was then diluted in drinking water to make 
up final concentrations for animal use.  
weonly studied the effects of leflunomide in Wistar rats (well matched group). 
This was due to the use of some animals at the beginning of the pilot study for 
the proof of the concept.  
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4.7.2		With	continued	immunosuppression	in	well	matched	group	
	
There were 7 Wistar animals in this group. The tumour cells were injected in the 
right flank and animals were gavaged with oral solution of leflunomide at the 
previously agreed dose of 20mg/kg/day. The rats were scanned in IVIS 
spectrum once weekly.  
Three out of 7 Wistar rats in this group rejected the tumour by the end of the 
study period. The remaining number of animals showed a trend towards 
reducing tumour load as well, but were unable to eliminate the bioluminescent 
signals completely during the course of study period.  
	
Figure	62	Well-matched	Wistar	animals	in	the	leflunomide	treatment	continue	arm.	There	was	a	steady	decline	in	
the	bioluminescent	signals	from	these	animals	from	tumour	injection	site.	Despite	weakening	signals	not	all	the	
animals	rejected	complete	tumour	load	by	the	end	of	the	study	period.	
	
4.7.3		With	treatment	withdrawal	in	well	matched	animals	
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Again 7 Wistar rats were studied in this group. Leflunomide was stopped after 
two weeks of continuous treatment and animals were monitored for tumour 
behaviour. By the end of the study period, four out of the 7 animals studied in 
this group had rejected the tumour and showed no bioluminescence. The rest of 
the animals although did have positive signals but the intensity of the signal was 
significantly lower than at the beginning of the study. 
 
	
 
Figure	63	Leflunomide	 treated	Wistar	 animals-treatment	withdrawal.	 Complete	 elimination	of	 the	 tumour	 load	
from	the	Wistar	rats.	There	is	considerable	background	“noise”	which	is	due	to	long	exposure	times	to	detect	any	
small	residual	tumour	bioluminescence.		
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Figure	64	Treatment	withdrawal	after	two	weeks	in	Leflunomide	treated	animals.	By	the	end	of	study	period	4/7	
animals	have	rejected	the	tumour	load	and	rest	were	showing	reducing	tumour	load.	
 
 
4.8		 COMPARATIVE	ANALYSIS		
	
The focuses of the comparative analyses were to look at the role of matching 
and acute rejection on the tumour elimination. The second part was focused at 
looking at the role of different immunosuppressive agents on the behaviour of 
transplanted tumour cells. 
	
4.8.1	 	 Role	of	matching	on	tumour	rejection	
	
As mentioned earlier when there was no immunosuppression given, the poorly 
matched animals were far more effective in rejecting the tumour load as 
opposed to the well-matched Wistar animals. This difference between groups 
was significant (p<0.05). The tumour elimination was much more rapid in the 
Lewis animals as below. 
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Figure	65	Direct	 comparison	between	Wistar	 and	 Lewis	 rats	 after	 tumour	 cells	 injection.	 Complete	 rejection	of	
transplanted	tumour	cells;	stronger	in	poorly	matched	Lewis	animals	
	
	
Similar effect was evident in the treatment groups. Although to some extent it 
could be appreciated among all treatments studied but this effect was most 
pronounced in the cyclosporine group. This was due to the observation that the 
tumour growth continues under this immunosuppression and at the time of 
withdrawal of treatment there was still a significant tumour load.  
Two different sets of observations proved our hypothesis of a positive role of 
acute rejection in tumour destruction. Firstly, reduction of tumour load after 
treatment withdrawal among the same group of animals, and secondly 
comparing the effects of withdrawal of treatment across well matched and 
poorly matched strains. 
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4.8.2	 	 Rejection	within	similar	strain		
	
The best example of role of rejection within a strain was in cyclosporine group 
as mentioned above. For Wistar rats, when the treatment was withdrawn, half 
the animals rejected the tumour load entirely as opposed to the continued 
growth of the tumour in the treatment continue group (fig 66 and fig112).  
	
	
	
Figure	66	Comparison	 between	 treatment	 continue/withdrawal	 groups	 in	 CsA	 treatment-Wistar	 animals.	 As	
opposed	to	continued	treatment,	there	was	significant	reduction	in	tumour	load	after	treatment	withdrawal.	For	
comparison	purposes	the	bioluminescent	ranges	are	kept	similar	on	Y	axis	hence	the	final	reading	in	CsA	group	is	
out	of	the	scale.	
	
The tumour load was significantly reduced at the end of the study period after 
treatment withdrawal (p<0.05 Mann Whitney U test). These statistical 
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differences were noted from week 3 and 4, before that the differences in the 
bioluminescence were not significant affirming the role of acute rejection after 
the treatment withdrawal. 
Similar effects were seen in the Lewis rats before and after treatment 
withdrawal (fig 67 and fig 113). 
	
	
	
Figure	67	Comparison	 between	 treatment	 continue/withdrawal	 groups	 in	 CsA	 treatment-Lewis	 animals.	 As	
opposed	to	continued	treatment,	there	was	significant	reduction	in	tumour	load	after	treatment	withdrawal.	For	
comparison	purposes	the	bioluminescent	ranges	are	kept	similar	on	Y	axis	hence	the	final	reading	in	CsA	group	is	
out	of	the	scale.	By	the	end	of	study	in	treatment	withdrawal	group,	all	the	animals	have	cleared	the	tumour	load	
fully.	
	
Again there were no differences between the two groups when compared up to 
week three of the treatment but by week 4 there was significant difference in 
signal emissions (p<0.05). 
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4.8.3	 	 Rejection	between	strains		
	
Again this effect was best shown in the cyclosporine group. When Wistar and 
Lewis rats were compared against each other after treatment withdrawal, poorly 
matched Lewis animals were significantly (p<0.05) well equipped in rejecting 
the tumour cells. This effect was likely due the wider MHC differences in these 
animals to the injected tumours cells from Wistar rats as all the animals in the 
Lewis group rejected the tumour load after treatment withdrawal while only half 
were able to clear the tumour load by the end of the study period (fig 68 and fig 
114). 
 
	
	
	
Figure	68	Direct	 comparison:	 treatment	 withdrawal	 Wistar	 v	 Lewis.	 Although	 well	 matched	 animals	 showed	
significant	tumour	rejection	after	treatment	withdrawal,	the	poorly	matched	Lewis	animals	were	most	effective	
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in	eliminating	complete	tumour	load.	These	results	were	clear	in	CsA	group,	as	there	was	significant	tumour	load	
at	the	time	of	withdrawal	of	treatment.		
	
Although there were brighter bioluminescent signals in the Lewis animals at the 
time of injection (time 0), by the end of the study period despite having more 
tumour load to start with, these rats were better in rejecting the tumour load (p 
<0.05 at week 4).  
As mentioned earlier due to effectiveness of sirolimus in tumour elimination 
even at low dose, we did not see any difference between treatment withdrawal 
and continuation groups and between the well-matched and poorly matched 
groups (fig 69 and fig 115).  
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Figure	69	Sirolimus	 treatment	 low	 dose.	 There	 was	 no	 difference	 between	 well-matched	 and	 poorly	 matched	
strains.	 This	was	most	 likely	due	 to	effectiveness	of	 Sirolimus	as	an	anti	neoplastic	 agent,	 leaving	both	animal	
strains	with	very	little	tumour	load	at	the	time	of	treatment	withdrawal.	
	
4.9	 	 ROLE	OF	IMMUNOSUPPRESSION	
	
The direct comparisons between the immunosuppressive groups pointed 
towards our hypothesis that newer immunosuppressive medication will be better 
in rejecting the transplanted tumours. 
4.9.1	Cyclosporine	v	High	dose	Sirolimus	
	
With high dose sirolimus treatment both Wistar and Lewis rats eliminated the 
entire tumour load within the study period as opposed to the cyclosporine 
treated animals where transplanted tumour continued to grow. These results 
were statistically significant (p <0.05). (fig70 and fig 116). 
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Figure	70	Direct	comparison	between	Wistar	rats	on	CsA	(Left)	or	Sirolimus	high	dose	(right)	immunosuppression.	
As	 opposed	 to	 steady	 increase	 in	 tumour	 load	 with	 CsA,	 there	 was	 complete	 elimination	 of	 bioluminescent	
signals	with	Sirolimus.	
	
Similar results were noted with Lewis rats (fig 71 and fig 117). 
	
	
Figure	71	Direct	comparison	between	Lewis	rats	on	CsA	or	Sirolimus	(high	dose)	immunosuppression.	As	opposed	
to	 steady	 increase	 in	 tumour	 load	 with	 CsA,	 there	 was	 complete	 elimination	 of	 bioluminescent	 signals	 with	
Sirolimus.	
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4.9.2	Cyclosporine	v	Low	dose	Sirolimus	
	
Both Wistar and Lewis rats eliminated the entire tumour load within the study 
period as opposed to the cyclosporine treated animals where transplanted 
tumour continued to grow. These results were statistically significant as well (p 
<0.05). These animals treated with low	dose took slightly longer than the high 
dose sirolimus group but still were able to entirely clear the tumour load within 
the 4 weeks of the study period (fig 72 and fig 118).	
	
	
	
Figure	72	Direct	comparison	between	Wistar	rats	on	CsA	or	Sirolimus	(low	dose)	immunosuppression.	As	opposed	
to	 steady	 increase	 in	 tumour	 load	 with	 CsA,	 there	 was	 complete	 elimination	 of	 bioluminescent	 signals	 with	
Sirolimus.	
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Results with Lewis (poorly matched) animals were similar with statistically 
significant improved results (fig 73 and fig 119). 
	
Figure	73	Direct	 comparison	 between	 Lewis	 rats	 on	 CsA	 and	 Sirolimus	 (low	 dose)	 immunosuppression.	 As	
opposed	to	steady	increase	in	tumour	load	with	CsA,	there	was	complete	elimination	of	bioluminescent	signals	
with	Sirolimus.	
	
	
4.9.3	Cyclosporine	v	Leflunomide	
	
Despite the lack of leflunomide treated animals’ complete elimination of tumour, 
there were 3 animals by the end of the study period that had managed to clear 
the tumour load (fig 74 and fin 120). This was in contrast to the continued 
tumour growth in the cyclosporine group.  
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Figure	74	Direct	 comparison	 between	Wistar	 rats	 on	 CsA	 or	 Leflunomide	 immunosuppression.	 As	 opposed	 to	
steady	 increase	 in	 tumour	 load	 with	 CsA,	 there	 was	 gradual	 reduction	 of	 bioluminescent	 signals	 with	
Leflunomide.	
	
	
	
4.10	 POST	EUTHANASIA	ANALYSIS	
	
	
At the end of the study period of four weeks, all the animals were euthanased 
by Home Office Schedule 1 of cervical dislocation. During every IVIS imaging 
session, the right flank was palpated for evidence of gross tumour growth as 
well. This examination was repeated on the euthanased animal after dissection 
of the subcutaneous tissue of initial tumour injection (fig). 
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Figure	75	Palpable	 tumour	 in	 the	 right	 flank	at	 the	 site	of	 injection	4	weeks	prior.	On	 right,	 comparison	with	a	
standard	21	gauge	needle.	This	was	a	Lewis	rat	with	continued	Cyclosporine	immunosuppression	for	4	weeks.	
	
Figure	76	Dissection	 of	 the	 right	 flank	 skin	 off	 the	 ventral	 abdominal	 wall.	 The	 tumour	 clearly	 visible	 with	
evidence	of	increased	vascularity	around	the	tumour.		
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The dissection of the injection area was performed whether or not there was 
any detectable positive signal. After this, a midline laparotomy was performed to 
assess any gross evidence of distant metastasis. The inguinal and para-aortic 
regions were carefully dissected to detect any grossly enlarged lymph nodes. 
Only in 5 animals with very bright bioluminescent signals there were detectable 
inguinal lymph nodes. Due to lack of lymph node yield, the spleen was used for 
the flowcytometric analysis for the sake of reproducibility. 
	
	
Figure	77	Dissection	and	isolation	of	subcutaneous	tumour	in	a	Wistar	rat	with	Cyclosporine	immunosuppression.	
	
	
4.11	 	 DISCUSSION	
	
	
The need for increasing the organs for transplantation is very real. Any 
increase, whether by increasing the standard pools of live and deceased donors 
or looking for new sources will help the cause. Whatever the source, it has to be 
able to provide safe allografts. Restored kidneys sourced from patients with 
small renal tumours have the potential to increase the donor pool significantly 
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as shown earlier but there is no clear evidence that these kidneys can be safe. 
After partial nephrectomy, in patients with T1a tumours the oncological 
outcomes and long-term survival is comparable with patients having radical 
nephrectomy, hence the shift towards partial nephrectomy as the preferred 
method of treatment in the majority of patients(43)(44). Although this finding 
was the background of the reported cases of deliberate transplantation of these 
restored organs, but there remains a few important clinical and ethical 
questions. First of all, what would happen if these organs were transplanted and 
the recipient given immunosuppression, would that increase the chances of 
recurrence and metastasis? What should be the best possible 
immunosuppression in order to prevent any recurrence? What would be the 
best strategy with regards to immunosuppression if there was a recurrence, 
should the immunosuppression be continued, stopped or replaced? Can we use 
the body’s natural immune response to fight any foreign tumour transplanted 
along with the allograft and would the tumour be significantly immunogenic for 
this strategy to work? There have been no experiments to answer these 
questions and hence the literature is completely lacking in this regards.  
We set up our experiments specifically to answer these particular questions.  
4.11.1	 Role	of	rejection		
 
Acute rejection, exercised by the hosts’ immune system is one of the barriers to 
transplantation. Although it provides its own challenges for transplantation, it 
has an important role in preventing the tumour growth. 
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Even before they are transplanted, the allografts undergo trauma of 
transplantation; harvesting, warm and cold ischaemic damage and ischaemia 
reperfusion injury. This “primes” these organs for the maximal immune 
response from the adaptive immune system (192).  
While the initial responses are non-specific and mediated by complement 
system, Natural killer cells and macrophages, the adaptive immune response is 
very specific to the donor antigens. MHC is the glycoproteins that are at the 
core of adaptive immunity. These are one of the most polymorphic proteins. 
MHC class I proteins are present on the cell surface of all nucleated cells and 
present intracellular antigens to CD8+ T cells. MHC class II proteins are present 
on the surface of antigen presenting cells and B cells. They present exogenous 
antigens to CD4+ T cells. Both subclasses of MHC play an important role in the 
allograft rejection as the graft survival can be prolonged when the transplanted 
donor tissue is lacking in either one or both of 
them(193)(194)(195)(196)(197)(198). For transplantation, greater the antigenic 
difference between donor and the recipient, the more is the propensity for 
rejection and vice versa. Hence as a general rule, it is preferable to transplant 
organs across minor MHC differences.  
Immune system also plays a paramount role in preventing tumour development. 
Cancer cells, in order to propagate have to evade the individual’s own immune 
system. This is due to the fact that the tumours either express tumour specific 
antigens or tumour associated antigens. These are non-self and are readily 
recognised by the host immune system. For the tumours to grow, they have to 
evade the immune system. This process of “immune editing” selects for the 
“escape mutants” that are less immunogenic and hence can propagate in the 
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presence of a competent immune system. Reduced MHC expression and poor 
costimulatory signals by the tumour cells are a few of the mechanism for such 
immune editing (199)(200)(201).  
Based on their ability to incite an immune response the tumour cells can be 
classified into immunogenic (regressors) which are rejected in the naïve 
syngenic animals, intermediate immunogenic (progressors) which require prior 
immunisation for rejection and non immunogenic tumours(202).  More 
immunogenic the tumour, the better equipped the immune system will be to 
cause rejection. Renal cell carcinoma is an immunogenic tumour (203) as is 
evident by the tumour infiltration of the T cells (204). Hence our experiments to 
assess the role of rejection in different experimental conditions are quite 
relevant.  
To assess the role of rejection we divided the experimental groups into well-
matched Wistar animals and poorly matched Lewis animals. As the tumour cells 
were of Wistar origin, there were far less differences in the MHC proteins when 
these tumour cells were transplanted into the Wistar animals as compared to 
the Lewis rats. Furthermore, as the Wistar rats were outbred and not syngeneic 
despite the donor cells of being same strain they were not identical to them. 
This recreates the human transplant scenario very closely, where even the most 
closely matched transplants (excluding identical twins) have some minor 
allogeneity(205).  
When the tumour cells were transplanted without any immunosuppression there 
was an aggressive response against the tumour cells by both the groups. This 
is in line with the hypothesis that the immunogenic renal cell tumours will incite 
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an immune response that will lead to their rejection in the presence of a 
competent immune system.  
This immune response was significantly stronger in the poorly matched Lewis 
animals as compared to the well-matched Wistar rats. This effect is again due 
to wider MHC differences in the poorly matched animals as highlighted above. 
These effects were also seen quite clearly in the cyclosporine 
immunosuppression arm of experiments. The tumour cells continued to grow in 
both the arms but when the immunosuppression was stopped in the treatment 
withdrawal arms of both well-matched and poorly matched groups there was a 
steady decline in the tumour load. This points towards the efficacy of acute 
rejection once the immunosuppression is stopped. Of interest here was the 
finding that this rejection was again found to be significantly more effective in 
the poorly matched Lewis animals due to wider MHC differences between the 
donor and recipient tissues.  
These findings have important clinical bearing. In cases of transplantation with 
restored kidneys after ex vivo resection of tumours, if there was any recurrence 
of tumour then acute rejection could be used to clear the recipients of any 
tumour load after the graft nephrectomy. In these situations, perhaps the 
allografts with less well MHC matching will prove better at rejecting any residual 
tumour load.  
4.11.2	 Effects	of	cyclosporine	immunosuppression	
 
Cyclosporine immunosuppression has revolutionised the field of 
transplantations since its introduction in 1980s. It has greatly increased the graft 
Chapter	4-168	
	
survival and is now the most commonly used immunosuppressive medication 
along with Tacrolimus for renal transplantation. It exerts its effects by reducing 
the production of Interleukin-2 (IL-2) and IL-2 receptor expression, thereby 
reducing T cell expression. 
Renal transplant confers significant quality of life and survival benefits for 
patients on dialysis but the risk of developing cancer after transplant also 
increases. The cumulative risk adjusted risk of cancer increases in direct 
proportion to the time since transplantation. In adults aged less than 35 years 
this risk after 10 years significantly higher than the general population while 55 
years and older patients this risk increases even further(206).  
	
Figure	78	Cumulative	risk	of	cancer.	Cumulative	risk	of	cancer	(excluding	non-melanocytic	skin	and	lip	cancer)	in	
kidney	transplant	recipients	by	age	at	transplantation(206)	
 
Cancer rates described in literature normally underestimate the real picture due 
to relatively short follow-ups and more focus on patients transplanted recently. 
A large US study looking at the incidence of cancer after renal transplantation 
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only reported cancers in the first three years after transplantation. Prevalence 
studies show a different picture, with an incidence of 34-50% if transplant 
recipients were followed for 20 years or more(207)(208)(209). 
Although the risk of cancer increases with increasing age and being on dialysis 
also increases incidence of cancers but the significantly higher incidence of 
cancer over and above the general population is believed to be due to the 
effects of immunosuppressive medications. An impaired immune response due 
to strong immunosuppression is one of the most important mechanisms. Other 
potential mechanisms include recurrent infections with oncogenic viruses. 
Then there is direct neoplastic effect of the cyclosporine immunosuppression. 
This is due to aberrant production of cytokines regulating tumour growth, 
metastasis and angiogenesis(210). 
All these factors make it of paramount importance that any restored kidney 
transplanted must be free of any gross cancer as cancer growth may be 
uninterrupted in immunosuppressed hosts. Also tailoring of immunosuppression 
to agents with antineoplastic properties may lead to better outcomes when 
transplanting these organs.  
Our experiments on both Wistar and Lewis rats showed these effects of 
cyclosporine immunosuppression. When the immunosuppression with CsA was 
continued in either strains there was on-going growth of the tumour cells 
despite, in both the strains.  
The growth was exponential towards the end of the study period due most 
probably to neoangiogenesis.  
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These findings have important clinical implications. If there was an inadvertent 
tumour transfer or de novo renal tumour development then under the influence 
of continued CsA immunosuppression the tumour cells are likely to grow 
uninterrupted. Hence not only it would be important to very closely monitor 
these implants but also change the immunosuppression if possible. 
4.11.3	 	 Immunosuppression	with	antineoplastic	agents	
	
Calcineurin nephrotoxicity was one of the main side effects of CNIs. mTOR 
inhibitors are devoid of this side effect and hence promised a great deal for 
renal transplant patients. Despite initial expectations these agents have not 
been able to replace CNIs for long-term immunosuppression due to their own 
side effects profile. But there is growing body of evidence that these can be 
good alternatives to CNIs after an initial period of with calcineurin inhibitors. 
Use of mTOR inhibitors as denovo immunosuppressive agents was studied by 
ORION and Symphony studies. ORION study had 469 patients who were 
divided into three groups. Group 1 had sirolimus and tacrolimus with gradual 
withdrawal of tacrolimus after week 13. Group two was given MMF and 
sirolimus. This group was discontinued early due to high rates of acute 
rejections. Group 3 was given tacrolimus and MMF. There were no significant 
differences in the primary end points of eGFR and graft loss among the groups 
but the rates of biopsy proven acute rejections were significantly higher in the 
sirolimus groups(211). The Symphony study – another randomised control trial, 
in its one year results reported better results in terms of acute rejection, eGFR 
and graft failure with tacrolimus, MMF and steroid based regime than three 
other regimes including one containing sirolimus. A further two years follow up 
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of the Symphony study showed continued benefit with Tacrolimus arm of the 
study with those patients maintaining eGFR and low rates of acute rejections. 
Although the total number of patients who remained on sirolimus by the end of 
the follow up had numerically high eGFR but due to higher incidence of acute 
rejections and side effects a significant patients crossed over to the tacrolimus 
arm and these results would not bear any clinical relevance(118,212).   
Sirolimus has been used with the combination of CNI’s. The rates of acute 
rejection episodes in the combination has been shown to be less than the other 
treatment arms(213,214). Although the rates of acute rejection were low, but the 
side effects including lymphocoele and the wound infections were higher. Also 
the one-year renal function was also worse off in the combination regime(215). 
Due to this, in the 2009 Kidney Disease: Improving Global Outcomes (KIDIGO) 
guidelines it was recommended against to use both CNI and sirolimus in 
combination(216).  
The other strategy of using mTOR inhibitors is to employ them as maintenance 
therapy as a replacement of CNI. One of the first large studies was published in 
2003, which randomised 430 patients into either receiving sirolimus, CsA and 
steroids or have CNI withdrawal after 3 months. The eGFRs and graft survival 
rates at 36 months were significantly better in the CNI withdrawal group, with 
better compliance rates as well(217). Due to chronic allograft nephropathy 
associated with CNIs, withdrawal of these agents after an initial period post 
transplant was shown to be beneficial(121). The timing of withdrawal of CNI is 
varied in different studies but to see the best results it is important to withdraw 
them before the irreversible changes of allograft nephropathy set in. The ZEUS 
study, a large multicentre RCT comparing CsA, MMF and prednisolone versus 
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everolimus, MMF and prednisolone showed significantly better results in terms 
of eGFR in the everolimus arm. Initially the acute rejection rates were higher but 
over the whole study period they were comparable as well(218).  
There was a lot of excitement about mTOR inhibitors in the beginning as 
potentially the agents that would be able to completely replace CNIs and 
prevent the problems associated with chronic allograft nephropathy but due to 
their own side effect profile they have been unable to replace CNIs completely. 
But as maintenance therapy after an initial period of 3-5 months of CNIs they 
have been found superior as described above. Along with these benefits, when 
the antineoplastic effects of these agents are taken into account they have very 
promising prospects, if not in all then definitely in special circumstances. 
Antineoplastic effects of mTOR inhibitors are well documented. These are not 
only shown to be helpful in skin cancers including melanomas but also in post-
transplant lymphoproliferative disorders and Kaposi sarcomas. There is 
gathering evidence for their effectiveness for metastatic renal cell carcinoma, 
HER 2 positive breast cancers, neuroendocrine and pancreatic 
tumours(128,219–224). 
The CONVERT trail, which had 830 patients, randomised to conversion to 
sirolimus or continuation with CsA immunosuppression has shown that the 
incidence of non melanoma skin cancer was significantly lower in sirolimus 
group (1.2 v 4.3 p<0.001). The rate of other malignancies was lower again in 
the sirolimus group but failed to reach statistical significance (p 0.058)(225). 
Similar results were noted when patients with one cutaneous cancer were 
randomly assigned to either continue on cyclosporine immunosuppression or 
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convert to sirolimus. In the conversion arm, the survival free from cutaneous 
squamous cell cancer was significantly longer than in CsA arm(226). 
Knoll and colleagues conducted a systematic review of 21 randomised control 
trials recently. This review looked at the data of 5876 transplant recipients and 
showed that there was 56% reduction in the incidence of non melanoma skin 
cancer and 40% reduction for the rest of malignancies with sirolimus switch. 
Patients receiving de novo sirolimus did not show any improvement in the 
cancer occurrence. These results in themselves are very promising but the 
conversion to sirolimus came at a cost of increased risk of non-cancer related 
deaths. Most likely causes postulated by the authors were increased 
cardiovascular risks and infections. These effects were more pronounced when 
higher doses of sirolimus were used. Increased risk of rejection could be due to 
over immunosuppression in the sirolimus group due to known higher risks of 
acute rejections requiring steroid pulsing(227).  
Despite the reduction in the incidence of cancer, increase in the non-cancer 
deaths in sirolimus group seems quite discouraging. But when this was looked 
at in the context of what happened to the patients who could not get an organ 
for transplantation then the situation was much more promising. The transplant 
waiting list is a “very dangerous” place to be, as the average risk of dying while 
being wait listed is between 6- 10% per year(228–230). This is also depended 
on the age of the patients listed, with worsening survival with advancing age. 
Patients becoming unfit and inactive on the waiting list complicates the situation 
as the risk of dying increases even further. According to an analysis about 30% 
deaths on waiting list occur in patients who had inactive status(231).  
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Figure	79	Death	rate	on	the	kidney	waiting	list	by	age	group,	1994-2003	(229)	
	
 
Thus an elderly patient who has to wait for longer (blood group O and B) the 
risk of dying may be more than 50% over a period of five years(229,232).  
In our experiments, when sirolimus was used as immunosuppressive agent all 
animals were able to reject tumour load within the study period. Although this 
effect was stronger in the higher dose sirolimus animals, the low dose group 
was also significantly better in rejecting the tumour load when compared to both 
CsA and leflunomide groups. 
Because the effect of sirolimus was found to be very strong, wewas unable to 
elicit any difference between the treatment continue and withdrawal groups as 
by the time of withdrawal of immunosuppression the tumour load was already 
very little. 
4.11.4	 	 Conclusions	
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In summary, we have shown with our experiments that we can use acute 
rejection, level of matching and manipulation of immunosuppression to our 
benefit. In the light of the above mentioned findings and extrapolating them to 
the clinical situation, we suggest that kidneys removed for small renal cell 
carcinoma can be used for transplantation in a select group of patients. Perhaps 
the best approach while using these organs will be to do vigilant wide local 
excision with US guidance if needed, to make sure there is no residual 
macroscopic tumour left in the restored organ. After transplantation, continue on 
CNI based immunosuppression for a period of 3-5 months followed by 
conversion to prevent common risks associated with mTOR inhibitors in the 
immediate post operative period. To use acute rejection for any tumour 
elimination, the donor recipient combination should perhaps be less than ideal 
HLA match.  
Of course patient selection and informed consenting when using these organs 
will be more important than any other ordinary kidney transplantation.  
High risk, elderly patients with unacceptably high risk of dying while waiting for a 
kidney will benefit the most from these relatively higher risk organs. Both the 
donor and recipient consent will need to be very thorough and clear. Potential 
recipients must know that these organs have less number of nephrons to start 
with due to partial resection. The risk of tumour recurrence and potential risk of 
relatively aggressive nature must be clearly indicated. Other side effects 
associated with transplanting these kidneys will include risk associated with 
mTOR inhibitors and risks of bleeding, urine leak and lymphocoeles due to 
partial resection. 
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On the other hand the benefits, both in terms of quality of life and survival must 
also be highlighted and the decision must be left for the patients to make to 
avoid any clinician bias. 
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Chapter 5  
FLOW CYTOMETRIC ANALYSIS  
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5.1	 AIMS	
	
Flow cytometric analysis was performed to assess the effect of tumour 
transplantation, different immunosuppression and matching with respect to the 
distribution of subclasses of T cells and Natural Killer population in our 
experimental model.  
5.2	 BACKGROUND	AND	PRINCIPLES	
	
Flow cytometry is the technique of measuring the characteristics of small 
particles as they flow in the fluid medium. The most important properties 
normally measured are the number, size, shape, granularity and, by labelling 
with fluorescent markers, the specific properties of the particles. The particles 
are passed through a laser beam suspended in a fluid medium. These particles 
cause dispersion of the light, which is then picked up by appropriately 
positioned photomultiplier tubes. These are then converted to electrical signals 
which are interpreted by the on board computer.  
The three main parts of the flow cytometer are the fluidics, optics and 
electronics. 
Fluidics acts are the medium through which the particles, usually cells are 
transported. The cells of sizes ranging between 0.2- 150 micrometres are 
suitable for flow cytometric analysis. This requires the cells to be isolated from 
tissues before they can be analysed e.g. spleen. For the results to be precise 
ideally only one cell should pass through the light beam at one time. The 
arrangement of the flow chamber is such that it makes it possible for the cells to 
be passed in a single file on low flow settings. 
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When the light strikes these cells it diverges into different directions. The extent 
of this depends on the physical properties of the cells. There are two different 
type of scattering that is detected by flow cytometer; forward scattered light 
(FSC) and side scattered light (SSC).  
FSC is detected just off the original laser beam path and gives the indication of 
the size of the cells. SSC is usually detected at around 90° angle and gives the 
indication about the shape and granularity of the cells. Combined together these 
measurements can be used to differentiate between different white blood cells 
for instance.  
	
Figure	80	Forward	and	side	scatter	of	incident	beam	of	light	as	a	basic	principle	of	flow	cytometry.	
 
 
The granulocytes being the biggest and most granular scatter the light most and 
appear farthest in both the FSC and SSC. Monocytes are large in size but are 
smoother hence appear to disperse the beam most for FSC. Lymphocytes are 
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the smallest and also non granular and hence are found towards the left of the 
SSC/FSC plot as shown.  
 
	
Figure	81	Forward	and	side	scatter.	An	example	of	forward	and	side	scatter	of	cells	separated	from	a	Wistar	rat’s	
splenic		tissue	after	euthanasia.	The	bigger	and	more	irregular	the	cell	shape	the	more	FSC	and	SCC	they	cause.	
 
A more targeted use of flow cytometry is to incubate the cells with antibodies 
conjugated with a fluorochrome that will bind to cell specific antigens. These 
fluorochromes are excited when hit by monochromatic light moving electrons 
out from their normal orbit to an unstable high-energy state. Upon their return to 
baseline they release energy in the form of photons of light, which invariably is 
of higher wavelength and is different from the excitation wavelength. These 
FSC, SSC and fluorescence signals are channelled by a set of filters and 
!
!Counting!beads!!!Granulocytes!!!Monocytes!!!Lymphocytes!
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mirrors to specific sensors. These sensors for the florescent light are called 
photo multiplier tubes (PMTs).  
These PMTs then convert the photon energy to electrical signals, which are 
then “read” by the attached computer to produce output data. 
	
	
	
Figure	82	BD	 FACSCanto	 II	 Flow	 cytometer.	Main	 flow	 cytometer	 is	 on	 the	 left	 of	 the	 picture	 and	 the	 data	 is	
analysed	by	the	attached	computer	towards	the	right	of	the	picture.		
	
	
5.3	 CELL	MARKERS	IN	TRANSPLANTATION	AND	CANCER	
	
The most important lymphocytes in the context of transplantation and tumour 
immunology are CD4+, CT8+ T cells and Natural killer cells. Thus these cell 
subsets were studied in our experimental animals. One of the earlier studies 
showing the role of CD4+ and CD8+ cells in allo-rejection, was from Cobbold et 
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al.(233). CD4+ and CD8+ cells were depleted separately and then together and 
the rate of skin graft rejection was studied. This study showed that the survival 
of skin grafts was similar among controls and the animals with removal of just 
CD8+ T cells.  When CD4+ cells were depleted there was a modest increase in 
the survival of skin allografts while a long-term graft survival was achieved when 
both CD4+ and CD8+ cells were depleted. This study pointed towards the 
crucial role that both these cell types play and also highlight their interplay with 
each other for graft rejection. 
 
	
Figure	83	Role	 of	 CD4+	 and	 CD8+	 T	 cells	 in	 skin	 allograft	 rejection.	Depletion	 of	 CD8+	 cells	 did	 not	 have	much	
effect	on	allograft	rejection	(similar	to	controls).	With	CD4+	cells	depletion	there	was	only	a	modest	increase	in	
the	allograft	survival	which	when	both	these	cell	populations	were	depleted	then	there	was	significant	increase	
in	 the	 survival	 of	 these	 allografts.	 This	 study	 highlighted	 the	 importance	 of	 both	 these	 cells	 in	 rejection.	
(reproduced	from	reference	233)	
	
	
5.3.1	 	 CD4+	T	cells	
	
These cells have pivotal role in transplant immunology. Once the T cells are 
activated in the presence of co-stimulatory signals they change into effector 
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cells. The CD4+ “helper” T cells upon activation produce a number of cytokines 
that help exert immunological attack on the non-self alloantigens. These can 
both be “normal” alloantigens from the transplanted kidney or it could be tumour 
antigens. The role of the CD4+ cells as the initiator of the graft rejection has 
been widely demonstrated by various groups(234)(235)(236)(237). Initiation of 
immune response is of paramount importance in body’s natural defence against 
pathogens as well as the transplanted or de novo tumour cells.  
 
5.3.1.1	 Activation	status	and	significance	
	
Majority of the CD4+ cells are naïve under resting conditions. For these cells to 
mount any immune response against transplanted cell they have to be 
activated. There are several markers that get expressed on the activated T 
cells. These include CD25, CD69 and CD154 among others(238)(239)(240).  
5.3.2	 	 CD8+	cells	
	
Cytotoxic T lymphocytes (CTLs) (CD8+) have the most profound effects against 
tumour development and progression. These cells are dependent on the 
production of cytokines mainly produced by the Th1 cells eliciting a coordinated 
defence mechanism against tumours. These cells are also the biggest 
mediators of acute rejection. CTLs are normally present in low levels in non 
rejecting allografts while in rejecting organs their number is significantly 
higher(241)(242) and rejection can be delayed by depletion of these 
lymphocytes(243). 
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5.3.3	 	 Natural	killer	cells	
	
These cells are part of the innate immune system. These are one of the first 
defence mechanisms of the body against foreign and tumour antigens. Although 
initially thought to be not important effector cells in solid organ 
transplantation(244), more recent studies have shown their role in small animal 
model(245). Although these cells alone may be insufficient to cause full blown 
acute rejection themselves, but by interaction with other cells of innate and 
adaptive immune system they have an important role to play. 
Their role against tumours is clearer both in small animals and humans. Mice 
deficient of NK cells have higher incidence of lymphomas and sarcomas, as is 
the case in humans(246)(247)(248)(249).  
The two ways by which NK cells are thought to play a anti neoplastic role is by 
recognising “missing self” – where tumour cells and virus infected cells under 
express the MHC class I proteins in order to evade the immune 
system(250)(251). This mechanism is of particular benefit to the host as one of 
the properties of the tumour cells is to not express MHC class I molecules in an 
attempt to evade the attack by CTLs. These tumour cells can escape cytotoxic 
T cells but are recognised by NK cells via “missing self” mechanism and 
eliminated.  The other mechanism by which NK cell exercise their defence is by 
the identifying “induced-self” antigens. These are the antigens which are 
either not expressed at all on normal healthy cells or are expressed at very low 
levels but as a result of malignancy, infection or trauma are up-regulated 
(252)(253)(254)(159). When these induced-self antigens are expressed in 
significant amount they are recognised by the NK cells, which eliminate them.  
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In short NK cells are an important player in the tumour cells destruction. 
5.3.4	 	 Regulatory	T	cells	
	
In the past 10-15 years there has been growing interest at the role of these 
subsets of T lymphocytes. From a phenotypic point of view these cells are 
identified as CD4+ CD25+ FoxP3+ cells(255). Liu et al. has described the 
down- regulation of CD127 as a potentially important marker of Treg cells(256), 
while TNFR2 has also been implicated as an alternative marker for these 
cells(257). Despite some evidence that there is a subpopulation of CD4+CD25-
FoxP3+ Treg that is positive for TNFR2 (258), the vast majority of studies use 
CD25 and FoxP3 positivity as a marker for identifying these cells.  
The role of Tregs as immunoregulatory cells has now been firmly established 
although there is still a lot about these cells that remains unanswered. They 
have been shown to keep in check the autoimmune and inflammatory 
processes both in humans and in rodents(259)(260). 
Experiments in humanised mice have shown their ability to counter graft versus 
host disease. In these mice, when human lymphocytes were transplanted, 
severe GVHD ensues but co-transfer of Tregs prevents this life threatening 
phenomenon(261). Their protective role has also been shown for the solid 
organ transplantation by the Oxford group(262). 
Tumour associated antigens expressed by the precancerous cells are 
recognised by the immune system thus preventing a large number of 
malignancies. It is only when these initial defences are evaded that the 
transition from pre-cancer to cancer occurs in at least some cases. With Treg 
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cells keeping immune system “in check”, it was hypothesised(263) that this 
could lead to tumour cells evading host defences. There has been evidence to 
suggest that this hypothesis may be correct as large number of Treg cells are 
isolated from established tumours and draining lymph nodes, thereby pointing 
towards their potential role(264). Similarly depletion of Treg cells resulted in 
better antineoplastic responses. Marabelle et al. showed that there were large 
numbers of Treg cells expressing OX40 and CTLA-4 as well as FoxP3. Presence 
of these Tregs at the vicinity of the tumour was a poor prognostic factor for the 
mice. When anti OX40 and anti CTLA-4 antibodies were injected to target these 
Treg cells directly, these mice achieved a systemic clearance of tumour 
load(265). Similar results have been reported by either depleting the tumours 
with Tregs or by injecting them with Treg depleted CD4+ T 
cells(266)(267)(268)(269)(270)(271)(272). 
 
5.4	MATERIALS	AND	METHODS	
	
5.4.1	Choice	of	cell	markers	
	
We selected CD25 as our T cell activation marker. This is expressed by both 
CD4+ and CD8+ T cells as well as by the Treg cells. By using this as one of the 
markers we were able to differentiate the populations of Treg (CD 4+ CD25+ 
FoxP3+) as well as activated CD4+ T cells (CD 4+ CD25+ FoxP3-). Effector 
CD8+ T cells also express CD25 as a marker of activation and was identified as 
CD 8+ CD25+.  CD161 (also called NK receptor protein 1) was used for the 
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detection of the NK cells. These are present on all NK cells and very small 
proportion of T cells(273,274). 
5.4.2		Antibodies	
	
The cell surface antigens targeted to identify the above-mentioned cell 
populations included CD4, CD8, CD25 and CD161. The cells were stained 
according to the protocols provided by the distributors. Antibodies to CD4, CD8, 
CD25, CD161 and FoxP3 were anti-rat and acquired from eBioscience Ltd. 
(Hatfield, United Kingdom), while CD161 was bought from BioLegend (London, 
United Kingdom). The following table shows the dilution used for flow cytometric 
analysis and the conjugated fluorochromes. 
 
 
Antibodies CD4 CD8 CD25 CD161 FoxP3 
 
Dilutions 
 
1/400 
 
1/100 
 
1/100 
 
1/200 
 
1/50 
 
 
Fluorochromes 
 
 
FITC 
 
FITC 
 
PE 
 
FITC 
 
PE-Cy 5 
 
 
	
5.4.3	 	 Isolation	of	Cells	for	Flow	Cytometry	
	
Concentration	of	the	antibodies	titers	used	for	staining	different	T	lymphocytes	as	
well	as	the	fluorochromes	for	the	detection	in	flow	cytometric	analysis.	
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Only a very small number of rats had positively detectable lymph nodes. Hence 
the FACS analysis was performed by harvesting the spleens at post mortem 
examination. 
The splenic tissue was cut into small pieces in a petri dish. With a 5ml syringe 
plunger against a cell strainer the tissue was teased into a single cell 
suspension. Any gross tissue was then removed carefully. Cells were 
suspended in 10 ml of PBS and strained again before being centrifuged at 400g 
for 5 minutes. The supernatant was discarded and to remove red blood cells 
were re-suspended in 5 ml RBC lysis buffer (eBioscience) and incubated for 5 
minutes before adding 15mls of PBS and centrifuging for 5 minutes before 
resuspending in PBS. For most of the analysis a single lysis cycle was sufficient 
to achieve good results but occasionally the process required repeating. 	
5.4.4	 	 Staining	the	Surface	Antigens	
	
The cells suspended in PBS were placed in aliquots of 50	µL and antibodies 
added at the correct dilution (see table) before incubation at 4°C for 30 minutes. 
After the incubation the cells were washed with 2 mls PBS followed by spinning. 
The supernatant was discarded and cells re-suspended in 2 ml of PBS, washed 
and spun again followed by re suspension in 0.5 ml of PBS prior to flow 
cytometric analysis. 
5.4.5	 	 Staining	for	FoxP3		
	
Intracellular staining for FoxP3 was performed after staining the cell surface 
antigens. Cells were pulse centrifuged and resuspended in 1ml of 
fixation/permeabilization working solution (eBioscience) followed by incubation 
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at 4°C for 30 minutes. Then 2 ml of PBS was added and the sample was spun 
at 400g for 5 minutes and supernatant was discarded. The pellet was re-
suspended in 100uL of permeabilization buffer and FoxP3 antibody was added 
at a dilution of 1/50 and the sample incubated for 30 minutes at room 
temperature. This was followed by addition of 2 ml of PBS and centrifugation. 
The supernatant was discarded and the above step repeated. Finally the 
sample was re-suspended in 0.5 ml of PBS prior to flow analysis. 
5.4.6	Flow	cytometric	analysis,	gating	and	compensation	
	
After the staining of both cell surface and intracellular antigens, the cells were 
analysed in the flowcytometer. Both the lymphocyte population and the counting 
beads were gated in order to count the absolute and relative number of cells 
analysed. These gated lymphocytes were then further analysed based on the 
different fluorochromes used. Fig 84 gives an example of our analysed data. 
Additional dot plots are shown in chapter 10 fig 121- 125. 
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Figure	84	Representative	 flow	data	 showing	 the	method	of	 analysis.	 Splenic	 cells	were	 isolated	 and	 stained	 to	
detect	 antigens.	 The	 cells	were	 first	 analysed	by	 forward	 scatter	 and	 side	 scatter	 to	 identify	 lymphocytes.	 The	
lymphocyte	 population	 was	 gated	 (P1)	 and	 the	 gated	 population	 was	 then	 analysed	 by	 fluorescence.	 In	 the	
representative	example	shown	the	lymphocytes	were	analysed	to	determine	the	%	of	CD4+,	CD25+	cells	
	
!
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For compensation settings, the unstained cells and the individual antibodies for 
CD4, CD8, CD161, Fox P3 (fixed and unfixed) were used for our experiments. 
Unstained tubes were used first to ensure that the populations of cells were in 
the right  place on the dot plot.  This was done using the FSC and SSC to 
screen the cells of interest. These cells of interest were then gated P1. These 
tubes are then run through the FACS machine and the data recorded as 
compensation control tubes. 
 The positive population was gated for each tube followed by adjusting the P1 
gate and then it was “applied to all compensation” controls. The P2 gate is 
adjusted to fit the positive populations. 
This process was repeated for each stained tube to create a compensation 
matrix for the fluorochrome used (as above). These compensations were then 
named and saved for all our future experiments. 
  
 
5.5	 STATISTICAL	ANALYSIS	
	
The flowcytometric data was analysed using the GraphPad Prism version 6.00 
for Windows, GraphPad Software, La Jolla California USA. Due to wide 
variations in the data points, non parametric analysis using Kruskal-Wallis test 
followed by post hoc analysis by Dunn’s multiple comparison testing were 
performed. The results with p  values of <0.05 were considered as statistically 
significant.  
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5.6	 	RESULTS	
	
5.6.1	 	 Control	comparison	
	
Before analysing the effect of tumour and different immunosuppressive agents 
on the distribution of different T cells subsets, we looked at the control Wistar 
and Lewis rats. These were normal animals with no tumour injection or 
immunosuppression.  
5.6.1.1	 CD4+	cells	
	
These were the percentage of CD4 + cells as a fraction of the total lymphocyte 
events. Interestingly, there were considerably more CD4+ cells in the Wistar 
control animals than Lewis animals.  
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Figure	85	Comparison	of	CD4+	cells.	The	difference	between	the	CD4	cells	distribution	between	Lewis	and	Wistar	
rats.	The	difference	was	statistically	significant	(p=0.028)	
The observed difference was statistically significant (p=0.028). 
	
5.6.1.2	 Activated	CD	4	cells	
	
Although the proportion of CD4 cells was significantly higher in Wistar than the 
Lewis animals, the percentage of activated (CD4+ CD25+) cells was 
significantly more in Lewis rats (p=0.0283). The significance of these results 
was unclear and we were unable to see any clear explanation in the literature. 
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Figure	86	Comparison	 of	 activated	 CD4+	 cells.	 Percentage	 of	 activated	 (CD4+	 CD25+)	 cells	 between	 Lewis	 and	
Wistar	rats.	P=0.028	
	
	
5.6.1.3	 Regulatory	T	cells	(Treg)	
 
Similar to the higher percentage of activated CD4+ cells in Lewis rats, the 
percentage of Treg cells as a fraction of the total CD4+ cells was higher in the 
Lewis rats. These results were statistically significant when compared to Wistar 
rats (p=0.0286). 
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Figure	87	Comparison	of	Treg	cells.	Treg	formed	bigger	proportion	of	CD	4+	cells	in	the	Lewis	rats	than	the	Wistar	
strain.		
	
5.6.1.4	 CD	8+	cells	
	
CD 8+ cells were between 5-15% of total lymphocytes in Lewis rats and 
between 3-8 % in the Wistar rats but the differences were neither marked nor 
reached statistical significance (p=0.114).  
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Figure	88	Comparison	of	CD8+	T	cells	among	Wistar	and	Lewis	rats.		
	
5.6.1.5	 Activated	CD8	cells	
 
The proportion of activated CD8+ T cells was very small in both the groups. 
These were the cells expressing both CD8 and CD25 cell surface markers. In 
Lewis rats the percentage of activated CD8 cells was between 0.1-0.3% while it 
was 0.08%-0.18% in Wistar rats. Again there was no statistical difference 
between these two strains (p=0.342). 
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Figure	89	Activated	CD8	cells	in	Wistar	and	Lewis	groups.	
 
wealso compared the percentage of activated CD 8 cells of the total CD8 + cell 
population. Again there was no significant difference (p=0.485). 
 
	
Figure	90	Percentage	activated	CD8	of	total	CD8	cells	
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5.6.1.6	 Natural	killer	cells	
 
The Natural killer cell proportion varied from 3-5% for the Lewis rats and for the 
Wistar rats it was between 1-4% with no statistically significant difference 
among these strains (p=0.485). 
	
Figure	91	Comparison	of	NK	 cells.	Natural	 killer	 cells	 distribution	 in	Wistar	 and	 Lewis	 rats	was	not	 significantly	
different	
 
5.6.2	Cell	population	comparison	between	treatment	groups-	
Wistar	group	
 
The cell population and their activated proportions were then analysed among 
different treatment groups. These included animals with tumour injection and 
cyclosporine, sirolimus or leflunomide immunosuppression for treatment 
continue and treatment withdrawal groups for the Wistar animals; and tumour 
injection only and tumour injection with cyclosporine or sirolimus 
immunosuppression for treatment continue and treatment withdrawal groups for 
Lewis animals. 
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5.6.2.1	 CD4+	cells		
	
There were wide variations for the CD4+ cell population among different groups 
but these cells were the most common. For the control and cyclosporine groups 
it varied from 8-70% of the total lymphocyte population studied. These cells 
were greatly suppressed in the sirolimus treated animals (0.3-15%). For 
leflunomide, again their percentage varied from 19-55%. 
Despite these wide variations, the difference in the percentages between CsA 
stop and sirolimus low dose; and between sirolimus low dose and leflunomide 
groups were statistically significant. All treatment groups and the controls were 
compared for CD4+ cells among each other. The comparisons with the 
significant differences are highlighted in the table below the graph. 
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CsA	Stop	
vs.	
Sirolimus	
low	
continue	
CsA	Stop	
vs.	
Sirolimus	
low	stop	
Sirolimus	
low	
continue	vs.	
Leflunomide	
continue	
Sirolimus	
low	
continue	vs.	
Leflunomide	
stop	
Sirolimus	
low	stop	vs.	
Leflunomide	
continue	
Sirolimus	
low	stop	vs.	
Leflunomide	
stop	
0.0346	 0.0153	 0.0014	 0.0069	 0.0005	 0.0029	
 
 
Figure	92	Comparison	 of	 proportions	 of	 CD4+	 cells.	 Comparison	 of	 proportions	 of	 CD4+	 cells	 under	 different	
immunosuppressive	 medications.	 The	 number	 of	 lymphocytes	 are	 shown	 on	 the	 Y	 axis	 as	 ranks	 as	 the	 non	
parametric	 test	 used	 for	 these	 comparison	 was	 Kurskal-Wallis	 test.	 The	 table	 below	 it	 shows	 the	 statistically	
significant	results	on	post	hoc	paired	analysis	with	Dunn’s	test.	
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5.6.2.2	 Activated	CD4	cells	
 
These were the cells expressing both CD4 and CD25 cell surface receptors 
only. The proportions of activated CD4 cells ranged from 0.06-12% among 
various groups studied. The only single statistically significant result was 
between sirolimus low dose and high dose treatment continuation groups (p 
<0.0103).  
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Figure	93	Comparison	of	proportions	of	activated	CD4+	cells.	Comparison	of	proportions	of	activated	CD4+	cells	
under	 different	 immunosuppressive	 medications.	 The	 only	 one	 statistically	 significant	 paired	 comparison	 was	
between	sirolimus	low	and	high	dose	treatment	continue	groups	(p	<0.0103).	
	
 
 
5.6.2.3	 Regulatory	T	cells	
	
These are the CD4, CD25 and FoxP3 expressing cells. Generally the animals 
treated with Sirolimus low dose had higher proportions of Treg cells population 
although the differences between the groups were too small to be significant.  
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Figure	94	Treg	comparisons.	Comparison	of	proportions	of	Treg	as	a	proportion	of	total	CD4+	cells	under	different	
immunosuppressive	medications	
5.6.2.4	 CD8	+	cells	
 
welooked at the total number of CD8 cells and activated CD8 (CD8+CD25+) as 
a proportion of total lymphocytes events as well as the number of activated CD8 
cells out of the total CD8 population. 
Control animals had very small CD8 population ranging from 0.08-0.19% of the 
total lymphocytes. This was in contrast to the animals with tumour injection and 
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immunosuppression, where the mean value varied from 5-9%. These results 
are in line with the fact that CD8+ cells are one of the main effector cells when it 
comes to rejection and tumour destruction. 
All treatment groups and the controls were compared for CD8+ cells among 
each other. The comparisons with the significant differences are highlighted in 
the table below the graph 
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Treatment	 Control	vs.	CsA	Stop	 Control	vs.	Leflunomide	continue	
Significance	 0.0042	 0.0378	
	
Figure	95	CD8+	cell	comparisons.	Comparison	of	proportions	of	CD8+	cells	of	total	 lymphocytes	under	different	
immunosuppressive	medications.	The	CD8+	cells	were	in	abundance	as	compared	to	the	control	animals	with	no	
tumour	injection.	
	
 
When the activated CD8 population was analysed, generally there were more of 
these cells in the animals with tumour injection, although the significant 
differences were only seen between control and Sirolimus low dose continue 
groups and sirolimus group versus leflunomide treatment continue group. 
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Treatments	 Control	vs.		
Sirolimus	
low		
continue	
Sirolimus	
low	continue	
vs.	Sirolimus	
high	
continue	
Sirolimus	
low	continue	
vs.	Sirolimus	
high	stop	
Sirolimus	low	
continue	vs.	
Leflunomide	
continue	
Significance	 0.0117	 0.0071	 0.0308	 0.0481	
	
	
	
Figure	 96	 Activated	 CD8	 T	 cell	 comparisons.	 Comparison	 of	 proportions	 of	 activated	 CD8+	 cells	 of	 total	
lymphocytes	under	different	immunosuppressive	medications.	The	cells	populations	with	significant	differences	
in	numbers	are	shown	in	brown	colour.	The	activated	CD8+	cells	were	generally	in	higher	number	as	compared	to	
the	control	animals	with	no	tumour	injection.	
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Next weanalysed the number of activated CD8+ cells as a proportion of total 
CD8+ cells. Sirolimus low dose group again had the most number of activated 
CD8+ cells among all groups and the results were significant when compared to 
controls, sirolimus high and leflunomide treatment continue groups. 
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Treatment		 Control	
vs.	
Sirolimus	
low	
continue	
Control	
vs.	
Sirolim
us	low	
stop	
Sirolimus	
low	
continue	vs.	
Sirolimus	
high	
continue	
Sirolimus	low	
continue	vs.	
Sirolimus	high	stop	
Sirolimus	
low	
continue	vs.	
Leflunomide	
continue	
Sirolimus	low	
stop	vs.	
Sirolimus	high	
continue	
Sirolimus	
low	stop	
vs.	
Leflunomid
e	continue	
Significance	 0.0073	 0.0435	 0.0005	 0.0188	 0.0050	 0.0046	 0.0379	
	
Figure	 97	 Activated	 CD8	 comparisons.	 Comparison	 of	 proportions	 of	 activated	 CD8+	 cells	 of	 total	 CD8+	 under	
different	 immunosuppressive	 medications.	 The	 cells	 populations	 with	 significant	 differences	 in	 numbers	 are	
shown	in	brown	colour.	The	numbers	of	activated	CD8+	cells	were	highest	among	the	sirolimus	low	dose	group.	
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5.6.2.5	 Natural	killer	cells	
	
There were no significant differences between the populations of NK cell among 
various immunosuppressives studied. The means ranged from 3-14%. 
	
Figure	 98	 NK	 cells	 comparisons.	 Natural	 Killer	 cells	 distribution	 among	 different	 experimental	 groups.	 The	
numbers	were	variable	under	different	conditions	with	generally	more	NK	cells	when	the	tumour	was	 injected	
but	none	of	these	reached	statistical	significance.		
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5.6.3	 	 Cell	population	comparison	among	treatment	groups	-	
Lewis	animals 
	
5.6.3.1	 CD4+	cells	
	
In Lewis animals, the proportion of CD4+ cells of the total lymphocyte was lower 
than the Wistar animals, with a mean of 3.7%. There were wide variations 
between the groups with the sirolimus low dose continue group having the most 
numbers of CD4 population (mean 28.6%). This was significantly higher than 
that of the control animals.  
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Treatment	 Control	vs.	Sirolimus	
low	continue	
Sirolimus	low	continue	vs.	
Sirolimus	low	stop	
Significance	 0.0295	 0.0026	
	
Figure	 99	 CD4+	 comparisons.	 Comparison	 of	 proportions	 of	 CD4+	 cells	 of	 all	 lymphocytes	 under	 different	
immunosuppressive	medications.		
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5.6.3.2	 Activated	CD4	cells	
	
These are the lymphocytes expressing both CD4 and CD25 cell surface 
receptors. Again the biggest and the only statistically significant difference was 
measured between the controls and sirolimus low dose treatment continue 
groups (p <0.0003). The mean of activated CD4 cells for control was 19.38% 
while for the sirolimus group it was 1.03%. 
	
	
	
Figure	 100	 Activated	 CD4	 comparisons.	 Comparison	 of	 proportions	 of	 activated	 CD4+	 cells	 of	 all	 lymphocytes	
under	 different	 immunosuppressive	medications.	 The	 only	 one	 significant	 difference	was	 between	 the	 control	
and	sirolimus	low	dose	continue	groups	(p	<0.0003).	
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5.6.3.3	 Regulatory	T	cells		
 
The control animals with no immunosuppression had a mean of 51% Tregs of the 
total number of CD 4 positive cells. There was a reduction in this proportion in 
the rats with immunosuppression and those with just the tumour injection. The 
biggest difference that was between the controls and the sirolimus treated 
animals in the continuation arm.  
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Treatment	 Control	vs.	Sirolimus	low	
continue	
Control	vs.	Sirolimus	high	
continue	
Significance	 0.0004	 0.0295	
	
Figure	 101	 Treg	 comparisons.	 Comparison	 of	 proportions	 of	 Treg	 cells	 of	 the	 CD4+	 population	 under	 different	
immunosuppressive	 medications.	 The	 cells	 populations	 with	 significant	 differences	 in	 numbers	 are	 shown	 in	
brown	colour	
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5.6.3.4	 CD	8+	cells	
 
Again welooked at the total number of CD8 cells and activated CD8 
(CD8+CD25+) as a proportion of total lymphocytes events as well as the 
number of activated CD8 cells out of the total CD8 population. 
The proportion of CD8 cells was quite evenly distributed throughout the groups 
and there were no significant differences between them. The range of the 
percentage of CD8+ cells of the total lymphocytes was between 3-19 %. 
 
	
Figure	 102	 CD8	 comparison.	 Comparison	 of	 proportions	 of	 CD8+	 cells	 of	 all	 lymphocytes	 under	 different	
immunosuppressive	medications.		
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The number of activated CD8+ T cells of the total population was a small 
fraction ranging between 0.3-2.9%. The sirolimus low dose stop group had the 
largest number of activated T cells of total lymphocytes (p <0.0385). 
 
	
	
Figure	 103	 Activated	 CD8	 comparisons.	 Comparison	 of	 proportions	 of	 activated	 CD8+	 cells	 of	 all	 lymphocytes	
under	 different	 immunosuppressive	medications.	 The	 cells	 populations	with	 significant	 differences	 in	 numbers	
are	shown	in	brown	colour.	Again,	like	Wistar	animals,	the	highest	numbers	of	these	activated	cells	were	seen	in	
sirolimus	low	dose	groups.	
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When we compared the proportion of the activated CD8+ cells of total CD8+ 
cells, we found wide variation among the groups. Again the biggest and highly 
significant difference was between the controls and the sirolimus low dose 
continue group (mean was 1.8% for controls and 45% for the sirolimus group). 
 
 
Treatment	 Control	vs.	Sirolimus	low	
continue	
CsA	Stop	vs.	Sirolimus	low	
continue	
Significance	 0.0006	 0.0460	
	
Figure	 104	 Activated	 CD8	 comparisons.	 Comparison	 of	 proportions	 of	 activated	 CD8+	 cells	 of	 all	 lymphocytes	
under	 different	 immunosuppressive	medications.	 The	 cells	 populations	with	 significant	 differences	 in	 numbers	
are	shown	in	brown	colour.	
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5.6.3.5	 Natural	Killer	cells		
	
There was no difference between the NK cells between the groups with the 
mean percentage ranging from 4.3-16%. There were wide variations even 
within the groups as well.  
	
Figure	105	 NK	 cells	 comparisons.	 Comparison	 of	 proportions	 of	 NK	 cells	 of	 all	 lymphocytes	 under	
different	immunosuppressive	medications.		
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5.7	 DISCUSSION	
 
Development of tumour is a complex and a multistage process in animals and 
humans. These factors could be intrinsic (genetic mutations, oncogenes) and 
extrinsic (radiation and carcinogenic exposure and certain viral infections). 
Whatever the mechanism, the tumours have tumour specific and tumour 
associated antigens that make them unique. These antigens are recognised by 
the immune system, which help in keeping these mutant/tumours cells under 
control. The interaction of the immune system with tumours was shown quite 
eloquently by Macfarlane Burnet. The syngeneic rats were injected with one 
type of irradiated tumour cells and divided into two groups. Then competent 
non-irradiated tumour cells of same type were injected in the first group of rats 
and another type in the other set. The “immunised” animals with same tumour 
type rejected the competent tumour cell load while the other immunised group 
showed tumour propagation(275). This work was one of the earliest proofs of 
the close interaction between the immune system and the tumour cells. 
We now know that almost all the effectors of immune system are actively 
involved in the tumour immunity. Macrophages and dendritic cells have a 
specific role in antigen presentation. CD8+ cell mediated cytotoxicity plays 
perhaps the most important role of them all. Then there are CD4+ cells and 
their various subsets and natural killer cells. Tumour cells are believed either to 
induce immune system thereby making them exposed to immune destruction or 
evade the immune system with various mechanisms. It is this interplay between 
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these two mechanisms that determines the fate of most of the tumours(276). 
More immunogenic tumour are easily attacked by the immune system and carry 
a better prognosis while the immune resistant variant are more difficult to 
control. The resistant variants have various mechanisms that help them evade 
immune system including; selective overgrowth of antigen negative variants of 
tumour cells, down-regulation of expression of MHC antigens and then selective 
selection of these cell lines. Other relatively newly discovered mechanisms 
include lack of costimulation that is required for continued propagation of the 
cytotoxic T cells and important role of regulatory T cells. 
There is a lot of information that we still don’t know fully about the role of 
immune system in tumour development and growth. But specifically the CD4+, 
CD8+, NK and Treg cells play important roles that are being recognised more 
and more.  
Literature regarding the role of cytotoxic CD8+ T cell as having anti-tumour 
properties is very clear. The role of CD4+ cells is becoming clearer in the recent 
years as well. They are known for a long time to be required for the priming, 
initial activation and expansion of CD8+ cells(277)(278)(279). As the direct 
effectors of anti-tumour effects are CD8+ cells, CD4+ cells play a pivotal role by 
making sure there are enough activated, primed and continuous supply of these 
CTLs at the tumour microenvironment. One of the main reasons of incomplete 
or ineffective tumour regression despite initial CTL response is the lack of CD4+ 
T cell help(280)(281). Most tumour cells express MHC class I molecules that 
are recognised by CTLs but there is now emerging evidence that for some class 
II expressing tumour cells, CD4+ cells behave as effectors as they are not 
recognised by the CTLs(282)(283).  
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Apart from the helper subset of CD4+ cells, there are regulatory T cells (CD4+ 
CD25+ FoxP3+). These cells were first characterised as mediators of self-
tolerance by Sakaguchi et al.(284). Along with development of tolerance and 
prevention of autoimmunity both in humans and animals, these cells are 
capable of dampening the tumour cytolytic responses by CD8+ cells. These 
cells are seen in increased numbers in the tumour microenvironment and their 
presence in most of the tumours is generally regarded as a negative prognostic 
sign(285–292). Movement of these cells are regulated either by direct 
chemokine driven mechanisms, local tissue expansion or by conversion of 
FoxP3- to FoxP3+ cells(293,294). Whatever the mechanism of infiltration, in 
majority of the established tumours, the higher the proportion of Treg cells at the 
tumour microenvironment or circulation the worse is the prognosis. 
Furthermore, Treg cells not only are important in tumour microenvironment but 
also in prevention of autoimmunity in normal subjects and may have a potential 
role in development of allograft tolerance in transplant subjects. In purely 
transplant setting, higher numbers of Treg cells is a good prognostic feature but 
the situation becomes a little complicated when these transplant recipients 
develop cancer.  
Role of different immunosuppressive agents have been widely studied on the 
immune phenotyping of the transplant recipients. Generally, CNIs in transplant 
setting either cause reduction in the number of Treg cells or inhibits their 
function. Gao et al. showed that whereas mTOR inhibitors were able to promote 
de novo generation of alloantigen specific Treg cells, CNIs completely inhibited 
this process(295). Several other studies have shown similar effects of CNIs on 
Treg cells(296–298). In contrast to the CNIs, mTOR inhibitors have generally 
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shown a more positive role on the population of Tregs, hence the potential 
promise for help in tolerance. They were first shown to expand Tregs in vitro by 
Battaglia et al.(299). These in vitro effects were seen both in humans and mice. 
Similar results were noticed in in-vivo studies where both the function and 
numbers of Tregs increased by mTORs inhibitors(300,301). In the context of 
transplantation without any tumour growth, these effects are desirable for 
potential tolerance but in cases of tumour development, high percentage of Treg 
population circulating or in the tumour microenvironment is a worse prognostic 
sign. This interplay between tumour development and Treg cells is a two way 
process with both having the potential to promote each other’s(302).  
Another potentially very important observation was made by Hope et al. on 
cancer related immune phenotype in kidney transplant recipients. They showed 
that although the number of Tregs was higher in the KTR with cancers as is 
shown by the previously mentioned studies, there was a decline in the number 
of Treg population after tumour resection(303). This observation could partially 
be due to removal of the positive feedback mechanism of tumour 
microenvironment on the Treg population or due to inevitable reduction of 
immunosuppression after the diagnosis of tumour in most KTRs(304). 
In our analysis, the T lymphocyte counts showed wide variations between the 
groups. It will be difficult and may be artificial to completely infer cause and 
effect relationship on the tumour rejection based on this analysis but there are 
some very interesting trends.  
Firstly, there were marked differences in the distribution of T cells between the 
two strains. Although the number of CD 4+ cells was significantly higher in 
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Wistar rats than the Lewis but the proportion of the activated CD4 cells was 
higher in Lewis rats in comparison. Similarly the Treg cells were more abundant 
in Lewis rats. With CD4 cells having more indirect role in activating the immune 
system and Treg having a “controlling” effect of the immune response these 
finding could be important in tumour control. The rest of the cell populations 
(CD8, activated CD8 and NK cells) were similar between both these strains.  
 Due to the above-mentioned differences, it was meaningful to compare the 
effect of different immunosuppressives on various cell populations in each strain 
separately.  
For the Wistar rats, CD 4+ cell population was lower in the sirolimus low dose 
group as compared to the controls and the CsA group. But the activated CD4+ 
cells were highest in the Sirolimus low dose group. There were no apparent 
differences for Treg population.  
The results from activated CD8 cells were more consistent. All of the animals 
had higher proportions of CD8+ cells as compared to the controls. Similar 
results were seen when specifically the activated CD8+ cells’ percentage of the 
total CD8+ population was studied. The highest number of CD8+ cells were 
seen in the animals treated with low dose of sirolimus. These cells are normally 
one of the first effective responses for destroying the tumour cells. The 
preservation of these cells in higher number in the sirolimus treated group may 
point towards the ability of sirolimus treated animals to destroy the tumour cells 
more effectively than the CsA immunosuppression. Interestingly, in the high 
dose sirolimus animas groups these cells were not in much numbers and 
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perhaps it points towards the excessive immunosuppression as a much higher 
immunosuppressive dose was used in this group. 
For the Lewis animals, the Treg population was the lowest in the sirolimus low 
dose group and activated CD8+ cells population was the highest. These results 
again, may explain the reason for the better response against the tumour cells 
in the sirolimus arm of animals. 
The effects on CD8+ cells were most consistent in our flowcytometric data and 
also in line with the clinical observation of better tumour clearance in these 
animals. 
Normally immunosuppression with sirolimus has shown an increase in the 
number of Treg cells, but in our model the population of Treg reduced along with 
an increase in the number of CTLs.  Although this result may seem against 
most of the literature but one important difference in our model was that it was 
not simply a transplant model but the transplanted cells were malignant as well. 
As shown by Hope et al.(303), when the SCC were excised in KTRs, the Treg 
cells population also went down. The reason we might be seeing decline in the 
number of Treg cells might be due to the strong anti-neoplastic effects leading to 
reducing tumour load and thereby eliminating the stimulus to keep the numbers 
high of Treg cells by the tumour microenvironment. Not a lot is known as to why 
the Treg numbers reduce after tumour excision and further research is needed in 
this area.  
For the natural killer cells we did not find any meaningful differences for any of 
the treatment regime. 
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There are a few limitations with our flow cytometric analysis. First of all, the 
results of the CsA may not be the true reflection of the actual lymphocyte count 
at the end of the study period. This is because of technical failure of the FACS 
machine at the beginning of the experiments and loss of a few samples from the 
Wistar animals with no immunosuppression. This also meant that by the time 
we were able to confidently do the flow cytometric analysis, the CsA treated 
animals had already finished four weeks of the experiments for a few weeks. 
The ideal time to look at the effects of tumour and immunosuppression with flow 
cytometry is immediately after the completion of four weeks of treatment 
according to the study protocol. Due to above mentioned reason CsA treated 
animals had a few weeks, without any treatment before they were euthanased 
for the flow cytometric analysis. This time might have caused the reversion of 
the lymphocyte count to baseline, which will not be the true reflection of the 
exact influence of tumour on the lymphocyte count. The results of the sirolimus 
and leflunomide are more reliable from this respect.  
The other possible limitation of the flow analysis could be the small number of 
animals in each arm. Some of the trends seen in our experiments as described 
above might have become clinically significant if we had big enough numbers. 
This may especially be true as the bioluminescent differences described in the 
previous chapter were far more drastic among different treatment arms and 
subtle but important changes in the various subpopulations of lymphocytes 
might need significantly bigger number to increase the power of our analysis.  
Finally, the ideal place to look for the immune effectors would have been the 
tumour microenvironment. This as we know has the most reflective population 
of lymphocytes. Such an analysis would be easily possible for the animals were 
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the tumour growth was good and by the end of experiment there were either 
palpable tumour or at least bioluminescent signals to enable accurate selection 
of tissue containing tumour microenvironment. But as all of the sirolimus treated 
and most leflunomide treated animals completely eliminated the tumour load 
such analysis could have become very subjective with lot of variations. Second 
best place to look for the lymphocytes would have been the regional lymph 
nodes but again they were only detectable in a very small proportion of rats. 
Hence to keep the analysis more objective and to minimise variability Wechose 
the splenic tissue as the source of these effectors of immune system. 
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6.1	 	 CLINICAL	CASES	
	
Previously mentioned case series/reports already pointed towards the feasibility 
of transplanting kidneys after ex vivo resection of tumours. With these results 
there was an indication to perhaps the best matching and immunosuppressive 
strategy.  
Based on the above-mentioned observations, we undertook transplantation of 
such restored organs in a controlled environment in Freeman Hospital, 
Newcastle upon Tyne.  
The clinical cases are divided into the benign and malignant.		
6.1.1	 	 Transplantation	with	kidney	removed	for	benign	
pathology	
	
The indications of nephrectomy due to benign causes are few. Most common 
causes include intractable haematuria, loin pain, refractory proteinuria to 
maximum medical therapy and iatrogenic kidney injury. Our case is presented 
below(305) 
6.1.1.1	 Case	report	
	
A 59-year-old male underwent a resection of a large retroperitoneal ‘tumour’, 
which involved the left colon for a pre-operatively diagnosed sarcoma. Final 
histology confirmed ‘‘Benign Fibromatosis’’ which is associated with an 
optimistic prognosis. The patients subsequently underwent a reversal of 
colostomy and intraoperatively sustained an iatrogenic injury to the left mid 
ureteric injury, which presented on the 10th post-operative day as loin pain and 
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sepsis. An initial nephrostomy and drainage of urinoma was performed followed 
by an unsuccessful attempt at antegrade and retrograde stent insertion. A 
defect measuring >4 cm was identified in the mid-ureter. A renogram confirmed 
a differential function of 41% on the left side and the patient’s glomerular 
filtration rate (GFR) was calculated at 68-ml/min/1.73 m2. 
The patient was counselled regarding the options of either nephrectomy 
followed by auto-transplantation (AT) or nephrectomy alone. The risks of both 
these options were discussed with patient in detail. The patient was not keen to 
pursue any reconstructive surgery and opted for a nephrectomy. We then 
discussed the possibility of ‘Altruistic domino donation’ with the patient. 
Permission for using the left kidney for potential transplantation was approved 
by UK Transplant (UKT) under the category of ‘‘domino donation’’ according to 
the Human Tissue Act(93) . 
A 70-year-old recipient on thrice weekly haemodialysis for 6-years was 
identified. The patient had ESRF secondary to hypertension and had 
concomitant ischemic heart disease. His mismatch was 1:1:1. This recipient had 
waited for 6 years for a cadaveric renal transplant and had no prospect of a live 
donor transplant. It would have been unlikely for him to receive a cadaveric 
transplant during his lifetime based on his performance status and co-
morbidities making him completely dialysis dependent for life. Both donor and 
recipient were scheduled for surgery on the same day and did not meet each 
other. An open nephrectomy was performed in view of the patient’s previous 
extensive open surgery and adhesions via a loin incision and the kidney flushed 
with cold preservation solution. The kidney was prepared for transplantation 
after a thorough examination by the transplant team (Figs. 1 and 2). 
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The donor organ was implanted into the right iliac fossa and the ureter was 
successfully anastomosed into the bladder over a stent. Post-operative 
recovery was unremarkable for both the donor and the recipient. Donor was 
discharged on 2nd post-operative day with creatinine of 1.25 mg/dl. Recipient 
had immediate graft function and creatinine on discharge was 1.53 mg/dl. The 
donor and the recipient have subsequently communicated anonymously with 
each other by letter and are doing well at 8-month follow-up. 
	
Figure	106	Left	kidney	after	back	benching.	Artery,	vein	and	ureter	demonstrated.	
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Figure	107	Left	kidney	after	reperfusion.		Ureter	being	anastomosed	over	the	JJ	stent.	
	
6.1.1.2	 Discussion	
	
Kidneys removed for small renal tumours have been successfully transplanted 
after ex vivo tumour resection with extremely low recurrence rates (55)(29). 
Kidneys removed for benign aetiologies are however not associated with any 
risk of tumour transmission. Transplantation with renal grafts from benign 
aetiologies can be potentially linked to the established concept of altruistic 
donation. With the ‘‘donor’’ being treated for their primary pathology with 
nephrectomy, such donations are regarded as Altruistic domino donation in the 
United Kingdom (UK) under Human Tissue Act (HTA). 
In current clinical practice the commonest indications for simple nephrectomy 
(SN) include intractable loin pain, renal artery aneurysm (58), ureteric injury 
(306) and refractory nephrotic syndrome (58). Auto transplantation (AT) can be 
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an option for these patients (excluding nephrotic syndrome) but on occasions 
this may not be the appropriate treatment in clinical situations such as extensive 
previous surgery, increasing risk of unsuccessful ureteric repair leading to post-
operative complications, medical co-morbidities or patient choice. Counselling 
of patients undergoing SN and recipients of these kidneys is extremely 
important. The recipient should be fully aware of the origin and quality of the 
organ. This technique has the advantage of favourable ischaemic times. Using 
this approach we successfully used the renal graft from our donor for 
transplantation. In normal clinical circumstances the graft would have ended up 
as a nephrectomy specimen and this recipient would have been continued to be 
on thrice weekly haemodialysis. Our approach was psychologically very 
rewarding for the donor who viewed this as a positive outcome from a surgical 
complication. Furthermore these organs should be transplanted locally as they 
may pose specific technical problems (short vessels, ureter, etc.) and 
transplanting them into local recipients may minimise the discard rates and 
potential risk of complications, a concept endorsed by NHS Blood and 
Transplant (NHSBT). We aim to highlight the importance of this new concept to 
urologists in the UK and worldwide as this could be a very important source of 
precious renal allografts worldwide. 
After the successful transplantation of this restored kidney and in the light of the 
available literature as mentioned earlier and promising results from our 
experiments we carefully selected suitable kidneys for transplantation after ex-
vivo resection of malignant tumours. 
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	6.1.2	Transplantation	with	kidney	removed	for	malignant	
pathology	
	
For transplantation of these restored organs we selected our recipients 
carefully, the information given to the patients was robust making sure that they 
understood the quality of the organs and the possibility of potential 
complications. 
The patients selected were elderly and high-risk from the transplant waiting list. 
These patients would not tolerate delayed graft function from normal cadaveric 
kidneys and were more likely to die from cardiovascular complication while on 
waiting list than the risks associated transplantation with these organs. 
Three patients with small renal cell carcinoma were identified. These patients 
were independently assessed by the urology teams and a decision to undergo 
radical nephrectomy was made totally independent of the possibility of 
transplantation. Once this decision was made these patients were approached 
for the possibility of donating these organs after ex vivo excision to which they 
readily agreed. The possibility of using the organs for transplantation had no 
bearing on the original decision of the type of cancer surgery. All these patients 
underwent staging CTs and baseline investigations. 
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Figure	108	CT	scan	of	a	donor	with	the	Left	exophytic	renal	tumour.	
	
Recipients were aged between 69-78 years with mean age of 72 years and had 
multiple comorbidities. They were explained in detail about the risks and 
benefits of such transplantation in detail before any decision to perform the 
surgery. We devised an information leaflet (see below), which was used as an 
additional tool to help these patients in understanding the procedure.  
 
	
	
Left	renal	tumour	
identified	on	CT	
abdomen	
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6.1.2.1	 	 Technique	
	
After the nephrectomy, the tumours were excised under direct vision +/- 
ultrasound guidance by an experienced urologist. The calyces were over sewn 
with 5/0 PDS and Surgicell and Tachosil was sewn into the defects as well. The 
implantation was as standard with particular attention at haemostasis.  
	
	
	
Figure	109	Excised	tumour	
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Figure	110	Back	benching	and	USS	to	assess	the	completion	of	resection	
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Figure	111	Kidney	following	repair	and	at	reperfusion	
	
	
The mean age of the three recipients was 72 years. One was taken off the 
deceased donor transplant list while other two were high risk as well and were 
unlikely to receive a kidney allograft from the deceased donor pool. The 
histology was clear cell in two while chromophobe carcinoma in the other with 
clear resection margins. One of the recipients had early post-operative renal 
vein thrombosis requiring graft nephrectomy at day 10. While the other two 
were dialysis independent with 18 month serum creatinine of 133 and 205 
µmol/L. One of the recipients had a urine leak, which was treated 
conservatively.  
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Both these patients were converted to sirolimus immunosuppression after the 
initial period on tacrolimus. The reason for not starting sirolimus earlier was the 
higher incidence of wound complications associated with it.  
There has been no evidence of tumour recurrence in these patients on the strict 
follow up. Both these patients remain off dialysis with good renal function, while 
in the absence of these kidneys they would have most likely had been still on 
dialysis.  
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FINAL DISCUSSION 
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7.1	 OVERVIEW	
	
Kidney transplantation still remains the best treatment for end stage renal 
failure; which is one of the most common chronic diseases. With the aging 
population and the increasing incidence of diabetes and obesity, the incidence 
of chronic renal failure is increasing as well, putting more pressure on the 
already stretched waiting lists for transplants. This situation is further 
compounded by the very success of transplantation, as it is becoming a much 
safer procedure meaning more elderly dialysis patients are now being 
considered for transplantation than ever before. This disparity has necessitated 
the need to look for new sources of organs for transplantation. 
In the past decade, the gold standard treatment for small renal tumours has 
changed from radical to partial nephrectomy. This is due to comparable 
oncological outcomes(85) and better long term eGFRs(45)(46). Despite this, a 
large number of patients still undergo radical nephrectomy for T1a tumours. 
These kidneys have been used in small limited series for transplantation after 
ex-vivo resection of the tumours. One of the first series looking at these 
transplants with restored organs was from Cincinnati, where Penn(55) reported 
on their data retrospectively. A perspective series by Nicol et al. (56) had 31 
cases of transplantation with kidneys with renal cell carcinomas after ex vivo 
resection. Since then there has been another 24 transplants again from 
Australia with no evidence of recurrence and good allograft function(307). Apart 
from these case series there have been multiple case reports with good results. 
So far there are close to 100 cases reported in the literature of such transplants 
from restored organs.  
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Despite the fact that there has been only one potential recurrence(56), the risk 
of malignancy is real as these patients are immunosuppressed. There is no 
single postoperative immunosuppressive strategy evident from literature. The 
immunosuppression was not modified in a majority, while CsA / tacrolimus was 
substituted with sirolimus after 3 months. This was not due to any direct 
experiments showing its efficacy in preventing recurrence or tumour destruction 
in such restored organs, but due to its previously known antiproliferative 
properties.  
The main aim of our work was to test different immunosuppressive agents to 
answer this question directly and find the best agent for immunosuppression for 
these organs. There have been no direct experiments to look at the effects of 
different immunosuppressive agents on tumour growth in vivo in a transplant 
model.  
	
7.2	 	 SUMMARY	OF	FINDINGS		
	
7.2.1	 	 Overview	
	
An experimental model of rat tumour transplantation was developed. One of the 
most important reasons for using the rodent model was the fact that there was 
already a large body of literature on transplantation, immunosuppression and 
tumour behaviour in these animals. These animals are big enough to consider 
kidney transplantation as part of future work of my project, yet small enough to 
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study enough numbers to give sufficiently powered analysis for the multiple 
groups. 
The rat kidney tumour cells were transfected with luciferase to enable real time 
in vivo monitoring of the tumour growth. Once successful transfection was 
confirmed by in vitro and pilot experiments, two different strains of rats (Wistar 
and Lewis) were selected for per protocol experiment. Two different strains of 
rats behaved as well matched and poorly match transplants groups after 
injection of tumour cells. These differences were important as they helped us 
study the effects of matching and role of rejection on transplanted tumour cells.  
Any success with transplanting restored organs in immunosuppressed hosts will 
rely very heavily on the choice of immunosuppression. We looked at the CNIs 
as the standard immunosuppression (majority of the patients these days are on 
Tacrolimus- a calcineurin inhibitor). This was compared directly with sirolimus 
and leflunomide as the agents having anti neoplastic properties as well as 
immunosuppression. 
7.2.2	 	 Role	of	matching	and	rejection	
 
The immune system plays a central role in the success and failure of the 
transplant. One of the biggest barriers in human organ transplant was to 
suppress immune system fully to enable longevity of the transplanted organs. 
This was achieved years ago and immunosuppression has come a long way 
from the days of total body irradiation and cyclophosphamide, but still remains a 
rapidly evolving science. Where on one hand the immune system is a big hurdle 
for the successful transplantation, on the other hand it plays a pivotal role in 
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preventing tumour development and progression. In transplant recipients a fine 
balance between these two mechanisms is very important for the patients as a 
whole. 
As already discussed, the organs are “primed” to trigger a strong immune 
response after the trauma of retrieval(141). On transplantation of these organs, 
the first line of attack is from the non-specific innate immune cells – NK cells, 
macrophages and complement system. The adaptive immune response is 
stronger, more important and lasting in damaging these organs after the initial 
attack from the innate system. These cells recognise both MHC class I and II 
molecules and both of them play a complementary role in transplant 
rejection(193–195,197). The more the differences between the donor and the 
recipient, the stronger the immune response and stronger the rejection. Hence 
generally we aim for less mismatching for better long-term outcomes.  
Tumour cells are also immunogenic to a varying extent. For tumours to develop 
and flourish, one of the prerequisites is to evade the host immune response. If 
the tumour associated and tumour specific antigens are recognised by the 
innate and adaptive immune system, the tumour cells expressing them are 
more likely to be destroyed. Tumours have various pathways of 
“immunoediting” to prevent elimination by strong immune response(199,200). 
Renal cell carcinoma cells are classified as regressors as they are strongly 
immunogenic(202,203) and hence can be suitable targets by the immune 
system.  
This interplay between the immune system, allograft and transplanted tumour 
cells was the basis of our hypothesis of using immune system to clear the 
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tumour load should a recurrence occurs in transplanted organs after ex vivo 
resection of tumours. 
7.2.2.1	 Rejection	in	controls	with	no	immunosuppression	
	
First of all, the tumour cells were injected into both Wistar and Lewis animals 
without any immunosuppression. Although such a scenario is not likely to be 
replicated in human transplant setting, these groups gave a lot of insight into the 
role of rejection. In the absence of any immunosuppression both the well-
matched and poorly-matched animals rejected the tumour load. This rejection 
was very effective and strong when compared to the later experiments on the 
animals receiving immunosuppression. Again when both these groups were 
compared with each other the rejection was significantly stronger in the Lewis 
(poorly-matched) rats than the well-matched Wistars. These difference were in 
line with the hypothesis that more the mismatch on MHC loci, the stronger the 
immunological response. All the Wistar rats rejected all tumour cells with two 
weeks of study period while Lewis rats only took one week to achieve this. 
7.2.2.2	 Rejection	in	immunosuppression	groups	
	
Rejection was found to play an important role in the rats receiving CsA 
immunosuppression. When the immunosuppression was stopped after two 
weeks of continued treatment, the transplanted tumour cells were exposed to 
the host immune response.  As opposed to the behaviour of these transplanted 
tumours under CsA immunosuppression, where these cells continued to 
flourish, when the treatment was withdrawn there was a sharp reduction in the 
bioluminescent signals in both the well-matched and poorly-matched groups. 
Chapter	7-246	
	
Theoretically this was a direct proof of our hypothesis again. When the 
immunosuppression was withdrawn the host immune response was quite 
effective in causing the destruction of the foreign tumour cells.  
These effects of rejection were not seen in the other immunosuppression 
groups. The reason was effective elimination of the tumour load to a great 
extent (or completely) by the anti-neoplastic properties of these newer agents 
(sirolimus and leflunomide). 
 
7.2.2.3	 Role	of	matching	in	rejection	of	tumours	
 
The role of donor recipient matching was best seen in the CsA group again, 
both in the treatment continue and treatment withdrawal groups. In the 
treatment continue group under the influence of CsA, towards the end of the 
study period there was exponential growth of the transplanted tumour cells. This 
growth although very strong in both the strains, was significantly more in the 
Wistar animals towards the end of the study period. With no statistical 
differences in the initial tumour load this could be explained due to wider MHC 
differences in Lewis rats to the injected tumour cells. 
Similarly, after the withdrawal of the immunosuppression, half of the Wistar 
animals were able to reject the tumour cells. This was in contrast to all the 
animals completely eliminating the tumour load in Lewis rats. With all the other 
experimental variables being same, this effect is due to poor matching. 
Considering these finding, from a clinical point of view, when restored kidneys 
after ex vivo resection of tumour are transplanted we can potentially employ 
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hosts immune system in cases of any future recurrence of tumour. Unlike the 
normal situation of trying to look for the best possible MHC match between the 
donor and recipient, in these transplants we might want to transplant across 
less than ideal tissue match. Thus, if there were any tumour recurrence or de 
novo tumour development, then withdrawal of immunosuppression would be 
helpful in the elimination of any possible distant (lymph node) spread via 
recipient’s immune system. 
7.2.3		Role	of	immunosuppression	
	
There have been significant advances in the past decade in the treatment of 
renal tumours. These days the proffered treatment for the T1a (<4cm) tumours 
is partial nephrectomy. This is because of similar oncological outcomes(308–
310) and preservation of the renal function by preserving the nephron mass. In 
urological patients partial nephrectomy can be the treatment of choice but the 
stakes will be very high if the kidneys removed for small renal cell tumours were 
to be transplanted after ex vivo resection in hosts that are immunosuppressed. 
Hence, establishing the role of immunosuppression in a tumour transplant 
model was our other main objective. 
With standard CsA immunosuppression Wefound that the tumour has continued 
to grow and such growth was very rapid towards the end of study period most 
probably due to neo-angiogenesis. This effect was seen in both well-matched 
and poorly matched groups. This is in line with the current available evidence 
on the effects of standard immunosuppression on cancer development. Not only 
does any immunosuppression takes out the protection provided by the immune 
system but also there is evidence that CsA can lead directly to cancer 
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development due to aberrant production of cytokines regulating tumour growth, 
metastasis and angiogenesis(210). 
The effects of standard immunosuppression by CsA were directly compared 
with the newer antineoplastic medication. Sirolimus is licenced for use in renal 
transplantation and has antineoplastic effects. Wetested a low and a high dose 
of this agent. With both doses, in both strains (Wistar and Lewis) there were 
complete elimination of cancer cells within the study period. The effects were 
slightly stronger with higher dose but still very equally effective in the low dose 
regimens.  
Similar effects, although relatively less dramatic were seen with leflunomide. 
These animals showed continued reduction in tumour load and by the end of 
study period more than half of the animals had rejected their tumour load fully, 
in contrast to the CsA immunosuppression where there was an exponential 
increase in the tumour growth.  
These results point favourably towards sirolimus as quite possibly the drug of 
choice after transplantation with these restored organs. 
7.2.4	Flow	cytometry	
	
The flow cytometry was performed to look at the direct effect of tumour cells 
transplantation and role of different immunosuppressive agents at immune 
effectors level. Welooked at non-specific effectors of immune system that have 
a direct role in tumour recognition and elimination-Natural killer (NK) cells(246–
249). These cells recognise the tumour cells or virus infected cells which under 
express the MHC class I molecules (missing self)(250,251). The other cells 
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looked at were the effectors from the adaptive immune system. These cells are 
important both in a transplant situation and also have an important role in cases 
of tumour development. CD4+ helper T cells exert their role by producing 
number of cytokines that initiate graft rejection by stimulating more direct 
effectors(234–236). CD8+ T cells are normally found in small numbers in non-
rejecting graft but their number increase in cases of acute rejection and also in 
the tumour microenvironment, highlighting their significance. Lastly, Welooked 
at Treg cells. There is a lot of literature pointing towards their role in tolerance 
and tumour behaviour.  
Before analysing the response of immune system Welooked at the control 
animals with no tumour or immunosuppression to establish a baseline. The 
analysis of both Wistar and Lewis strains revealed that there were marked 
differences in the distribution of T cells among them. The absolute number of 
CD4 cells was significantly higher in Wistar rats but the number of activated 
CD4 cells was more in the Lewis rats. Although, the reason for this is not very 
clear it might explain more powerful rejection by the Lewis rats. Similarly the Treg 
cells were more abundant in Lewis rats. With CD4 cells having a more indirect 
role in activating the immune system and Treg having a “controlling” effect of the 
immune response these finding could be important in tumour control. The rest 
of the cell populations (CD8, activated CD8 and NK cells) were similar between 
both these strains.  
In the immunosuppressed animals, there were subtle differences in the cell 
populations among different agents as well. For Wistar rats, the number of 
CD4+ cells were the lowest in sirolimus low dose treatment arm as compared to 
the CsA group while the activated CD4 cells population was the highest in the 
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sirolimus low dose group. For these animals there were no apparent differences 
in the populations of NK and Treg cells. 
Activated CD8+ results were more consistent. All the animals had higher 
proportion of CD8 cells when compared to the controls. This will be due to their 
primary role in the acute rejection and tumour immunology. Similar results were 
seen when specifically the activated CD8+ cells’ percentage of the total CD8+ 
population was studied. The highest number of CD8+ cells were seen in the 
animals treated with low dose of sirolimus. These cells are normally one of the 
first effective responses for destroying the tumour cells. The preservation of 
these cells in higher numbers in the sirolimus treated group may point towards 
the ability of sirolimus treated animals to destroy the tumour cells more 
effectively than the CsA immunosuppression. Interestingly, in the high dose 
sirolimus animals groups these cells had reduced numbers and perhaps this 
points towards the excessive immunosuppression, as a much higher 
immunosuppressive dose was used in this group. 
For the Lewis animals, the Treg population was the lowest in the sirolimus low 
dose group and activated CD8+ cells population was the highest. These results 
again, may explain the reason for the better response against the tumour cells 
in the sirolimus arm of animals. 
The effects on CD8+ cells were most consistent in our flowcytometric data and 
also in line with the clinical observation of better tumour clearance in these 
animals. 
Normally immunosuppression with sirolimus has shown an increase in the 
number of Treg cells, but in our model the population of Treg reduced along with 
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an increase in the number of CTLs.  Although this result may seem against 
most of the literature but one important difference in our model was that it was 
not simply a transplant model but the transplanted cells were malignant as well. 
As shown by Hope et al. (303), when the SCC were excised in KTRs, the Treg 
cells population also went down. The reason we might be seeing a decline in 
the number of Treg cells might be due to the strong anti-neoplastic effects 
leading to reducing tumour load and thereby eliminating the stimulus to keep 
the numbers high of Treg cells by the tumour microenvironment. Not a lot is 
known as to why the Treg numbers reduce after tumour excision and further 
research is needed in this area.  
7.3	 Clinical	implications		
	
Chronic renal failure is one of the most common chronic diseases and for the 
majority of the patients renal transplant is the optimal treatment. Not only does it 
improve the quality of life but it also has survival benefits(15–17). Unfortunately, 
the prevalence of disease is such that we still do not have enough organs 
available for transplantation. This is despite recent increase in the numbers of 
available organs, via the use of more and more marginal organs, increasing 
DCD donation and a general increase in live donors. Thus there is still a need to 
look at new sources to increase the number of available organs for 
transplantation.  
Use of kidneys for transplantation after ex vivo resection of small renal cell 
tumours may not seem practical but there have been a few cases where this 
type of transplantation has either happened deliberately or inadvertently. The 
first report was by Penn(55) in 1995 from Cincinnati where he looked at their 
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database for types of transplantation and reported 14 such transplants with no 
recurrence. Longer follow up by Buell et al. (54) also did not report any tumour 
recurrence in 2005. Subsequently, Nicol et al. reported a series where a total of 
41 such organs were transplanted after ex vivo resection. Off these 10 were 
benign tumours and the rest were malignant. They also reported excellent 
results with only one recurrence 9 years after the original transplant. Notably 
this recurrence was away from the site of original resection. All these reports, 
although very encouraging, were done at a small and well controlled 
environment. There was no mention of any specific immunosuppressive 
strategies post operatively.  
With around 5000 RCC diagnosed every year in the UK and the majority of 
them being T1a tumours, potentially there is a large source that can be tapped 
for precious organs. Although, partial nephrectomy is now considered the 
treatment of choice for these small cancers, there is clear evidence both 
nationally and also from our local regional urology referral centre (section 
1.4.4.1) that a large proportion of patients with small renal tumours still undergo 
radical nephrectomy(53). This means these radically resected kidneys can 
potentially be transplanted in selected patients. The biggest hurdle of course is 
the fact that the transplant recipients are immunosuppressed thus high risk of 
developing recurrence with standard immunosuppression. Our study was aimed 
at looking at the role of using newer agents to better tailor the 
immunosuppression after such transplantations.  
We have shown quite clearly in the animal model that sirolimus was best at 
destroying the transplanted tumour load. This effect was independent of the 
level of matching between the donor and the recipients. Sirolimus is already 
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licenced for use in transplant and there is evidence to support its use beyond 
the initial few months in special situations if not in all cases(121,225–227) in 
order to reduce CNI induced nephrotoxicity or due to sirolimus’ role in 
preventing skin cancers. Thus, clinically if these kidneys are transplanted then 
the patients should be electively converted to sirolimus immunosuppression. 
The other finding from our study was the role that host’s immune system played 
in rejecting the tumour load once the immunosuppression was stopped. 
Clinically, this can be potentially important in rare situations of recurrence after 
transplantation of such organs. In cases of recurrence, the patients can undergo 
transplant nephrectomy and simply stopping the immunosuppression can be 
enough to stop any microscopic spread of the donor-derived tumour. For this to 
happen effectively, extrapolating from our experiments, the matching between 
the donors and recipients should be less than ideal. This will make any donor 
derived malignancy more immunogenic and thus prone to be acutely rejected.  
With initial encouraging results from the literature and using sirolimus with a 
degree of mismatch between the donor and recipient, transplanting these 
organs can become a very real possibility at a larger scale.  
Of course the most important factors to consider before any of these organs can 
be transplanted are patient selection and consenting. 
Although it might seem a big ethical dilemma to offer an organ removed for 
cancer from one patient and then offer it for transplantation to another. But 
when we consider that some of the elderly and high risk patients on the waiting 
list have very little chance of getting an organ for transplantation and the risk of 
dying while waiting is quite high, the situation becomes quite clear. According to 
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many reports the risk of dying while being wait listed is between 6-10% per 
year(228–230). This is also dependent on the age of the patients listed, with 
worsening survival with an advancing age. Patients becoming unfit and inactive 
on the waiting list complicates the situation as the risk of dying increases even 
further. According to an analysis about 30% of deaths on waiting list occur in 
patients who had inactive status(231). Thus an elderly patient who has to wait 
for longer (blood group O and B) the risk of dying can be 50% over five 
years(232). This is far more than any risk associated with transplanting these 
restored organs. Thus elderly high-risk patients who would otherwise be unlikely 
to get a transplant from the normal waiting list will benefit the most from such 
restored organs. 
It is of paramount importance to consent both the donors and recipients without 
any bias. The decision to do partial or radical nephrectomy should be purely 
clinical and must be made in discussion with the patient after discussing the 
pros and cons of each procedure. Potential of transplanting the organ after ex 
vivo resection should have no bearing on what type of treatment is offered to 
the RCC patients. If for some reason either clinically or due to patient’s choice 
the radical nephrectomy is being performed only then should the “donors” be 
asked for their consent using these organs for transplantation. 
For recipients as well the consenting process must be very vigorous and it must 
be ensured by the senior clinicians that the recipients fully understand the 
source of these organs, the small nephron mass to start with and the potential 
for recurrence and metastasis of tumour. Only when everyone is fully satisfied 
can these transplants go ahead.  
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After transplantation, perhaps these patients would need routine US monitoring 
of the allografts to pick up any early signs of recurrence, all in order to reduce 
any potential morbidity associated with a recurrence. 
7.4	 Limitations	to	the	study	
	
Perhaps the central limitation to our study would be the use of rat kidney tumour 
cells in a rodent transplant model. To extrapolate the results from animal 
studies onto human scenario, always has its inherent risks of not being a true 
representation of real life situation. But with a large body of work done on rats 
and mice both on immunology, transplantation and tumour behaviour this was 
the closest model to test our hypothesis.  
With sirolimus immunosuppression in the treatment withdrawal arm, the effect 
on tumours was so strong that there were hardly any tumour cells left by the 
time Westopped immunosuppression to look at the role of rejection. Perhaps a 
higher initial tumour load would have meant that there were still significant 
number of cells present at the time of withdrawal to study the effects of rejection 
better. But this would mean that Wewould have to increase the tumour load 
across all arms of the study period for the results to be comparable. Plus there 
was no way of us predicting such a strong response with sirolimus before the 
start of experiments. 
With flow cytometry, the results of the CsA may not be the true reflection of the 
actual lymphocyte count at the end of the study period. This is because of 
technical failure of the FACS machine at the beginning of the experiments and 
loss of a few samples from the Wistar animals with no immunosuppression. 
This also meant that by the time we were able to confidently do the flow 
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cytometric analysis, the CsA treated animals had already finished four weeks of 
the experiments for a few weeks. This time might have caused the reversion of 
the lymphocyte count to baseline, which would not be the true reflection of the 
exact influence of tumour on the lymphocyte count. The results of the sirolimus 
and leflunomide are more reliable from this respect.  
The other possible limitation of the flow analysis could be the small number of 
animals in each arm. There were very clear differences in bioluminescent 
signals under different treatment conditions but only subtle changes in the 
various subpopulations of lymphocytes. Perhaps with bigger numbers these 
differences would be more pronounced. This however would have come at the 
cost of using significantly larger number of rats with no guarantee that there will 
be any clear answer.  
Finally, the ideal place to look for the immune effectors would have been the 
tumour microenvironment or regional lymph nodes. The reason for choosing 
splenic tissue was to ensure consistency as not all the animals were left with 
any residual tumour and regional lymph nodes were only found in a very small 
proportion of the subjects. Hence to keep the analysis more objective and 
minimise variability Wechose the splenic tissue as the source to study the 
immune system. 
	
7.5	 Future	work	
 
The main role of this project was to prove the concept of using acute rejection to 
eliminate the tumour load and the role of level of matching on the strength of 
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rejection. The other aim was to determine the best immunosuppressive 
medication in tumour transplant scenario.  
The future work can take this project forward by injection the tumours into the 
renal subscapular regions followed by kidney transplantation.  This will be 
followed by using Sirolimus as the agent with antineoplastic properties at low 
dose (the best immunosuppressive agent with most effective dose based on our 
work). The biggest benefit of this project will be not only to look at the effect of 
sirolimus on the tumour but it will also determine the acute rejection episodes in 
the renal parenchyma as it is a known weakness of sirolimus. This will mimic 
the transplantation situation more closely as opposed to the subcutaneous 
injection. 
A further step proposed is to use nude or humanised mice with human kidney 
tumour cells. This will resemble the human transplant scenario even further. 
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Renal transplantation confers improvement in quality of life and survival when compared to patients on dialysis. There is a
universal shortage of organs, and eﬀorts have been made to overcome this shortage by exploring new sources. One such area
is the use of kidneys containing small tumours after resection of the neoplasm. This paper looks at the current evidence in the
literature and reviews the feasibility of utilizing such a source.
1. Introduction
Renal transplantation is the optimal mode of treatment for
the patients with end stage renal failure. One of the major
problems for transplantation is the discrepancy between
the donor and recipient numbers with far less donor than
recipients. As a consequence, patients with renal failure have
to wait for a long time before they can be oﬀered an allograft.
This situation is especially worse in some countries like
Japan, with small cadaver programme where the average
waiting time is 16 years [1].
A significant number of patients die from the compli-
cations of chronic renal insuﬃciency on long-term dialysis
before they get a transplant. This situation is more important
especially in cases where chronic kidney disease has lead
to other medical problems and patient either die of the
complications or become too unwell for a transplant [2].
Various measures including the use of marginal donors
and use of kidneys from Maastricht category II non-heart-
beating donors (NHBD) [2] have been utilized to increase
the donor pool along with measures to improve and prolong
graft function and survival. In addition, increasingly elderly
donors are used, therefore increasing the risk of renal
malignancy.
One potential area, first described by Penn [3] has been to
transplant kidneys after ex vivo resection of small tumours.
This was a very radical idea, because firstly, there has
been evidence of transmission of donor-derived malignancy
into recipient from the very early days of transplantation
[4]. Secondly as a general rule, organs from donors with
malignancies have not been used for the same fear with
some exceptions such as central nervous system tumours [5].
Surprisingly-outcomes of the patients described in Penn’s
series were not as bad as could have been anticipated.
The contemporary experience with partial nephrectomy
and its success for the treatment of small renal cell cancers
has lead to extrapolation of similar technique for the
management of allograft malignancy [6] albeit sporadically.
The purpose of this paper is to summarise the current
evidence with regards to the utilization of kidneys with
tumours for transplant and the use of conservative surgery
for allografts where possible.
2. Material andMethods/Review Criteria
Pubmed, medline, EMBASE and CINHAL were linked
searched for “renal tumour/tumor,” “kidney tumour/tumor,”
“allograft tumour/tumor,” “nephron sparing surgery,” “par-
tial nephrectomy,” and “transplant” to indentify potentially
relevant articles. Articles concerning the use of kidneys
after resection of renal tumour for transplant and partial
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nephrectomy of allograft for renal tumours were selected.
References of the selected article were also searched to
identify further articles of interest.
3. Results
From the above-mentioned criteria of the literature search
the following diﬀerent types of case reports/case series were
identified which are discussed separately.
3.1. Use of Kidneys after Resection of Tumours. Normal
practice when confronted with a tumour of kidney on
procurement is to return it to the donor and not use any
other organs [7]. In cases of deceased donors it meant that
the contralateral kidney cannot be used as well because of
the concerns of micro metastasis and bilaterality of some of
the renal cell carcinomas (RCC).
Penn [3], reviewing the Cincinnati transplant tumour
registry (CTTR), described a total of 14 cases of ex vivo
resection of small renal cell cancers detected incidentally
followed by transplantation. Frozen section was employed,
and where margins were clear, kidneys were used although
it is not clear whether all of the tumour bearing kidneys
underwent frozen section. Of the cadaveric donors, the
contralateral kidneys, all of which appeared healthy, were
transplanted as well. Apart from these cases of renal carci-
nomas, there was one case of oncocytoma within the kidney
which was transplanted after resection. Of all the cases where
the tumour was adequately resected before transplantation
there was no recurrence in a followup ranging up to 210
months.
Buell et al. [7] presented 14 cases of transplantation after
renal tumour resection from the same database as used by
Penn. No recurrence has been noted up to a followup of
200 months. Median tumour size was 2.0 cm (range 0.5–
4.0 cm) and all were of low histological grade. They have
described two further cases since the initial data review with
no recurrence and good graft function.
A similar case series from Australia [8] only included
elderly recipients or those with significant comorbidities and
high chance of death without transplantation. Furthermore
the recipients had high levels of HLA mismatching with the
donors and were selected on the basis that if there was a
recurrence to occur, stopping immunosuppression may help
in tumour lysis by recipient’s immune response. 41 patients
received kidneys after ex vivo resection of tumour of which
10 were reported as benign lesion on histopathology. One
patient returned to dialysis after 30 months. 4 patients died
of unrelated causes. There was only one recurrence noted 9
years after transplantation out of the remaining 30 patients.
Notably this tumour recurrence was at a distance from the
initial resection site, this therefore may not be a tumour
recurrence but another primary within a “field” change renal
tissue. The patient refused any further treatment, and the
lesion has grown 0.2 cm in 18 months since diagnosis. In
a followup study on these patients this group has recently
published long-term outcomes which are significantly better
than wait-listed patients on dialysis and are comparable to
the live unrelated transplants [9].
Mannami et al. [10] from Japan published a series
of 42 “restored” kidneys from live donors. Eight donors
with small renal cell carcinoma (<3.5 cm) underwent donor
nephrectomy and ex vivo resection of the tumour followed by
transplantation of the kidney. Five patients were alive, three
with functioning grafts, two died with functioning grafts
from unrelated caused, and one was lost to followup. No
tumour recurrence has been noted in any of these patients.
Another 8 patients had donor nephrectomies which had
benign diseases of which 5 had partial resection and kidney
used for transplantation. Three recipients are alive with
functioning grafts, while four have gone back to dialysis
(after 3,18,51,73 months). One recipient died of unrelated
pathology.
There have also been 6 case reports [11–16] of live related
kidney donation when a tumour was detected incidentally in
or ex vivo and the kidney was transplanted after resection.
No recurrence has been noted in any of these cases with a
followup of up to more than 10 years.
3.2. Partial Nephrectomy for Tumours Diagnosed after Trans-
plantation. Renal cell carcinoma represents around 4.6% of
all the tumours in allograft recipients with only 10% of these
occurring in the allograft itself [3].
The other main subgroup is when a tumour was detected
after transplant. Again the standard practice here has been
to perform transplant nephrectomy [17] with the patient
invariably returning to dialysis and normally being put on
a waiting list for another transplant if feasible.
Until now, more than 50 cases of allograft renal cell
tumours have been described in the literature of which at
least 35 cases have had nephron sparing surgery (NSS) for
their allograft tumour [6, 11, 18–36]. Tumour sizes have
range, from 0.5 to 4.0 cm although there have been two
case reports of larger (6–8 cm) tumours all being successfully
treated with NSS [18, 19]. Postoperative followup is from
one month to more than 10 years with one recurrence 5
years after NSS in renal allograft [37]. This was in a 74 year
old recipient five years after initial transplant. A 2.4 cm RCC
was incidentally detected without any evidence of distant
metastasis. It was treated with radical nephrectomy and
patient has been disease free on hemodialysis.
3.3. Contralateral Transplanted Kidney with a Renal Tumour
in Cadaveric Donor. These kidneys again are normally not
used as RCC can be bilateral especially the papillary subtype
[38]. Penn [3] has described 14 cases in which the con-
tralateral kidney was transplanted from patients with renal
tumour. One patient had recurrence in the allograft which
was removed for rejection. This patient died 75 months after
transplantation from a de novo cancer of one of his own
kidneys. The remaining patients did not have any recurrence
with a followup ranging from 0.5 to 153 months.
Nicol et al. [8] described 2 similar cases with no
recurrence. Barrou et al. [38] has described a case of two
allograft recipients from a single donor with tubulopapillary
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tumour (17mm) in the right kidney; only the left kidney was
utilized for transplantation. Shortly after transplantation, the
recipient underwent an ultrasound (US) examination of the
allograft which did not reveal any tumour. 3 months later
a biopsy was done for rejection which revealed a poorly
diﬀerentiated tumour and the patient underwent radical
allograft nephrectomy. No additional chemotherapy was
given apart from discontinuation of immunosuppression
(prednisolone and azathioprine). Lymph nodes that had
been noted to be enlarged on CT scan disappeared two
month after nephrectomy. The patient underwent re trans-
plantation two years later and was disease free and dialysis
independent at 3 year followup. Another patient received the
heart transplant from the same donor but died from bony
metastasis from the renal cell carcinoma.
3.4. Accidental Transplantation. In at least 4 cases [3, 13,
20, 39] there have been accidental transplantation of RCC
mistaken as a benign pathology on procurement. Partial
nephrectomy/enucleation in all these cases was performed
before transplantation with adequate resection margins.
Routine histopathology revealed the resected tumour to be
malignant. All recipients retained the allograft because of
complete excision of the tumour and were kept under close
follow-up with no recurrence so far.
The cases where there have been transplantation of
tumour, either partially resected or unrecognized at the time
of transplant have resulted in disastrous outcomes [3, 38].
3.5. Miscellaneous. Manammi et al. [10] reported a series
of 8 patients who underwent nephrectomy for a distal
ureteric transitional cell carcinoma (TCC). One patient had
a recurrence of TCC after 15 months and was oﬀered graft
nephrectomy but opted for partial resection of ureteric
tumour to prevent returning to dialysis. He died three years
after partial resection from a squamous cell carcinoma of
lung with liver metastasis. His TCC also had squamous
metaplasia and a DNA study to determine exact origin
of primary tumour could not be established because of
inadequate tissue samples. The remaining patients were
either alive with functioning grafts or died of unrelated
causes.
3.6. Opinion of Patients and Transplant Specialists. Trans-
plantation of kidneys with cancers is a novel idea not only
among patients but also among the transplant community.
To be able to exploit this potential donor pool it is of utmost
importance that both the health care specalists; transplants
surgeons and nephrologists and the patients both donors
and recipients are comfortable with the idea of using such
kidneys. To determine this, structured questionnaires were
sent to focus group of patients on the North East renal
transplant waiting list, postnephrectomy patients for small
renal cancer, nephrologists and transplant surgeons in the
UK [40].
Results are shown in Table 1 and have a generally high
response rate. Those respondents that had lost their kidney,
removed for tumour, had the highest consent rate and
Table 1
Respondents Response rate
Support use of
kidneys
Potential recipients on
waiting list
97% (113/116) 59% (67/113)
Previous nephrectomy
(potential donors)
100% (15/15) 93% (14/15)
Nephrologists 58% (94/161) 78% (73/94)
Transplant surgeons 66% (43/65) 72% (31/43)
patients potentially receiving such kidney the lowest. The
transplant surgeon and nephrologists had views somewhere
in between.
This survey was done in UK from where there have been
no case reports of using organs after removal of tumour and
but still the response was largely favourable. Given that since
this survey there has been an increase in total number of such
organs being utilized, one can extrapolate that current belief
may be more favourable.
3.7. Role of Immunosuppression. One of the worries about
transplantation of tumour aﬀected kidneys is the potential
of tumour recurrence and growth in state of potential
immune inattention due the immunosuppressive therapy.
Renal cell carcinoma is known to be an immunogenic
tumour [21] but in the presence of immunosuppression, if
there was any transplantation of tumour cells in the host,
then the potential of continued growth will be higher in
a host with a compromised immune system. Furthermore,
immunosuppression in itself has been known to increase the
incidence of de novo malignancy [41, 42]. Because of these
concerns, an immunosuppressive agent with no potential
to increase de novo malignancy and better still to have
antitumour activities would probably be ideal. Rapamycin
has shown some promise as being a protective agent against
RCC progression [21, 43, 44].
4. Discussion
Incidence of RCC has increased in Western countries in
the last few years owing to the widespread use of US and
CT scanning [45, 46]. Most RCC are now picked up at an
early stage on investigations done for other reasons [47].
Furthermore the incidence of RCC in allografts will continue
to increase as older people donate organs and graft survival
is improved by better immunosuppression. Longitudinal
studies have shown that many small tumours have a slow
growth pattern with low metastatic spread in tumours of
<3 cm [48, 49]. Autopsy studies have shown that RCC are
present in 1%–20% of patients dying from unrelated cases,
meaning that many of the tumours will not prove to be
clinically significant in the course of patient’s life [50, 51].
The gold standard treatment of resectable renal cell
carcinoma has been radical nephrectomy. Recent evidence
has changed this practice dramatically as survival after
radical nephrectomy (RN) and partial nephrectomy (PN)
has shown to be comparable [52]. Favourable outcomes
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have been observed after NSS for <4 cm RCCs and RN has
been described as “surgical overkill” [53] for these tumours.
Furthermore, local recurrence after NSS has been reported
to be <5% with recurrences mostly associated with large and
multifocal tumours.
A significant risk of dying in patients on dialysis partic-
ularly in older patient has been one of the driving forces to
increase the number of kidney donors. Renal transplantation
seems to confer a substantial survival advantage over dialysis
in patients with end-stage renal failure [2]. A significant
number of patient accepted for dialysis are older patients,
who have a mortality risk of 25%. With longer waiting times
for a transplant, it is inevitable that many of the patients will
die before they can receive a transplant which would have
improved their quality of life and longevity [2]. Furthermore
16% to 23% of suspicious lesion resected from kidneys are
either benign or of low malignant potential [53–55] and
not using these kidneys with small tumours after partial
nephrectomy for transplantation seems wastage of precious
organs when one considers the benefits of transplantation
over dialysis.
A suspicious lesion found at multiorgan retrieval should
have an excision biopsy and histological confirmation of
clear margins before any of the organs can be transplanted.
A malignant lesion in the kidney when unrecognized and
transplanted continues to grow under the immunosup-
pression carries high risk of metastasis and can result in
fatal outcome. If the biopsy confirms clear margins with
favourable histology then these organs could be used for
transplantation as risk of recurrence is very low. Situation is
more complex when it comes to using restored organs from
live (related/unrelated) renal cell carcinoma patients. Major
diﬀerence being that these are live cancer patients first and
therefore must never be treated primarily as potential organ
donors to prevent any bias in treating their primary problem
which may lead to provision of less than optimal treatment
and ultimately harm to these patients [8, ed]. This is shown
by Takahara et al. [56] in their review ofMannami et al. series
concerning ureteric carcinoma patient, where adherence to
standard practice for treating these tumours was not prac-
ticed with disastrous consequences. With changing trends,
radical nephrectomy is now regarded as an alternate standard
of care to partial nephrectomy for T1a tumours when partial
nephrectomy is not technically feasible. This is due to the
comparable oncological outcomes after partial nephrectomy
and evidence that radical nephrectomy is an independent
predictor of low GFR. A positive outcome for a recipient
can never justify harm to a live donor; on the contrary, for
a transplant with a live donor to be regarded as a success
means that both the recipient and the donor have done well
[57]. Live related donors in Nicol et al. series were given
the options of observation, radical or partial nephrectomy
without any mention of the possibility of use of organs for
transplantation. Only after the patients had decided to opt
for radical nephrectomy possibility of domino donation was
discussed. This approach has the benefit of making sure that
patients make their own decisions without any pressure from
clinicians. Other important factor is to make sure that beliefs
of the clinician do not aﬀect patient’s treatment choices.
Importance of detailed informed consenting cannot be over
emphasised for the recipients of such restored organs. All the
relevant information especially of the origin of the organ and
potential of recurrence and associated risk must be discussed
fully and patients understanding checked.
Routine followup of the patients with annual US have
been suggested to make sure any recurrence is diagnosed as
early as possible. Tumours have been detected at early stage
with better outcomes because of regular followups. If one
kidney is found to have a tumour it is important that the
other kidney is closely followed up. It is easier in the live
donor setting when the donor can be carefully followed up
but in cadaveric donation there has to be a central database
for tracking the contralateral kidney [22] which might be
transplanted into a recipient in a diﬀerent unit.
Immunosuppression is essential after transplant and
unfortunately this has been associated with the higher
incidence of cancers in recipients as opposed to the general
population [42]. Certain newer immunosuppressive agents
have anti tumour [58] activity and their use can, in theory
not only reduce the chances of recurrence but they can also
be used to treat patient should a recurrence occur.
Furthermore Human Tissue Act 2004 [59] that covers
the use of organs for transplant in the UK allows anyone
to be a donor including live related and unrelated (altruistic
donor) provided there is adequate consenting. This means
that donation can also occur from patients suﬀering from
small renal cell carcinoma who have radical nephrectomy as
primary treatment provided measures are taken to ensure
that these patients are treated appropriately in the first place
and both donor and recipients had given informed consent.
5. Conclusion
To increase the donor pool new sources have to be exploited.
Use of kidneys after tumour resection seems a feasible source.
There are several important issues in using such marginal
and potentially dangerous organs; patients should have com-
plete understanding of the implications of the type of organ
they are donating and receiving, good surgical technique and
rigorous pathological testing of the resected tissue to make
sure there is no tumour left behind, regular followup with
adequate investigations, and a reliable organ tracking system
to investigate the recipient of contralateral organ should
one organ develop a recurrence. On top of this, transplant
surgeons and nephrologists should be comfortable in using
such organs. Usage of such organs is still in its infancy, and
for a much wider acceptance of this source to occur, there
is need for more research. One interesting area will be to
explore the new immunosuppressive agents with antiprolif-
erative properties on such recipients with the potential to
reduce recurrence rate or better still to prevent it altogether
while either replacing standard immunosuppressive agents
or reducing their required dose thereby reducing side eﬀects.
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MALIGNANT KIDNEYS FOR RENAL TRANSPLANTATION 
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 Renal transplantation confers improvement 
in quality of life and survival when 
compared with patients on dialysis. There is 
a universal shortage of organs, and efforts 
have been made to overcome this shortage 
by exploring new sources. One such area is 
the use of kidneys with benign pathologies 
or containing small tumours after resection 
of the neoplasm. Our comment investigates 
the possibility of using either of these two 
potential valuable sources. 
 There is still a large gap between the 
number of renal grafts available for 
transplantation and the number of patients 
on waiting lists. A signifi cant number of 
patients awaiting renal transplantation 
either die or become too unwell from 
complications of chronic renal insuffi ciency 
on long-term dialysis before they can get a 
transplant  [ 1 ] . Over the years many different 
sources of renal allografts have been 
exploited with variable success but the 
fundamental problem of low donor numbers 
persists. One potential source of renal 
allografts could be transplantation with 
kidneys by urologist for benign and 
malignant pathologies at the time of 
nephrectomy. 
 Recent evidence suggests that small renal 
cell tumours (T1a) could be safely treated by 
nephron-sparing surgery (NSS), such as 
partial nephrectomy (PN), with comparable 
outcomes to radical nephrectomy (RN)  [ 2 ] . 
Current guidelines recommend a PN for 
small renal tumours, but the procedure itself 
has a steep learning curve and many centres 
continue to perform RN for small RCCs  [ 3 ] . 
Despite the recommendation from European 
Association of Urology guidelines  [ 4 ] , many 
patients with localised RCC still undergo RN 
 [ 5 ] . In view of the above, there is a potential 
to use these organs as renal grafts for 
transplantation once the tumour has been 
resected  ex vivo and confi rmation with 
frozen section of clear margins followed by 
transplantation in selected groups of 
patients. 
 In 1995 Israel Penn  [ 6 ] published the results 
from Cincinnati transplant tumour registry 
with 14 patients receiving restored organs 
after  ex vivo resection of small tumours with 
no recurrence in a follow up period ranging 
up to 210 months. A further series by Buell 
 et  al .  [ 7 ] , again from Cincinnati in 2004 
reported similar results. Nicol  et  al .  [ 8 ] , from 
Brisbane published their experience over an 
11-year period from 1996 – 2007, where 31 
patients received RCC affected kidneys after 
tumour resection with only one possible 
recurrence 9 years after transplantation 
(away from the location of primary tumour 
resection). There has been another case 
series from Japan  [ 9 ] with eight such 
patients and at least seven published case 
reports  [ 10 ] . The possibilities of using benign 
kidneys continues to be enormous. At our 
institution we have recently transplanted a 
kidney from a patient with a ureteric injury 
into a recipient successfully, with the 
donor being aware of the possibility of 
auto-transplantation. 
 Despite these published cases, before such a 
source could be widely popularised there are 
a few important practical issues that will 
need addressing. Patients with small RCCs 
must be informed of the option of NSS and 
RN clearly with associated risks involved 
with both techniques. Once the patients 
have made the decision to undergo RN, only 
then the potential of transplantation should 
be discussed. This approach avoids the 
potential bias towards RN and use of kidney 
for transplantation from clinicians and this 
was the approach employed by Nicol  et  al . 
 [ 8 ] in their series. The consenting of the 
potential recipients must be very thorough 
as well to ensure that they understand the 
origin of these kidneys and the potential 
risks involved. There has to be general 
acceptance of the idea especially among the 
potential recipients before the wide spread 
use of such organs could occur. 
 In our centre we have completed a regional 
questionnaire to potential recipients 
(patients on transplant waiting list) in North 
East of England, to see if they will accept 
such organs and 59% responded positively 
 [ 10 ] . With current guidelines recommending 
NSS and new evidence suggesting better 
long-term GFR with NSS, the biggest 
criticism of this approach is subjecting 
patients to RN for small RCCs. But despite 
clear recommendations and current evidence 
favouring NSS, still a large proportion of 
patients undergo RN for various reasons. In 
an ideal world the number of RN should be 
very small meaning that exploring such a 
new source will not be feasible as the 
number of potential organs generated will 
be very small. But the reality is quite the 
opposite. Data from the USA and UK suggest 
that more patients undergo RN than PN for 
these small tumours. Whether it is due to 
patients ’ wishes, technically diffi cult cases, 
lack of facilities or expertise, is irrelevant as 
these precious organs are potentially wasted 
when they could have been transplanted. The 
other big question is who should receive 
these potentially  ‘ dangerous ’ organs. Most of 
the modern practice of medicine is a balance 
between the risks and benefi ts to the 
patients and this area should not be any 
different. These organs should be 
transplanted to patients who are at the 
highest risk of dying on long-term dialysis 
without a renal transplant. After 
transplantation there should be strict 
follow-up of these patients to detect any 
new growth at a very early stage. 
 Under the Human Tissue Act 2004 anyone 
could be a donor (live related or unrelated), 
so these kidneys after resection of tumour 
can be used for transplantation under the 
umbrella of domino donation. With  ≈ 7000 
new cases of RCCs diagnosed each year in 
the UK, more than half of which are T1a and 
with still most of these undergoing RN, 
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there is a huge potential to increase the 
organ-donor pool with these marginal 
organs, if the ethical issues involved could 
be addressed appropriately. 
 CONFLICT OF INTEREST 
 None declared. 
 REFERENCES 
 1  Johnson  DW ,  Herzig  K ,  Purdie  D  et  al . 
 A comparison of the effects of dialysis 
and renal transplantation on the survival 
of older uremic patients .  Transplantation 
 2000 ;  69 :  794 – 9 
 2  Butler  BP ,  Novick  AC ,  Miller  DP , 
 Campbell  SA ,  Licht  M .  Management of 
small unilateral renal cell carcinomas: 
radical versus nephron-sparing surgery . 
 Urology  1995 ;  45 :  34 – 41 
 3  Russo  P .  Open partial nephrectomy: an 
essential operation with an expanding 
role .  Curr Opin Urol  2007 ;  17 :  309 – 15 
 4  Ljungberg  B ,  Cowan  NC ,  Hanbury  DC 
 et  al .  EAU guidelines on renal cell 
carcinoma: the 2010 update .  Eur Urol 
 2010 ;  58 :  398 – 406 
 5  Nuttall  M ,  Cathcart  P ,  van der Meulen 
 J ,  Gillatt  D ,  McIntosh  G ,  Emberton 
 MA .  description of radical nephrectomy 
practice and outcomes in England: 
1995-2002 .  BJU Int  2005 ;  96 :  58 – 61 
 6  Penn  I .  Primary kidney tumors before 
and after renal transplantation . 
 Transplantation  1995 ;  59 :  480 – 5 
 7  Buell  JF ,  Hanaway  MJ ,  Thomas  M 
 et  al .  Donor kidneys with small renal 
cell cancers: can they be transplanted? 
 Transplant Proc  2005 ;  37 :  581 – 2 
 8  Nicol  DL ,  Preston  JM ,  Wall  DR  et  al . 
 Kidneys from patients with small renal 
tumours: a novel source of kidneys for 
transplantation .  BJU Int  2008 ;  102 : 
 188 – 93 
 9  Mannami  M ,  Mannami  R ,  Mitsuhata  N 
 et  al .  Last resort for renal transplant 
recipients,  ‘ restored kidneys ’ from living 
donors/patients .  Am J Transplant  2008 ; 
 8 :  811 – 8 
 10  Khurram  MA ,  Sanni  AO ,  Rix  D ,  Talbot 
 D .  Renal transplantation with kidneys 
affected by tumours .  Int J Nephrol  2010 ; 
 [Epub ahead of print] 
 Correspondence: Nikhil Vasdev, Department 
of Urology, Freeman Hospital, Newcastle 
Upon Tyne NE7  7DN, UK.
 e-mail:  nikhilvasdev@doctors.org.uk 
 Abbreviations :  NSS ,  nephron-sparing 
surgery ;  (P)(R)N ,  (partial) (radical) 
nephrectomy. 
Chapter	268	
	
Therapeutic	kidney	donation:	A	potential	source	of	precious	
organs	
	
	
Please  cite  this  article  in  press  as:  Khurram  MA,  et  al.  Therapeutic  kidney  donation:  A  potential  source  of  precious
organs.  Br  J  Med  Surg  Urol  (2012),  http://dx.doi.org/10.1016/j.bjmsu.2012.04.003
ARTICLE IN PRESSBJMSU-290; No. of Pages 3
British Journal of Medical and Surgical Urology (2012) xxx, xxx—xxx
CASE REPORT
Therapeutic  kidney  donation:  A  potential  source
of precious  organs
Muhammad  Arslan  Khurrama,  Colin  Wilsona,  Nikhil  Vasdeva,b,∗,
Derek Manasa, David  Talbota, David  Rixa,b
a Department  of  Transplantation,  Freeman  Hospital,  Newcastle  upon  Tyne  NE7  7DN,  UK
b Department  of  Urology,  Freeman  Hospital,  Newcastle  upon  Tyne  NE7  7DN,  UK
Received  20  February  2012;  received  in  revised  form  15  April  2012;  accepted  18  April  2012
KEYWORDS
Renal transplant;
Altruistic domino
donation
Abstract  The  number  of  patients  awaiting  a  renal  transplant  considerably  exceeds
the number  of  organ  grafts  available.  A  successful  kidney  transplant  is  the  most
clinically and  cost  effective  treatment  for  patients  with  end  stage  renal  disease.  A
proportion  of  patients  currently  die  awaiting  a renal  transplant  as  their  continues
to be  a  global  deficiency  of  renal  allografts.  Efforts  continue  to  be  made  in  order
to improve  the  current  situation  of  waiting  lists  and  there  is  now  an  urgent  clinical
need to  explore  potential  new  sources  to  increase  the  number  of  renal  allografts
for transplantation.  We  describe  a  successful  case  of  a  renal  transplant  with  a  kid-
ney removed  for  benign  aetiology  and  transplanted  into  a  patient  who  was  on  the
cadaveric renal  transplant  waiting  list  for  6  years.  We  predict  that  this  of  ‘Altruistic
domino donation’  concept  could  potentially  reduce  the  waiting  list  for  cadaveric
renal transplantation  and  more  importantly  become  a  valuable  source  for  new  renal
allografts.
©  2012  British  Association  of  Urological  Surgeons.  Published  by  Elsevier  Ltd.  All  rights
reserved.
Case report
A  59-year-old  male  underwent  a  resection  of  a
large retroperitoneal  ‘tumour’  which  involved  the
left colon  for  a  pre-operatively  diagnosed  sarcoma.
Final histology  confirmed  ‘‘Benign  Fibromatosis’’
∗ Corresponding author at: Department of Urology, Freeman
Hospital, Newcastle upon Tyne NE7 7DN, UK.
Tel.: +44 01912336161; fax: +44 01912137127.
E-mail address: nikhilvasdev@doctors.org.uk (N. Vasdev).
which  is  associated  with  an  optimistic  prognosis.
The patients  subsequently  underwent  a  reversal
of colostomy  and  intraoperatively  sustained  an
iatrogenic injury  to  the  left  mid  ureteric  injury
which presented  on  the  10th  post-operative  day  as
loin pain  and  sepsis.  An  initial  nephrostomy  and
drainage of  urinoma  was  performed  followed  by
an unsuccessful  attempt  at  antergrade  and  retero-
grade stent  insertion.  A  defect  measuring  >4  cm  was
identified in  the  mid-ureter.  A Renogram  confirmed
a differential  function  of  41%  on  left  side  and  the
1875-9742/$ — see front matter © 2012 British Association of Urological Surgeons. Published by Elsevier Ltd. All rights reserved.
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patients  glomerular  filtration  rate  (GFR)  was  calcu-
lated at  68  ml/min/1.73  m2.
The  patient  was  counselled  with  the  options
of either  a  ureteric  repair  (Uretero-ureterostomy,
Transuretero-ureterostomy plus  Boari-flap  and
reimplantation) or  auto-transplantation  (AT).  The
risks of  all  options  were  discussed  with  patient
including the  potential  of  an  on  table  nephrec-
tomy and  unsuccessful  repair.  The  patient  was
not keen  to  pursue  reconstructive  surgery  and
opted for  a  nephrectomy.  We  then  discussed  the
possibility of  ‘Altruistic  domino  donation’  with
the patient.  Permission  for  using  the  left  kid-
ney for  potential  transplantation  was  approved
by UK  Transplant  (UKT)  under  the  category  of
‘‘domino donation’’  according  to  the  Human  Tissue
Act [1].
A 70-year-old  recipient  on  thrice  weekly
haemodialysis for  6-years  was  identified.  The
patient had  ESRF  secondary  to  hypertension  and
had concomitant  ischemic-heart-disease.  His  mis-
match was  1:1:1.  This  recipient  had  waited  for  6
years for  a  cadaveric  renal  transplant  and  had  no
prospect of  a  live  donor  transplant.  It  would  have
been unlikely  for  him  to  receive  a  cadaveric  trans-
plant during  his  lifetime  based  on  his  performance
status and  co-morbidities  making  him  completely
dialysis dependent  for  life.
Both donor  and  recipient  were  scheduled  for
surgery on  the  same  day  and  did  not  meet  each
other. An  open  nephrectomy  was  performed  in
view of  the  patient’s  previous  extensive  open
surgery and  adhesions  via  a  loin  incision  and
the kidney  flushed  with  cold  preservation  solu-
tion. The  kidney  was  prepared  for  transplantation
after a  thorough  examination  by  the  transplant
team (Figs.  1  and  2).
The donor  organ  was  implanted  into  the  right
iliac fossa  and  the  ureter  was  successfully  anasto-
mosed into  the  bladder  over  a  stent.  Post-operative
recovery was  unremarkable  for  both  the  donor
and the  recipient.  Donor  was  discharged  on  2nd
post-operative day  with  creatinine  of  1.25  mg/dl.
Recipient had  immediate  graft  function  and  cre-
atinine on  discharge  was  1.53  mg/dl.  Donor  and
recipient have  subsequently  communicated  anony-
mously with  each  other  by  letter  and  are  doing  well
at 8-month  follow-up.
Discussion
Kidneys  removed  for  small  renal  tumours  have
been successfully  transplanted  after  ex  vivo  tumour
resection with  extremely  low  recurrence  rates
Figure  1  Left  kidney  after  back  benching.  Artery,  vein
and  ureter  demonstrated.
[2,3,7].  Kidneys  removed  for  benign  aetiologies
are however  not  associated  with  any  risk  of
tumour transmission.  Transplantation  with  renal
grafts from  benign  aetiologies  can  be  potentially
linked to  the  established  concept  of  altruistic  dona-
tion. With  the  ‘‘donor’’  being  treated  for  their
primary pathology  with  nephrectomy,  such  dona-
tions are  regarded  as  Altruistic  domino  donation  in
the United  Kingdom  (UK)  under  Human  Tissue  Act
(HTA) [4].
In current  clinical  practice  the  commonest
indications for  simple  nephrectomy  (SN)  include
intractable loin  pain,  renal  artery  aneurysm
[5], ureteric  injury  [6]  and  refractory  nephrotic
Figure  2  Implantation  in  right  iliac  fossa.  The  ureter
being  anastomosed  to  bladder  over  a  stent.
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syndrome  [5].  Auto  transplantation  (AT)  can  be
an option  for  these  patients  (excluding  nephrotic
syndrome) but  on  occasions  this  may  not  be  the
appropriate treatment  in  clinical  situations  such  as
extensive previous  surgery,  increasing  risk  of  unsuc-
cessful ureteric  repair  leading  to  post-operative
complications, medical  co-morbidities  or  patient
choice.
Counselling of  patients  undergoing  SN  and  recip-
ients of  these  kidneys  is  extremely  important.
The recipient  should  be  fully  aware  of  the  ori-
gin and  quality  of  the  organ.  This  technique  has
the advantage  of  favourable  ischaemic  times.  Using
this approach  we  successfully  used  the  renal  graft
from our  donor  for  transplantation.  In  normal  clin-
ical circumstances  the  graft  would  have  ended
up as  a  nephrectomy  specimen  and  the  donor
would have  been  continued  to  be  on  thrice  weekly
haemodialysis. Our  approach  was  psychologically
very rewarding  for  the  donor  who  viewed  this
as a  positive  outcome  from  a  complex  surgical
scenario and  the  recipient  who  is  now  dialysis
free.
Furthermore these  organs  should  be  trans-
planted locally  as  they  may  pose  specific  technical
problems (short  vessels,  ureter,  etc.)  and  trans-
planting them  into  local  recipients  may  minimise
the discard  rates  and  potential  risk  of  compli-
cations, a  concept  endorsed  by  NHS  Blood  and
Transplant (NHSBT).  We  aim  to  highlight  the
importance of  this  new  concept  to  urologists
in the  UK  and  worldwide  as  this  could  be  a
very important  source  of  precious  renal  allografts
worldwide.
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Background: Tumour transfer/development is one of the more serious risks associated with transplantation. The
behaviour of a tumour can be unpredictable in immunosuppressed recipients. We report a highly sensitive
method tomonitor tumour behaviour in real time in a rodent tumour transplantmodel. This paper also explores
the effect of MHC matching on tumour growth among control and immunosuppressed hosts.
Methods: Luciferase expressing Wistar rat kidney tumour cells were transplanted into either Wistar or Lewis
recipients which mimic a well and poorly matched combination to assess the effects of MHC matching on
transplanted tumour cells. Experimental groups included controls with no immunosuppression and animals
immunosuppressed with cyclosporine. The latter group was further divided into a continuous treatment group
which received four weeks of immunosuppression and a treatment withdrawal group where immunosuppres-
sion was stopped after two weeks to assess the effects of rejection on tumour growth.
Results: All the tumour cells were rejected in the control animals that received no immunosuppression, within
2 weeks among well-matched combination and within one week in the poorly matched combination
(p 0.001). The transplanted tumour cells continued to grow in both well-matched and poorly matched groups
who were treated with cyclosporine, but growth was signiﬁcantly faster in the well-matched combination
(p 0.033). After treatment withdrawal the tumour cells were rejected in all the animals of the poorly matched
group compared to 50% in well matched animals within the four-week study period (p 0.039).
Conclusion: In the absence of immunosuppression the hosts reject the transplanted tumour cells, and the anti-
tumour response is stronger when there is a greater mismatch in MHC with the recipient. In the presence of
cyclosporine immunosuppression the tumour continues to grow, however, after withdrawal of the immunosup-
pression, tumour clearance is quicker in the poorly matched background. This data supports the idea of
expansion of the donor pool by using kidneys after ex vivo resection of small renal tumours and that these organs
should be transplanted into a less well-matched HLA recipient. We hypothesise that should a tumour recurrence
occur a poorly matched recipient could clear the tumour through withdrawal of immunosuppression.
© 2015 Elsevier B.V. All rights reserved.
1. Background
Transplantation has revolutionised the treatment of patients with
renal failure. It not only improves quality of life but also has a signiﬁcant
survival advantage compared with dialysis [1]. Although graft survival
and the absolute number of allografts have increased over the past cou-
ple of decades, there remains a large gap between the number of organs
available and potential recipients [2]. Over the years new sources of or-
gans have been explored but the problem persists and there is still a
need to increase donor numbers.
There is a large body of evidence that patients with small renal cell
carcinomas (RCC) can be treated with nephron sparing surgery (NSS)
with comparable outcomes to the previous gold standard of radical ne-
phrectomy [3,4]. Consequently for a patient electing to have their whole
kidney removed for a small RCC there is a potential for the removal of
the tumour and then allotransplantation of the remaining kidney. This
approach has been utilised by a few groups with good results [5–9].
One of the most important and perhaps potentially dangerous differ-
ences between a urology patient that has undergone NSS for a small
RCC and a potential allograft recipient of an NSS kidney is that trans-
plant recipients are on lifelong immunosuppression. Immunosuppres-
sive agents inhibit the natural checks on cancer cells by the immune
system. It is not known how tumour cells will behave in a HLA incom-
patible immunosuppressed host, if there is any inadvertent transplanta-
tion along with such restored kidneys.
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In the absence of any immunosuppression the allograft is rejected.
Theoretically any tumour cells transplanted along with the allograft
should be rejected as they both originate from the same donor. Howev-
er, cancerous cells have the ability to make themselves less immuno-
genic thereby evading the donor immune system in the ﬁrst instance
and it is not clear how they will behave in a new host [10].
2. Objectives
The aim of this study was to establish a rodent tumour transplant
model and study the effects of immunosuppression on tumour growth.
The other main aim was to study the effects of acute rejection on
tumour cells in a transplantation setting.
3. Study design and methods
3.1. Cell culture
The tumour cell line, BP36b was acquired from Riken Bio
Resource Centre (BRC) Cell Bank© Japan. This is a rat kidney tumour
cell line derived from male Wistar rats that received N-ethyl-N-
hydroxyethylnitrosamine (NHEN) in drinking water to induce tumour
growth. The cell line is stable and maintained its characteristics after
100 passages over a 3 year period [11]. Cells were grown in RPMI
1640 supplemented with glutamine and antibiotics (penicillin
10,000 units ml−1, streptomycin 10 mg ml−1, gentamicin 50 μg ml−1
and amphotericin B 25 μg ml−1). The doubling time of the cell line
was consistent with the reported time in the literature (17 h) [11].
3.2. Transfection
For real time in vivo imaging of the tumour cells, the cell line was
transfected with a commercial lentiviral construct that is stably inte-
grated and constitutively expresses the enzyme luciferase for biolumi-
nescence and green ﬂuorescent protein (GFP) for ﬂorescence [12,13].
Puromycin (10 μg ml−1) was used for selection of stable transfectants.
Puromycin supplemented media was replaced every 48–72 h to
select for single colonies of stable transfectants. Transfectants were
initially assessed by the expression of GFP by ﬂorescence microscopy.
Bioluminescence was determined initially by a luminometer and then
by direct visualisation using the IVIS® spectrum imaging system
(Caliper Inc.) (Fig. 1).
3.3. Tumour transplantation
Animals were injected with a ﬁxed number of cells (1.8 × 107) into
the right ﬂank under Isoﬂurane anaesthesia after shaving the fur. The
animals were anaesthetised in the induction chamber of the IVIS spec-
trum imaging system and then transferred into the dark chamber
where they were scanned for varying lengths of time (60–300 s). Ani-
mals were kept anaesthetised in the imaging chamber to enable long
exposure times required to detect even very faint bioluminescent sig-
nals. Luciferin was injected intraperitoneally at the dose of 150 mg/kg
10–15min before scanning to allow circulatory distribution throughout
the animal before detection. Timing of luciferin injection was calculated
by plotting the kinetic curve prior to the experiments. To compensate
for variations in luciferin distribution, 2–3 images were taken of each
animal at different time points and the only image with the strongest
signal used for further analysis. Regions of interest (ROIs) were the
areas of cell injection and any other areas with positive signals. The
background luminescence was calculated for each animal and signal
intensity was calculated by subtracting this from the ROI value to get
the accurate value of signals from the transplanted tumour cells (Fig. 2).
3.4. Experimental groups
To study the effects ofmatching on transplanted tumour growth two
different strains of rats, Wistar and Lewis were used. Since tumour cells
were ofWistar origin,when injected intoWistar rats (outbred) [14] this
combination served as a well-matched group as both the animals were
of the same strain. Despite the similarities between the tumour cell line
and the recipients, these animalswere not true syngeneic to the tumour
cells due to being outbred [15]. The other groupwas of inbred Lewis an-
imals that served as a poorly matched group due to transplantation
across the strain, leading to more marked immunological differences.
Fig. 1. IVIS spectrum image of non-transfected cells (left) and transfected cells (right). The
system produces a heat map image that can be compared to the scale seen to the right of
the image and the intensity of the luminescence calculated (P/s/cm2/sr).
Fig. 2. Day 0 IVIS spectrum image of Wistar rat after injection of transfected tumour cells
into the right ﬂank. Imagingwas performed 15min after intra-peritoneal injection of lucif-
erin for maximum signal intensity. Region of interest (ROI, solid red circle) is the area of
positive signals from the injection site while the background bioluminescence (dotted
red circle) is calculated for each image to calculate bioluminescence.
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To keep the variables to a minimum, only male Wistar or Lewis rats
were used for experiments as follows:
Controls; not receiving any immunosuppression and cyclosporine
(Cyc) group; receiving 25 mg/kg of Cyc daily via oral gavage. The
cyclosporine group was further divided into treatment continue
group receiving four weeks of continuous immunosuppression and
the treatment withdrawal group where immunosuppression was
stopped after 2 weeks to study the effects of rejection on the
transplanted tumour cells. All the animals were kept in a clean air
conditioned rodent area with 12 hour dark/light cycle and were
fed standard rodent blocks and with free access to tap water.
Animals were weighed weekly to adjust the doses of cyclosporine
and luciferin.
3.5. Statistical analysis
To detect a ﬁve-fold difference in tumour size with a standard
deviation of 0.2 with a 90% certainty and alpha of 0.05 we calculated a
sample size of 6 rats per group. Statistical analysis was performed
with the PASW 18.0.0 (IBM Inc. 2009) and GraphPad Prism (Version
5.04 GraphPad Inc.) softwares. The normality of the data was tested
prior to performing either ANOVA or the non-parametric Mann–
Whitney tests accordingly.
4. Results
4.1. Controls
The kinetics of tumour rejection was ﬁrst studied in the absence of immunosuppres-
sion. With well-matched animals there were still good signals at week one, but all the an-
imals subsequently rejected the tumour cells and lost signal, even after long exposure, at
week two. All poorly matched animals rejected the tumour cells and lost signal within
the ﬁrst week (p b 0.001 at week 1) (Fig. 3).
4.2. Cyclosporine treatment
The effect of Cyclosporine on the rate of rejection was then studied in well-matched
and poorly matched groups. These groups were further sub-divided into the animals
receiving the immunosuppression for a full four weeks and the animals receiving the
treatment for 2 weeks followed by treatment withdrawal. The rats in the treatment
withdrawal group were scanned as normal for the study period of four weeks before
euthanasia.
The tumour continued to grow in both the well and poorly matched animals when
immunosuppressive treatment was continuous. There was no signiﬁcant difference in the
growth of the transplanted tumour cells in the initial three weeks of the study, however
growthwas signiﬁcantly faster in thewellmatchedWistar animals compared to the poor-
ly matched Lewis rats (p 0.033) by week 4 (Fig. 4).
In 4 of 8 animals of the well-matched Wistar rats after treatment withdrawal tumour
signal could still be detected at 2weeks post-treatmentwithdrawal. However, in thepoor-
ly matched Lewis animals the whole group had rejected the tumour by the end of the
study period (two weeks post-treatment withdrawal) (p 0.039) (Figs. 5 & 6).
5. Discussion
Better immunosuppressive therapies have resulted in long allograft
survival with reduced side effects. The risk of cancer development,
however, even from standard allografts without any obvious donor
malignancy still persists. The initial results of function and recurrence
rates from transplanting restored organs after ex vivo resection of
tumour remain favourable [16] from the limited data available so far.
However, there remain some serious questions regarding the safety of
such an approach in immunocompromised hosts. The behaviour of a
tumour in a transplant setting can be unpredictable since all patients
will be immunocompromised to some degree in order to prevent graft
rejection. Consequently any study, which investigates the effect of
tumour cell growth in a transplant model to investigate whether the
immunosuppressive treatment, or MHC mismatch has any bearing on
tumour growth is worthwhile.
The stability of the tumour cells (BP36B) used for our study has been
demonstrated by the observation that the cells retained their properties
after multiple passages [11]. The cells being of Wistar origin made it
possible for us to study the effects of tissue matching on the tumour be-
haviour by using outbredWistar and inbred Lewis strains for implanta-
tion.When these cells were injected in the Lewis animals, they behaved
as a poorly matched group as the transplantation was between two
different strains with marked immunological differences. When these
cells were injected into the Wistar rats, they behaved as relatively
well-matched combination when compared to the Lewis animals but
strictly speaking they could not be classiﬁed as syngeneic transplanta-
tion. This is because of inter-individual variations in RT1 (rat major
histocompatibility complex) among any outbred strain of the rats [15,
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Fig. 3. Graph showing the time taken for rejection of tumour cells among control animals
without immunosuppression. Well-matched Wistar animals (green) took two weeks to
reject the tumour load while poorly matched Lewis (blue) animals rejected the tumour
load within one week (P b 0.001) (the error bars representing standard error of mean).
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Fig. 4.Cyclosporine treatment continue group: Comparison betweenwell matchedWistar
(green) and poorly matched Lewis (blue) groups. Transplanted tumour cells continued to
grow between both the groups but again the growth was stronger in well-matched ani-
mals compared to the poorly matched combination.
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17,18]. This slight variationmade our tumourmodel closely reﬂective of
scenarios in human transplantation; as even the very well matched in-
dividuals (excluding identical twins-syngeneic transplantation) would
have subtle differences in histocompatibility loci due to the very wide
variations in the HLA haplotype [19].
Tumour cells injected into hosts normally take a long time to become
palpable. Even cells with short doubling times often take a long time to
become clinically signiﬁcant and enable accurate measurements. The
BP36B cells, used in our study took two months to establish when
transplanted in immunocompromised nude mice [11]. Consequently
we decided to transfect the tumour cells with luciferase in order to de-
tect and monitor tumour growth by sensitive bioluminescent imaging
techniques. Furthermore, the quantitative measurements made by this
method were objective and less susceptible to human error and bias
since tumour load was calculated computationally by signal intensity
from the injected tumour cells rather than the more subjective method
of visually grading the tumour size.
The behaviour ofwell and poorlymatched transplanted tumour cells
under conditions of immunosuppression and rejection (treatment
withdrawal) has potential important clinical implications. The tumour
cells were, as expected, rejected in the absence of any immunosuppres-
sion in both groups of animals since there are likely to be some differ-
ences between the donor and recipient even in the well-matched
combination. However, the time taken for the poorly matched animals
to reject the tumour was signiﬁcantly shorter (p 0.001), and it is likely
that this was due in part to the stronger allogeneic response having an
anti-tumour effect. Similar results were noted when the immunosup-
pression waswithdrawnmidway in the study period to monitor the ef-
fects of rejection (p 0.039). All the Lewis animals rejected the tumour
two weeks after withdrawal while only half in the well-matched
group did so. The clinical signiﬁcance of this ﬁnding is that if we were
to transplant kidneys after ex vivo resection of T1a tumours, then per-
haps choosing a less well-matched donor recipient combination
would be preferable. This would mean, should a recurrence occur in
the recipient, simplywithdrawing the immunosuppression (with trans-
plant nephrectomy)may aid “rejection” of extra renal tumour cells [20].
This was the approach utilised by Nicol et al. in their series, although
theywere not able to test this hypothesis as the only patient developing
recurrence in their series declined any further treatment [7].
The other clinically signiﬁcant implication is the fact that under stan-
dard immunosuppression the tumour continued to grow. There were
subtle but statistically signiﬁcant (p 0.033) differences in the rate of
growth, with higher rate of tumour growth in well-matched animals.
However, in both strains by the end of study period the signal intensity
was high and in the majority of immunosuppressed rats the tumours
were palpable. Therefore, the risk of unchecked tumour growth and
perhaps metastasis would be a real concern should a tumour be
transplanted inadvertently with a restored organ. The behaviour of
tumours with immunosuppression usingmore contemporary immuno-
suppressants that have reported anti-neoplastic activity, such as
rapamycin and leﬂunomide, needs to be investigated. Such immuno-
suppressive agents may prove to be effective in preventing recurrence
or eliminate the cancer cells should they be transplanted inadvertently.
A strategy to transplant these kidneys into less well-matched recipients
and to use non-calcineurin inhibitor immunosuppression may provide
the best outcomes.
6. Conclusions
Subtle variations in the growth of the tumour cells based on MHC-
dependent differences in various experimental conditions were detect-
ed with great accuracy using the IVIS spectrum imaging system. There
are two clinically relevant deductions of our experiments. Firstly,
transplanted tumour cells continue to grow unchecked in immunosup-
pressed hosts. This ﬁnding makes it of paramount importance that any
kidney transplanted after ex vivo resection must be devoid of any
tumour load. Secondly, poorly matched combination of donor and
hosts were signiﬁcantly better in rejecting any donor-derived tumour
if immunosuppression was withdrawn in this animal model. Should a
recurrence occur in a clinical situation after such transplants, it might be
better to have less well matched donor recipient combination so that host's
own immune system can be used at least in part to reject the transplanted
tumour by withdrawal of immunosuppression.
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Fig. 5. Effect of treatment withdrawal in well matched and poorly matched combination
groups. All the poorly matched animals (blue) rejected the transplanted tumour cells
within four weeks of study period as opposed to only 50% in well-matched Wistar
(green) during the same study period.
Fig. 6. Serial IVIS scans of Lewis rats: At the end of 2 weeks of immunosuppression (left), 1 and 2 week post-treatment withdrawal (middle and right). Tumour continued to growwhen
animals were kept on cyclosporine immunosuppression.With treatmentwithdrawal there has been steady rejection of tumour cells till all the injected cells were destroyed (signiﬁcantly
stronger rejection than well matched combination of Wistar animals).
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Figure	112	 Cyclosporine	 immunosuppression:	 Direct	 comparison	 between	 treatment	
continue/withdrawal	well	matched	animals	
	
	
	
Figure	113	 Comparison	 between	 treatment	 continue	 and	 withdrawal	 groups	 in	 CsA	 treated-Lewis	
animals.		
As	opposed	to	continued	treatment,	there	was	complete	elimination	of	tumour	load	after	treatment	withdrawal.	
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Figure	114	 CsA	treatment	withdrawal:	Wistar	and	Lewis	animals	
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Figure	115	 Sirolimus	 low	 dose.	 Comparison	 between	 treatment	 withdrawal	 and	 treatment	 continue	
groups	in	both	strains	and	also	direct	comparison	between	Wistar	and	Lewis	treatment	withdrawal	arm.	
	
	
	
	
	
	
Figure	116	 CsA	vs.	 Sirolimus	high	dose	Wistar	animals.	Direct	 comparison.	Complete	 removal	of	all	 the	
tumour	load	in	Sirolimus	arm.	
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Figure	117	 CsA	 vs.	 Sirolimus	 high	 dose	 Lewis	 animals.	 Direct	 comparison.	 Complete	 removal	 of	 all	 the	
tumour	load	in	Sirolimus	arm.	
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Figure	118	 CsA	 vs.	 Sirolimus	 low	dose	Wistar	 animals.	 Direct	 comparison.	 Complete	 removal	 of	 all	 the	
tumour	load	in	Sirolimus	arm.	
	
	
	
Figure	119	 CsA	 vs.	 Sirolimus	 low	 dose	 Lewis	 animals.	 Direct	 comparison.	 Complete	 removal	 of	 all	 the	
tumour	load	in	Sirolimus	arm.	
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Figure	120	 CsA	 vs.	 Leflunomide	 Wistar	 animals.	 Direct	 comparison.	 Continued	 growth	 with	 CsA	
immunosuppression	while	with	leflunomide	three	out	of	four	animals	have	complete	elimination	of	the	tumour	
load.	
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Figure	121	 CD4+	cells.	Q1	&	Q2	are	the	total	CD4	cells.	The	events	in	the	Q2	are	both	CD4	(FITC)	and	CD25	
(PE)	positive.	
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Figure	122	 Estimation	of	regulatory	T	cells.	The	cells	in	the	Q2	in	the	top	right	hand	histogram	are	CD4	25	
(PE	 flurochrome)	positive	while	 the	 cells	 in	 the	Q2-2	 (bottom	 right)	 are	 the	CD4,	 FoxP3	 (PE	Cy	 5	 flurochrome)	
positive.		
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Figure	123	 CD8+	T	cells.	FITC	anti	rat	CD8	staining	for	estimation	of	CD8+	cells	(Q1+Q2)	
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Figure	124	 Activated	CD8	T	cells.	Cells	in	Q2	are	positive	for	both	CD8	and	CD25.	The	cells	in	Q1-1	are	only	
positive	for	CD25.		
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Figure	125	 Natural	killer	cells	(CD161+).	FITC	+ve	in	Q1.	
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